

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

High risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058369
Article Type:	Original research
Date Submitted by the Author:	14-Oct-2021
Complete List of Authors:	<p>Albuquerque, Maria de Fátima; Centro de Pesquisas Aggeu Magalhaes Souza, Wayner; Centro de Pesquisas Aggeu Magalhaes Montarroyos, Ulisses; University of Pernambuco Pereira, Cresio ; Ministry of Health of Brazil Braga, Cynthia ; Centro de Pesquisas Aggeu Magalhaes Velho Barreto de Araújo, Thalia ; Universidade Federal de Pernambuco, Departamento de Medicina Social Arraes de Alencar Ximenes, Ricardo; Federal University of Pernambuco, Department of Tropical Medicine Miranda-Filho, Demócrito de Barros; University of Pernambuco Szwarcwald, Célia; Institute of Scientific Communication and Information and Technological (ICIT), FIOCRUZ Souza-Junior , Paulo Roberto ; Institute of Scientific Communication and Information and Technological (ICIT), FIOCRUZ-RJ Xavier, Morgana ; Centro de Pesquisas Aggeu Magalhaes Morais, Clarice ; Centro de Pesquisas Aggeu Magalhaes Albuquerque, Gabriela ; Centro de Pesquisas Aggeu Magalhaes Bresani-Salvi, Cristiane; Centro de Pesquisas Aggeu Magalhaes Araújo Mariz, Carolline ; Centro de Pesquisas Aggeu Magalhaes Teixeira de Siqueira-Filha, Noemia; University of York, Department of Health Sciences Galindo, Jadson ; Centro de Pesquisas Aggeu Magalhaes França-Neto, Cláudio Luiz; University of Pernambuco Barbosa, Jessyka Mary Vasconcelos; Centro de Pesquisas Aggeu Magalhaes Veras, Maria Amelia ; Faculty of Medical Sciences of Santa Casa de São Paulo Lima, Luana ; Universidade do Estado do Para Cruz, Luciane; Institute of Health Technology Assessment (IATS) Kendall, Carl; Universidade Federal do Ceara; Tulane University School of Public Health and Tropical Medicine Kerr, L; Universidade Federal do Ceara Turchi Martelli, Celina Maria; Centro de Pesquisas Aggeu Magalhaes</p>
Keywords:	COVID-19, Epidemiology < TROPICAL MEDICINE, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

High risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach

Maria de Fátima Pessoa Militão de Albuquerque¹, PhD, MD, Wayner Vieira de Souza¹, PhD, Ulisses Ramos Montarroyos², PhD, Cresio Romeu Pereira³, PhD, MD, Cynthia Braga¹, PhD, MD, Thália Velho Barreto de Araújo⁴, PhD, MD, Ricardo Arraes de Alencar Ximenes^{2,5}, PhD, MD, Demócrito de Barros Miranda-Filho³, PhD, MD, Célia Landmann Szwarcwald⁶, PhD, Paulo Roberto Borges de Souza Junior⁶, PhD, Morgana do Nascimento Xavier^{1,7}, PhD, Clarice Neuenschwander Lins de Moraes¹, PhD, Gabriela Diniz Militão de Albuquerque², Spc, Cristiane C. Bresani Salvi¹, PhD, MD, Carolline de Araújo Mariz^{1,8}, PhD, Noêmia Teixeira de Siqueira Filha⁹, PhD, Jadson Mendonça Galindo¹, MSc, Cláudio Luiz de França Neto², BSc, Jessyka Mary Vasconcelos Barbosa¹, PhD, Maria Amelia de Sousa Mascena Veras¹¹, PhD, MD, Luana Nepomuceno Gondim Costa Lima¹², PhD, Luciane Nascimento Cruz¹⁰, PhD, MD, Carl Kendall^{13,14}, PhD, Ligia Regina Franco Sansigolo Kerr¹⁴, PhD, MD, Celina Maria Turchi Martelli^{1*}, PhD, MD

¹Aggeu Magalhaes Institute (IAM), Oswaldo Cruz Foundation (Fiocruz), Recife, Brazil

²University of Pernambuco, Recife, Brazil

³Ministry of Health of Brazil, São Paulo, Brazil

⁴Department of Social Medicine

⁵Department of Tropical Medicine, Federal University of Pernambuco, Recife, Brazil

⁶Institute of Scientific and Technological Communication and Information (ICIT), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil

⁷Department of Biology, Federal University of Pernambuco, Vitória de Santo Antão, Brazil

⁸Olinda Medical School, Olinda, Brazil

⁹Department of Health Sciences, University of York, UK

¹⁰Institute for Health Technology Assessment (IATS), Porto Alegre, Brazil and Hospital, Porto Alegre, Brazil

¹¹Faculty of Medical Sciences of Santa Casa de São Paulo, São Paulo, Brazil

¹²State University of Pará, Belém, Brazil

¹³Department of Social, Behavioral and Population Sciences and Tulane University School of Public Health and Tropical Medicine, New Orleans, USA

¹⁴Federal University of Ceará, Fortaleza, Brazil

1
2
3 **Corresponding Author:** Celina Maria Turchi Martelli, PhD
4

5 Aggeu Magalhaes Institute (IAM), Oswaldo Cruz Foundation (Fiocruz)

6 Address: Av. Prof. Moraes Rego, S/N – Cidade Universitária – 50670-420 Recife, Brazil
7

8 Telephone: +55 11 98685-5734
9

10 E-mail: turchicm@gmail.com
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Introduction: The disparities in the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among frontline health care workers (HCWs) and the unique work circumstances are poorly documented for low-and middle-income countries.

Methods: We assessed the frequency of SARS-CoV-2 infection, personal protective equipment (PPE) shortages, PPE use, and accidents involving biological material among HCWs in the Recife metropolitan area, Northeast Brazil. Using respondent driven sampling (RDS), we included HCWs attending suspected or confirmed COVID-19 patients from May 2020 to February 2021.

Results: We analyzed 1,525 HCWs (527 physicians, 471 registered nurses, 263 nursing assistants/technicians, and 264 physical therapists). Women predominated in all categories (81.1%). Nurses were older and had more comorbidities (hypertension and overweight/obesity) than the other HCWs. The overall prevalence of SARS-CoV-2 infection was 61.8% after adjustment for the cluster random effect, weighted by network, and reference population size. The independent risk factors for a positive RT-PCR test were being a nursing assistant (OR adjusted: 2.56), not always using all recommended PPE in routine practice (ORadj: 2.15), and reporting a splash of biological fluid/respiratory secretion in the eyes (ORadj: 3.37).

Conclusions: The high risk of infection among HCWs reflects PPE shortages and younger, possibly less experienced, frontline HCWs. There were disparities in the risk of SARS-CoV-2 infection among HCWs, with nursing assistants being the most vulnerable, possibly due to their longer and frequent contact with COVID-19 patients.

Strengths and limitations of this study

- One of the strengths of this study is that the design enables the health care system and community in general to get a comprehensive picture of the physicians, nurses, nursing assistants, and physical therapists at the frontline during the COVID-19 pandemic in Northeast Brazil.
- Using respondent driven sampling (RDS) methodology allowed the inclusion of frontliners from different healthcare settings, in the private and public health sector. The results captured the full extent of characteristics of the workforce and the risk factors for infection during the pandemic in our setting. There was also an advantage of applying an online questionnaire which avoided face-to-face interviews. This fieldwork approach was appropriated during the lockdown and/or social distancing restrictions. It also aimed at reducing errors in data transcription, and in obtaining timely results.
- This study had some limitations inherent of RDS methodology regarding the representativeness of the participants recruited. We also acknowledge that there was also an imbalance in recruitment among the HCW categories. In our study physicians and nurses were more rapidly enrolled by RDS methodology than nursing assistants and physical therapists at the frontline.

Introduction

The unprecedented rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its potentially severe outcomes have highly impacted the healthcare system, the global economy, and security.^{1,2} According to the World Health Organization (WHO), the global cumulative number of confirmed coronavirus disease 2019 (COVID-19) cases had reached approximately 190.5 million with four million deaths by July 19, 2021.³ In Brazil, approximately 19 million COVID-19 cases and 514,000 related deaths were reported within the same period. These figures represent almost 10% and 13% of the global COVID-19 cases and registered deaths, respectively, yet the Brazilian population represents approximately 2.5% of the global population. Since the beginning of the pandemic, the federal government has opposed the recommendations for social distancing and individual protection measures while endorsing ineffective pharmaceutical interventions, hampering the epidemic control efforts of the public health authorities at the state and municipal levels.⁴

Healthcare workers (HCWs) are considered a high-risk group due to the nature of their work. An Anglo-American prospective cohort that included approximately 100,000 HCWs showed a 3.4-fold higher risk of COVID-19 among frontline workers compared with the general community.⁵ This comprehensive study used an online survey with the advantage of potentially avoiding personal contact during the pandemic, as well as allowing timely responses and dissemination of results.⁵ A systematic review and meta-analysis, covering the period from the inception of the pandemic to July 2020, included 46 studies: approximately 70% were conducted in Europe (n=31), nine in the USA, six in Asia, and none in Latin America. Among symptomatic HCWs, the pooled overall prevalence of SARS-CoV-2 infection was 19% using reverse transcription-polymerase chain reaction (RT-PCR).⁶

In the Americas, 569,304 COVID-19 cases, including 2,506 deaths, had been reported among HCWs by August 2020.⁷ According to public health surveillance, approximately 32% of Mexico City HCWs (n=11,226) had been infected with SARS-CoV-2 by July 2020.⁸ Additionally, cross-sectional studies conducted in Brazil, Colombia, and Ecuador revealed lack of personal protective equipment (PPE) among 70% of frontline workers in the early pandemic response.⁹ In Brazil, studies conducted using RT-PCR in teaching hospitals showed a varying prevalence of SARS-CoV-2 infection (42.4%–15%).^{10,11,12} However, information on the prevalence of SARS-CoV-2 infection among frontline HCWs and risk factors for most regions of Brazil is limited.

This study assessed the prevalence of SARS-CoV-2 infection and evaluated PPE shortages, use of individual protective measures, and biological accidents among HCWs in Recife metropolitan area of Northeast Brazil.

Methods

Study design

This prospective study assessed the frequency of infected HCWs and their risk factors, using the respondent-driven sampling (RDS) methodology, and collecting data with a smartphone-based application. RDS was chosen as a sampling approach for two main reasons: restrictions in conducting face-to-face interviews due to lockdown and the lack of a frame list of frontline HCWs attending emergency rooms, hospitals, and new field hospitals. RDS approach is based upon direct participant involvement.

The baseline findings are described following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for RDS.¹³

Setting

The study was conducted in the Recife metropolitan region, Pernambuco State, Northeast Brazil, where the first COVID-19 case was reported on March 12, 2020. The peak of the pandemic was during the 21st epidemiologic week in 2020.^{14,15} This densely populated region comprises 15 municipalities with approximately four million inhabitants, corresponding to 42% of the state population.¹⁶ The Brazilian unified health system (Sistema Unico de Saude—SUS) has provided universal coverage since 1990, with heterogeneity among the regions.¹⁷

Formative research

Formative research (FR) was conducted with the four HCW categories included in the study (physicians, nurses, nurse assistants, and physical therapists). The FR applied in-depth interviews to explore workplace changes, use and access to PPE, routine attendance, and possible acceptability of the study.

Participants and Public Involvement

Participants and/or the public were not involved in the design. However, the formative research was valuable to adequate the research questions considering participants' priorities, experience, and preferences. Also the chosen methodology RDS requires direct involvement of the study

1
2
3 participants in the recruitment and in indicating other members of the network. Therefore, the
4 participants had an active role in the enrollment of other participants and in the development
5 of the field work. This project was planned in collaboration with the official health care
6 department and professional associations. The coordinators issued periodic reports with
7 preliminary results to the institutions, local newspapers and social media. The final results will
8 be disseminated by institutional platforms.
9
10
11
12
13
14
15

16 *Participants*

17 We recruited HCWs attending suspected or confirmed COVID-19 patients from May 21, 2020
18 to February 10, 2021. Recruitment started with five “seeds” for each category, non-randomly
19 selected from the target population. We asked each participant to identify five other members
20 of the same professional network category, providing their names and mobile phone numbers
21 to the fieldworkers. The process continued until a suitable sample size was reached. This study
22 did not offer any incentive.
23
24
25
26
27

28 We calculated a sample size of 1,100 HCWs, considering a 95% confidence level (CI) to
29 estimate a 40% prevalence of infections with a 5% error and a design effect of three.
30

31 The network size of each HCW was measured by the final answer to the following questions:

32 1) “How many colleagues do you know, who also know you by name, work in the Recife
33 metropolitan region and are assisting COVID-19 patients?”, 2) “How many of those colleagues
34 have been in professional contact with you in the last two weeks?,” and 3) “How many of them
35 are close to you and you would invite to participate in this study?.”
36
37
38
39
40
41

42 *Variables*

43 The variables collected were adapted from the WHO interim guidance (March 2020) on health
44 workers’ exposure risk assessment and management in the context of the COVID-19 pandemic.
45

46 The variables were:

- 47 (1) Age, sex, and professional category;
- 48 (2) Self-reported comorbidities (diabetes mellitus, hypertension, overweight or obesity,
49 cardiopathy, nephropathy, and others);
- 50 (3) Healthcare attending—public or private sector, outpatient, emergency rooms and intensive
51 care units (ICU); number of healthcare facilities.
- 52 (4) Adherence to infection prevention and control (IPC). We checked for gloves, medical
53 masks, face shields, goggles or protective glasses, and waterproof aprons.
54
55
56
57
58
59
60

1
2
3 (5) Adherence to IPC when performing aerosol-generating procedures (AGPs) using the
4 abovementioned grading criteria. In this section, we added the N95 respirator. The variables
5 related to adherence to IPC (items 4 and 5) were grouped as always versus not always.
6
7

8 (6) Accidents with biological material—I) during the period of healthcare interaction and II) if
9 there was an accident with biological fluid or respiratory secretions, which type it was (splash
10 in the mucous membrane of eyes, mouth, or nose; non-intact skin; and puncture-sharp
11 accident).¹⁸ The outcome was a self-reported positive RT-PCR test for SARS-CoV-2.
12
13
14
15

16 17 *Data collection*

18 Data were collected using a web-based software platform by FITec (Recife, Pernambuco,
19 Brazil). The HCWs answered the questionnaire by accessing a link that could be opened on a
20 smartphone or a computer browser.
21
22

23 Providing electronic informed consent was mandatory to participate and access the
24 questionnaire. The project was approved by the National Ethics Committee (CONEP; CAAE:
25 30629220.8.0000.0008).
26
27
28
29

30 31 *Data analysis*

32 Participants were weighted by the size of each category, provided by each professional board,
33 and by the inverse of the size of their professional network, based on the following question:
34 “How many of these colleagues are close to you and would you invite to participate in this
35 study?” To avoid the influence of extreme network sizes on the weight of each professional,
36 we limited the network size to 3 to 150 for outlier correction.¹⁹ For missing data—representing
37 around 8% of the total—we used available information from the other two questions related to
38 network size, and when necessary, we applied the overall mean of the stratum. The seeds
39 (primary) were used to define the cluster of the study.
40
41
42
43
44
45

46 Categorical variables are presented as percentages and 95% CIs by HCW category and overall
47 frequencies adjusted for the design. The chi-squared test was used for comparison between
48 groups. We calculated the means, medians, and 95% CIs for continuous variables. Bivariate
49 analysis was performed to assess the association between potential risk factors and RT-PCR
50 positivity. Variables associated with the outcome at $p < 0.20$ were included in the multivariate
51 model. In the final model, we considered variables at the $p < 0.10$ level statistically significant.
52
53
54
55
56
57
58
59
60 All statistical analyses were performed using Stata, version 15.0 (StataCorp LLC, College
Station, TX, USA).

Role of the funding source

The funding source had no involvement in any stage of the project.

Results

Participants

We recruited 2,474 health care workers and 1,525 of them were included in the analysis, in the following categories: 527 physicians, 471 registered nurses, 263 nursing assistants, and 264 physical therapists. The exclusions were: 638 HCWs who did not sign the informed consent; 238 that refused to participate and 28 did not complete the questionnaires. Figure 1 illustrates the recruitment chain for each category.

Descriptive data

Overall, women represented 81.1% of the sample after adjustment to the reference population and for the study design (Table 1). Women also predominated in all professional categories, with the lowest percentage among physicians (63.4%) and the highest among nurses (86.7%) and nursing assistants (85.5%). The age distribution was as follows: 32.7% and 35.6% were <30 and 30–39 years old, respectively. Only 0.1% of the participants were aged ≥ 60 years. Physicians and physical therapists were the youngest groups, comprising 56.6% and 45.0%, respectively, of those 20–29 years old. Comorbidities affected 30.0% of the studied population. Overweight/obesity (12.6%) and hypertension (11.9%) were the most prevalent comorbidities among nursing assistants and nurses than among the other categories. In total, 71.4% of HCWs attended COVID-19 cases exclusively in the public sector, including hospitals, emergency units, ambulance services, and primary care units. Most HCWs (73.5%) worked either in emergency rooms or ICU. Notably, 55.8% of the physicians and 37.8% of the physical therapists indicated working in three or more institutions during the pandemic (Table 1).

Overall, 78.0% of the participants received training on the use of PPE. Physical therapists (87.0%) and nursing assistants (81.1%) received a higher and similar frequency of training compared to the other categories. Almost half of the HCWs (47.7%) reported a shortage of PPE items during the COVID-19 pandemic. Regarding wearing PPE in routine activities, the overall frequencies varied widely for each item: 90.1% for single-use gloves to 29.9% for face shields. Most HCWs (82.2%) reported performing AGPs on COVID-19 patients. Almost all participants reported having always used single-use gloves (98.4%) and N95 respirators (86.4%) during AGPs. The N95/PPF2 respirator was reused for more than seven days by approximately 28.3% of the participants, with highest and lowest frequencies reported by

1
2
3 physicians (49.3%) and nursing assistants (20.6%), respectively. Overall, 63.7% of the HCWs
4 reported always wearing all PPE items as recommended by the WHO. The self-perception of
5 SARS-CoV-2 risk of infection in the previous 15 days varied: 33.4% for “performing a
6 procedure on a patient with COVID-19;” 17.7% for “sharing the break room with their
7 colleagues;” 16% for the “reuse of N95 respirators;” 10.6% for the “use of poor quality PPE;”
8 10.2% during “doffing;” 9.6% for “working with colleagues with COVID-19 symptoms;” 1.9%
9 for “lack of PPE in the service;” and 0.5% for “donning PPE.” HCWs reported 186 episodes
10 of exposure to biological fluids/respiratory secretions during healthcare interaction with
11 COVID-19 patients. Accidents were more frequent among physicians (13.9%) and less
12 frequent among physical therapists (7.6%) (Table 2).

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The frequency of COVID-19 testing varied from 41.2% for physical therapists to 51.1% for
physicians. Individuals with any comorbidity were more likely to get tested (56.8%) than those
without comorbidities ($p<0.001$). HCWs who worked in three or more health services were
also more likely to get tested (54.9%) than those who worked in only one health service (42.1%)
($p<0.001$). There was no statistical difference in the likelihood of testing, according to sex, age
group (<30 versus ≥ 30 years old), work setting (outpatients, inpatients, and emergency rooms
and ICU), self-perception of risk (no risk to high risk of exposure), reported accidents with
biological fluid/respiratory secretion, and when performing AGPs (Supplementary Table 1).

For the tested HCWs, mostly symptomatic, the overall self-reported SARS-CoV-2 infection
was 61.8% after adjustment for random cluster effects, weighted by network and population
size. The highest infection positivity was among nursing assistants (70.0%), followed by
physicians (55.0%), physical therapists (54.7%), and nurses (48.1%), adjusted for random
cluster effects (Figure 2). RT-PCR screening was performed mainly among symptomatic cases
in all categories, ranging from 81.8% to 91.8% for physicians and nursing assistants,
respectively.

Almost half of the HCWs (47.8%) reported taking sick leave due to COVID-19, with a similar
trend among the other categories ($p=0.159$). The median length of health leave was 14 days for
all professional categories, reflecting a standard procedure. Of 399 symptomatic SARS-CoV-
2 infected HCWs, 10% ($n=41$) were hospitalized.

In a bivariate analysis, the nursing assistant category was positively associated with infection
(odds ratio [OR]=2.77, $p<0.001$) compared to nurses. Reporting any accident involving body
fluid/respiratory secretion was associated with infection (OR=2.67, $p<0.014$). When
considering each accident, splashes in the eyes were a stronger predictor of infection (OR=4.07,
 $p<0.031$). During routine assistance of COVID-19 patients, not always wearing the complete

1
2
3 set of recommended PPE items was associated with infection (OR=2.14; $p=0.013$) when
4 compared to always using PPE. Not always using the complete recommended PPE items during
5 AGPs was also associated with infection (OR=1.69; $p=0.063$) when compared with always
6 using PPE (Supplementary Table 2).
7
8
9

10 In the final multivariate logistic regression model, the following were risk factors for infection:
11 being a nursing assistant (OR adjusted=2.56, $p=0.002$), not always having used PPE during
12 care of patients with COVID-19 (OR adjusted=2.15, $p=0.044$), and having suffered a splash to
13 the eyes (OR adjusted=3.37, $p=0.034$) (Table 3).
14
15
16
17

18 Discussion

19
20 The current study showed substantial heterogeneity in demographic and self-referred
21 comorbidities between HCW categories during the COVID-19 pandemic. Of note, physicians
22 and physical therapists at the frontline were younger and mainly worked in the Intensive Care
23 Units and emergency rooms when compared with nurses. This reflects the expansion of the
24 healthcare workforce with the inclusion of younger physicians and physical therapists, possibly
25 inexperienced professionals, forcibly driven to work as front liners in a high-risk environment.
26 Nurses and nursing assistants were older and reported more comorbidities, particularly
27 hypertension and overweight/obesity. According to the accumulated evidence, the public
28 health strategy was to prevent exposure among older age groups and/or individuals with
29 comorbidities, as older age and comorbidities are strong prognostic factors for hospitalization
30 and death.²⁰
31
32
33
34
35
36
37
38

39 To our knowledge, our study depicted one of the highest frequencies of SARS-CoV-2
40 infections among HCWs. One likely explanation is that most of the participants tested were
41 symptomatic, reflecting the policy of making RT-PCR tests for COVID-19 diagnosis available
42 to frontline HCWs. Thus far, there has been no mass RT-PCR testing strategy for the Brazilian
43 population despite WHO recommendations.²¹ Worldwide, the prevalence closest to that of our
44 study was 55%, by RT-PCR among 177 symptomatic medical residents in New York City at
45 the beginning of the COVID-19 pandemic.²² In Southeast Brazil, a high prevalence of SARS-
46 CoV-2 infection (42%) tested by RT-PCR was found among symptomatic HCWs at a teaching
47 hospital in Sao Paulo, from March to May 2020.¹⁰ Another study found a prevalence of 14%
48 (701 out of 4,987) using RT-PCR in a group composed of mainly symptomatic HCWs, at a
49 hospital in the south of Brazil from April to June 2020.¹² This variation might be attributable
50 to the dynamics of the pandemic in different regions of the country, the availability/quality of
51 PPE, and training in different healthcare settings.
52
53
54
55
56
57
58
59
60

1
2
3 Our study found a 7% prevalence of infection (by RT-PCR) among the 105 asymptomatic
4 HCWs, which is similar to the overall 5% prevalence of infection found by a large screening
5 study for SARS-CoV-2 infection in the metropolitan area of Mexico City.²³ As expected, these
6 results reflect the positive predictive value of clinical manifestations. Although seroprevalence
7 studies cannot be directly compared to our findings, the frequencies of SARS-CoV-2 infection
8 among HCWs in São Paulo city ranged from 5.5% (IgG ELISA) in a private hospital to 14%
9 (IgG/IgM antibody, WONDFO™) in a large public hospital in 2020.^{11,24} Both hospital settings
10 stated that they adopted high-quality hospital infection control and provided complete PPE in
11 the early stages of the COVID-19 pandemic. This may reflect especially high-quality
12 healthcare facilities in more developed regions of the country and the rates reported were
13 similar to those reported in another meta-analysis of seroprevalence studies.²⁵

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Critical aspects for the high risk of SARS-CoV-2 infection included shortage of PPE items
reported by approximately half the HCWs. Moreover, 22% of HCWs reported not been trained
on PPE use. The lack of preparedness of the health workforce to respond to the COVID-19
pandemic was not only encountered by low- and medium-income countries like Brazil but also
in high-income countries at the beginning of the pandemic.²⁶ At the individual level, one-fourth
of the HCWs reported that PPE was not always used according to the WHO
recommendations.²¹ When performing AGPs, the nursing staff had the highest frequency (over
35%) of not fully adhering to complete PPE.²⁷ Furthermore, not using the recommended PPE
during routine attendance of COVID-19 cases caused a 2.2-fold increased risk of a SARS-
CoV-2 positive RT-PCR test result. Accidents with biological fluids occurred in all categories,
however, they were most frequently reported among physicians, the youngest, and perhaps the
group with the least experience working in critical conditions. Reporting an accident with
biological fluids, such as a splash in the eye, was positively associated with infection in the
final multivariable model. Although it is uncertain whether viruses occasionally present in
biofluids are infectious, these fluids should be considered potentially infectious.²⁸ Moreover,
the eye has been considered a possible route of SARS-CoV-2 entry through drainage via the
nasolacrimal duct to the upper respiratory tract.²⁹ These accidents with biological fluids should
be further investigated in other studies, as recommended by the WHO guidelines.¹⁸ The
prevalence among HCWs in the current study was at least 20-fold higher when compared to
the 3.2% seroprevalence in a population-based survey using SARS-CoV-2 antibody rapid tests
conducted during the first wave of the pandemic in the same region.³⁰ Therefore, there is strong
evidence that HCWs are at a high risk of SARS-CoV-2 infection in low- and medium-income
settings, such as Northeast Brazil.

To the best of our knowledge, this is the largest Latin American study of HCWs during the COVID-19 pandemic, with the inclusion of the four main healthcare professionals in the public and private sectors and multiple levels of health services. Previous investigations conducted in Brazil were mainly restricted to one hospital setting and did not apply the WHO questionnaire.¹⁸ One advantage of using the RDS methodology was that it allowed the inclusion of frontline HCWs from different healthcare settings, including the private and public health services, providing a more comprehensive picture of frontline HCWs during the pandemic. Furthermore, as HCWs worked in more than one health service and/or in newly implemented “field hospitals/units,” this strategy allowed us to capture the full extent of characteristics of the workforce and the risk factors for infection. Another advantage of applying an online questionnaire was to avoid face-to-face interviews during the lockdown and/or social distancing restrictions, reduce errors in data transcription, and obtain timely results.

This study had some limitations. First, there was an imbalance in recruitment among the HCW categories; physicians and nurses were more rapidly enrolled by RDS than nursing assistants. One possible explanation is that physicians and nurses seem to understand research methodology better and/or to have either better smartphones or data plans required to answer the approximately 15-minute online questionnaire. Physicians and nurses were also a more vocal category early in the pandemic, publicizing the constraints/pressure of the workplace. Conversely, nursing assistants, as routine healthcare assistants, spend more time providing direct patient care and have low wages. They could also be less confident/willing to participate due to work overload or unfavorable socio-economic conditions when compared to the other categories that require university degrees. Additionally, disclosure of the work environment concerning PPE and infection control prevention may be problematic for nursing assistants whose jobs are less stable and more prone to replacement in our setting. The current study did not discriminate the source of SARS-CoV-2 infection among HCWs. Accidents involving biological fluids should be further investigated in other studies to validate this finding.

Finally, our findings provide a comprehensive picture of the factors associated with SARS-CoV-2 infection among HCWs. This study highlighted the high prevalence of SARS-CoV-2 infection among all HCW categories, with nursing assistants being the most affected.

Data availability statement

Proposals for the dataset (de-identified participant data, data dictionary) should be directed to the corresponding author: turchicm@gmail.com. To gain access, data requestors will need to present their plan of analysis and sign a data access agreement.

Ethics statements

Providing electronic informed consent was mandatory to participate and access the questionnaire. The project was approved by the National Ethics Committee (CONEP; CAAE: 30629220.8.0000.0008).

Acknowledgments

We thank HCWs for their participation. We acknowledge the Institute of Health Technology Assessment and MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020 for support. The following researchers received scholarship (CNPq-Pq): 308974/2018-2 to CMTM, 309722/2017-9 to RAAX, 301905/2017-7 to MFPMA, no. 30735/2018-1 to CB and 303661/2017-8 to WVS. CRP received scholarship from CNPq, EV-1 no. 315877/2020-0. We thank all participants for their important contribution in this project.

Author contributions

MFPMA, WVS, CMTM, RAAX, DBMF, TB, CK, and LRFSK contributed to the study concept and design. CB, MNX, CNLM, GDMA, CBS, CAM, NTSF, JMG, CLFN, and JMVB contributed to the acquisition of data. MFPMA, URM, WVS, CLS, PRBSJ, and CRP contributed to the data analysis and creation of tables and figures. MFPMA, WVS, CMTM, RAAX, DMF, TVBA, MASMV, LNGCL, CB, and LNC contributed to data interpretation. MFPMA, WVS, URM have verified the underlying data. CMTM, MFPMA, WVS, and CRP drafted the initial manuscript and all other coauthors contributed scientific inputs equally towards the interpretation of the findings and the final draft of the manuscript. All authors confirm that they had full access to all the data in the study and accept responsibility to submit for publication.

Funding

This investigation was funded by Health Technology Assessment Institute (IATS) and by MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020. The funding agency had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Declaration of interests

We declare no competing interests.

References

- 1 Fauci AS, Lane HC, Redfield RR. Covid-19—navigating the uncharted. *N Engl J Med* 2020; **382**: 1268–9. doi:10.1056/NEJMe2002387.
- 2 Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's box—another novel coronavirus. *N Engl J Med* 2020; **382**: 1293–5. doi:10.1056/NEJMp2002106.
- 3 World Health Organization, URL: www.COVID19.who.int, accessed July 19, 2021.
- 4 The Lancet. COVID-19 in Brazil: “So what?”. *Lancet* 2020; **395**: 1461. doi:10.1016/S0140-6736(20)31095-3
- 5 Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health* 2020; **5**: 475–83. doi:10.1101/2020.04.29.20084111.
- 6 Gómez-Ochoa AS, Franco OH, Rojas LZ, et al. COVID-19 in health-care workers: a living systematic review and meta-Analysis of prevalence, risk factors, clinical characteristics, and outcomes. *Am J Epidemiology* 2021; **190**: 161–17. doi:10.1093/aje/kwaa191.
- 7 Pan American Health Organization/World Health Organization. Epidemiological alert: COVID-19 among health workers. August 31, 2020 <https://www.paho.org/en/documents/epidemiological-alert-covid-19-among-health-workers-31-august-2020> [Accessed May 8, 2021].
- 8 Antonio-Villa NE, Bello-Chavolla OY, Vargas-Vázquez A, et al. Assessing the burden of coronavirus disease 2019 (COVID-19) among healthcare workers in Mexico City: a data-driven call to action. *Clin Infect Dis* 2021; **73**: e191–8. doi:10.1093/cid/ciaa1487.
- 9 Martin-Delgado J, Viteri E, Mula A, et al. Availability of personal protective equipment and diagnostic and treatment facilities for healthcare workers involved in COVID-19 care: a cross-sectional study in Brazil, Colombia, and Ecuador. *PLoS One* 2020; **15**: e0242185. doi:10.1371/journal.pone.0242185.
- 10 Buonafine CP, Paiatto BNM, Leal FB, et al. High prevalence of SARS-CoV-2 infection among symptomatic healthcare workers in a large university tertiary hospital in São Paulo, Brazil. *BMC Infect Dis* 2020; **20**: 917. doi:10.1186/s12879-020-05662-8.
- 11 Costa SF, Giavina-Bianchi P, Buss L, et al. SARS-CoV-2 seroprevalence and risk factors among oligo/asymptomatic healthcare workers (HCW): estimating the impact of community transmission. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa1845.
- 12 Schmidt Fernandes F, de Castro Cardoso Toniasso S, Castelo Branco Leitune J, et al. COVID-19 among healthcare workers in a Southern Brazilian hospital and evaluation

- of a diagnostic strategy based on the RT-PCR test and retest for Sars-CoV-2. *Eur Rev Med Pharmacol Sci* 2021; **25**: 3365–74. doi:10.26355/eurrev_202104_25748.
- 13 White RG, Hakim AJ, Salganik MJ, et al. Strengthening the reporting of observational studies in epidemiology for respondent-driven sampling studies: "STROBE-RDS" statement. *J Clin Epidemiol* 2015; **68**: 1463–71. doi:10.1016/j.jclinepi.2015.04.002.
- 14 Souza WV, Martelli CMT, Silva APSC, et al. The first hundred days of COVID-19 in Pernambuco State, Brazil: epidemiology in historical context. *Cad Saude Publica* 2020; **36**: e00228220. doi:10.1590/0102-311X00228220.
- 15 Ximenes RAA, Albuquerque MFPM, Martelli CMT, et al. Covid-19 in the Northeast of Brazil: from lockdown to the relaxation of social distancing measures. *Cien Saude Colet* 2021; **26**: 1441–56. doi:10.1590/1413-81232021264.39422020.
- 16 IBGE. Instituto Brasileiro de Geografia e Estatística. Censo demográfico Brasileiro. 2010. <https://www.ibge.gov.br/cidades-e-estados/pe/recife.html> [Accessed July 10, 2021].
- 17 Castro MC, Massuda A, Almeida G, et al. Brazil's unified health system: the first 30 years and prospects for the future. *Lancet* 2019; **394**: 345–56. doi:10.1016/S0140-6736(19)31243-7.
- 18 World Health Organization. Health workers exposure risk assessment and management in the context of COVID-19 virus: interim guidance. March 4, 2020. <https://apps.who.int/iris/handle/10665/331340> [accessed April 15, 2020].
- 19 Gonçalves B, Perra N, Vespignani A. Modeling users' activity on twitter networks: validation of Dunbar's number. *PLoS One* 2011; **6**: e22656. doi:10.1371/journal.pone.0022656.
- 20 Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. *BMJ* 2020; **370**: m3339. doi:10.1136/bmj.m3339.
- 21 World Health Organization. Responding to community spread of COVID-19). Interim guidance 7 March 2020.
- 22 Breazzano MP, Shen J, Abdelhakim AH, et al. New York City COVID-19 resident physician exposure during exponential phase of pandemic. *J Clin Invest* 2020; **130**: 4726–33. doi:10.1172/JCI139587.
- 23 Rajme-López S, González-Lara MF, Ortiz-Brizuela E, et al. Large-scale screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among healthcare workers: prevalence and risk factors for asymptomatic and pauci-symptomatic carriers, with

- 1
2
3 emphasis on the use of personal protective equipment (PPE). *Infect Control Hosp*
4 *Epidemiol* 2021. doi:10.1017/ice.2021.68.
5
6
7 24 Oliveira MS, Lobo RD, Detta FP, et al. SARS-Cov-2 seroprevalence and risk factors
8 among health care workers: Estimating the risk of COVID-19 dedicated units. *Am J*
9 *Infect Control* 2021; **49**: 1197–9. doi:10.1016/j.ajic.2021.03.010.
10
11
12 25 Hossain A, Nasrullah SM, Tasnim Z, Hasan MK, Hasan MM. Seroprevalence of
13 SARS-CoV-2 IgG antibodies among health care workers prior to vaccine
14 administration in Europe, the USA and East Asia: a systematic review and meta-
15 analysis. *E Clinical Medicine* 2021; **33**: 100770. doi:10.1016/j.eclinm.2021.100770.
16
17
18 26 Paffenholz P, Peine A, Hellmich M, et al. Perception of the 2020 SARS-CoV-2
19 pandemic among medical professionals in Germany: results from a nationwide online
20 survey. *Emerg Microbes Infect* 2020; **9**: 1590–9. doi:10.1080/22221751.2020.1785951.
21
22
23 27 Anvisa Nota Técnica Gvims/Ggtes/Anvisa N° 04/2020. Orientações para Serviços de
24 Saúde: Medidas de prevenção e controle que devem ser adotadas durante a assistência
25 aos casos suspeitos ou confirmados de infecção pelo novo Coronavírus (SARS-CoV-2)
26 (updated 08/05/2020).
27
28
29 28 Schindler SE, Jicha GA, Nelson PT, et al. Maximizing safety in the conduct of
30 Alzheimer’s Disease fluid biomarker research in the era of COVID-19. *J Alzheimer’s*
31 *Dis* 2020; **76**: 27–31. doi:10.3233/JAD-20068.
32
33
34 29 Abobaker A, Alzwi A. The eye: a possible new route of infection in COVID-
35 19. *Disaster Med Public Health Prep* 2020; **14**: e25–6. doi:10.1017/dmp.2020.270.
36
37
38 30 Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil:
39 results from two successive nationwide serological household surveys. *Lancet Glob*
40 *Health* 2020; **8**: e1390–8. doi:10.1016/S2214-109X(20)30387-9.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic, clinical, and working baseline characteristics of health care workers in the metropolitan region of Recife, Northeast Brazil, 2020 to 2021

	Physicians (n = 527)		Nurses (n = 471)		Nursing assistants (n = 263)		Physical therapists (n = 264)		Total	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Sex										
Female	63.4	58.6–67.9	86.7	82.7–89.9	85.5	79.8–89.7	70.3	63.6–76.3	81.1	77.8–84.1
Male	36.6	32.1–41.4	13.2	10.1–17.3	14.5	10.2–20.2	29.7	23.7–36.4	18.9	15.9–22.2
Age, years										
< 30	56.6	51.7–61.4	25.8	21.6–30.6	26.9	20.8–33.9	45.1	38.3–52.1	32.7	28.8–36.9
30– 39	34.1	29.6–38.9	37.3	32.5–42.4	34.5	28.0–41.6	45.3	38.5–52.4	35.6	31.5–40.0
≥ 40	9.3	6.8–12.6	36.9	32.1–41.9	38.6	32.0–45.7	9.6	6.2–14.4	31.7	27.6–36.0
Any comorbidity										
Any	23.3	19.5–27.6	33.9	29.2–38.8	32.0	25.8–38.9	19.0	14.1–25.1	30.1	26.1–34.3
None	76.7	72.4–80.5	66.1	61.2–70.8	68.0	61–74.2	81.0	74.9–85.9	69.9	65.7–73.8
Diabetes	1.0	0.4–2.6	2.1	1.1–4.1	2.0	0.8–5.1	0.4	0.1–3.1	1.8	0.9–3.4
Hypertension	4.0	2.5–6.4	13.2	10.0–17.1	14.4	10.1–19.9	4.8	2.5–8.9	11.9	9.2–15.1
Overweight/Obesity	7.3	5.3–10.0	11.1	8.2–14.6	14.9	10.6–20.4	8.9	5.6–13.7	12.6	9.9–15.9
Heart disease	0.4	0.1–1.3	1.2	0.5–3.0	0.9	0.2–3.5	0.0	..	0.1	0.3–2.1
Kidney disease	0.0	..	0.2	0.03–1.5	0.1	0.02–1.1	0.8	0.2–3.1	0.2	0.1–0.6
Others comorbidities	13.1	10.1–16.7	14.8	11.6–18.8	9.4	5.9–14.7	6.9	4.2–11.4	10.8	8.4–13.8
Number of workplaces										
< 3	44.2	39.4–49.0	91.8	88.4–94.2	95.2	92.0–97.2	62.2	55.2–68.7	84.2	82.1–86.1
≥ 3	55.8	51.0–60.6	8.2	5.8–11.6	4.8	2.8–8.0	37.8	31.3–44.8	15.8	13.9–17.9
Missing	2		0		1		0		3	
Institution provider										
Private	5.2	3.5–7.8	7.2	4.8–10.5	7.0	4.1–11.5	14.8	10.4–20.5	7.2	5.3–9.8
Public	44.5	39.7–49.3	81.2	76.8–85.0	79.8	73.5–85.0	35.2	28.9–42.2	71.4	67.6–74.9
Both	50.3	45.5–55.2	11.6	8.7–15.4	13.2	9.1–18.9	50.0	43–56.9	21.4	18.4–24.7
Work setting										
Outpatient/Inpatient clinics	12.0	9.1–15.6	41.6	36.6–46.8	27.7	21.6–34.7	11.5	7.6–17.0	26.5	22.7–30.8
ICU/Emergency	88.0	84.4–90.9	58.4	53.2–63.4	72.3	65.3–78.4	88.5	83.0–92.4	73.5	69.2–77.3

Frequency for each professional category: adjusted for cluster random effect and weighted by network size. Total frequency: adjusted for cluster random effect and weighted by network and population size. CI, confidence interval; ICU, intensive care unit

Table 2. Adherence to infection prevention and control during healthcare interactions with COVID-19 patients and accidents with biological materials

	Physicians (n = 527)		Nurses (n = 471)		Nursing assistants (n = 263)		Physical therapists (n = 264)		Total	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Training on PPE use										
Yes	68.9	64.2–73.2	72.3	67.4–76.7	81.1	74.8–86.1	87.0	81.6–91.0	78.0	74.2–81.3
No	31.1	26.8–35.8	27.7	23.3–32.6	18.9	13.9–25.2	13.0	9.0–18.4	22.0	18.7–25.8
Missing	3		0		0		0		3	
While providing routine assistance to patients with COVID-19, have you used these PPE:										
Single Gloves										
Always	74.1	69.6–78.1	84.4	80.3–87.8	95.4	90.9–97.7	96.1	92.1–98.1	90.1	87.7–92.0
Not always	25.9	21.9–30.4	15.6	12.2–19.7	4.6	2.3–9.1	3.9	1.9–7.9	9.9	8.0–12.3
Missing	2		2		0		1		5	
Surgical mask										
Always	45.3	40.6–50.2	58.6	53.5–63.6	51.0	43.8–58.1	36.9	30.3–44.0	50.5	46.0–54.9
Not always	54.7	49.8–59.4	41.4	36.4–46.5	49.0	41.9–56.1	63.1	56.0–69.6	49.5	45.1–53.9
Missing	2		2		0		1		5	
N95 respirator										
Always	64.4	59.6–68.9	57.4	52.3–62.4	66.3	59.1–72.9	87.3	81.6–91.4	65.9	61.4–70.0
Not always	35.6	31.1–40.3	42.6	37.6–47.7	33.7	27.1–40.9	12.7	8.6–18.4	34.1	30.0–38.6
Missing	2		2		0		1		5	
Face shield										
Always	19.6	16.0–23.9	28.8	24.4–33.7	31.6	25.3–38.6	42.4	35.7–49.3	29.9	25.9–34.2
Not always	80.4	76.1–84.0	71.2	66.3–75.6	68.4	61.4–74.7	57.6	50.7–64.3	70.1	65.8–74.1
Missing	2		2		0		1		5	
Goggles/protective glasses										
Always	18.7	15.3–22.7	24.6	20.4–29.3	38.3	31.6–45.4	45.6	38.7 - 52.6	33.2	29.1–37.6
Not always	81.3	77.2–84.7	75.4	70.7–79.5	61.7	54.6–68.4	54.4	47.4–61.3	66.8	62.3–70.9
Missing	2		2		0		1		5	
Disposable gown										

1											
2											
3	Always	48.0	43.3–52.9	50.8	45.6–55.9	63.8	56.6–70.4	67.2	60.3–73.3	59.2	54.8–63.5
4	Not always	52.0	47.1–56.7	49.2	44.1–54.4	36.2	29.5–43.4	32.8	26.7–39.7	40.8	36.5–45.2
5	Missing	2		2		0		1		5	
6	Waterproof apron										
7	Always	30.5	26.2–35.2	38.6	33.7–43.7	48.9	41.6–56.3	62.6	55.3–69.4	44.9	40.5–49.5
8	Not always	69.5	64.8–73.8	61.4	56.3–66.3	51.1	43.7–58.4	37.4	30.6–44.7	55.1	50.5–59.5
9	Missing	14		11		11		18		54	
10											
11	During provision of routine										
12	assistance to COVID-19										
13	patients, did you wear all PPE										
14	items as recommended by the										
15	WHO?										
16	Always	89.6	86.2–92.3	79.2	74.7–83.1	70.0	63.1–76.1	69.0	62.2–75.1	74.7	70.5–78.5
17	Not always	10.4	7.7–13.8	20.8	16.9–25.3	30.0	23.9–36.9	31.0	24.9–37.8	25.3	21.5–29.5
18	Missing	2		2		0		1		5	
19	Participated in AGP*										
20	Yes	79.6	75.3–83.2	75.6	70.8–79.8	83.4	77–88.3	95.8	91.7–97.8	82.2	78.4–85.5
21	No	20.4	16.8–24.7	24.4	20.2–29.2	16.6	11.7 - 23	4.2	2.1–8.3	17.8	14.5–21.6
22	Missing	1		1		1		2		5	
23											
24	While participating in AGPs,										
25	have you used:										
26	Single Gloves										
27	Always	97.8	95.5–98.9	97.7	95.1–99	98.5	94.2–99.6	99.7	98.1–99.9	98.4	96.4–99.3
28	Not always	2.2	1.1–4.5	2.3	1–4.9	1.5	0.4–5.8	0.3	0.04–1.9	1.6	0.7–3.6
29	Missing	0		0		0		1		1	
30	Surgical mask										
31	Always	61.5	56.2–66.6	49.9	44.1–55.7	46.5	38.9–54.3	60.2	52.9–67.1	50.5	45.6–55.3
32	Not always	38.5	33.4–43.8	50.1	44.3–55.9	53.5	45.7–61.1	39.8	32.9–47.1	49.5	44.7–54.4
33	Missing	0		0		0		1		1	
34	N95 respirator										
35	Always	92.4	89–94.9	85.0	80.3–88.8	84.2	77.8–89.1	93.3	88.2–96.3	86.4	82.5–89.5
36	Not always	7.6	3.1–11	15.0	11.2–19.7	15.7	10.9–22.2	6.7	3.7–11.8	13.6	10.5–17.5
37	Missing	0		0		0		1		1	
38	Face shield										
39											
40											
41											
42											
43											
44											
45											
46											

1											
2											
3	Always	51.6	46.2–56.9	48.3	42.6–54.1	48.0	40.3–55.7	41.4	34.5–48.6	48.1	43.2–53.0
4	Not always	48.4	43.1–53.8	51.7	45.8–57.4	52.0	44.2–59.7	58.6	51.4–65.5	51.9	47.0–56.8
5	Missing	0		0		0		1		1	
6	Goggles/Protective glasses										
7	Always	62.5	57.1–67.6	59.3	53.5–64.9	51.4	43.6–59.1	47.1	40–54.3	54.0	49.1–58.9
8	Not always	37.5	32.4–42.8	40.7	35.1–46.5	48.6	40.9–56.4	52.9	45.7 - 60	46.0	41.1–50.9
9	Missing	0		0		0		1		1	
10	Disposable gown										
11	Always	60.3	55.0–65.4	60.1	54.3 - 65.7	64.0	60.3–74.9	68.3	61.3–74.4	65.6	60.8–70.1
12	Not always	39.7	34.6–45.0	39.9	34.3–45.7	32.0	25.1–39.7	31.7	25.6–38.7	34.4	29.9–39.2
13	Missing	0		0		0		1		1	
14	Waterproof apron										
15	Always	55.2	49.7–60.6	60.7	54.8–66.3	62.5	54.4–69.9	74.6	67.4–80.7	61.9	57.0–66.7
16	Not always	44.8	39.4–50.3	39.3	33.7–45.2	37.5	30.1–45.6	25.4	19.3–32.6	38.1	33.3–43.0
17	Missing	9		7		9		17		42	
18	When performing an AGP in COVID-19 patients, did you wear all recommended PPE items as in WHO guidance?										
19	Always	66.0	60.0–71.4	58.0	51.4–64.3	63.8	54.1–72.6	74.7	64.2–82.8	63.7	57.8–69.2
20	Not always	34.0	28.6–40.0	42.0	35.7–48.6	36.2	27.4–45.9	25.3	17.2–35.8	36.3	30.8–42.2
21	Missing	0		0		0		1		1	
22	Duration of N95 respirator use										
23	< 8 days	50.7	45.8–55.6	71.4	66.6–75.8	79.4	73.0–84.6	54.6	47.6–61.5	71.7	67.9–75.3
24	≥ 8 days	49.3	44.4–54.2	28.6	24.2–33.4	20.6	15.4–27.0	45.4	38.5–52.4	28.3	24.7–32.1
25	Missing	9		5		8		4		26	
26	Any accident involving body fluid/respiratory secretion										
27	Yes	13.9	11–17.4	10.8	7.9–14.5	11.7	7.9–17.1	7.6	4.9–11.7	11.6	9.1–14.8
28	No	86.1	82.6–89	89.2	85.5–92.1	88.3	82.9–92.1	92.4	88.3–95.1	88.4	85.2–90.9
29	Organ involved										
30	Splash in the Mouth	1.9	1.02–3.8	1.9	0.85–4.3	0.2	0.04–1.5	0.7	0.2–3.1	0.8	0.5–1.4
31	Splash on the Skin	2.4	1.4–3.9	3.4	1.9–6.0	1.3	0.5–3.2	3.9	1.9–7.7	2.0	1.3–3.0
32	Splash on the Eyes	2.3	1.4–3.9	3.5	1.9–6.1	2.1	0.8–5.8	2.5	1.2–5.0	2.4	1.4–4.2
33											
34											
35											
36											
37											
38											
39											
40											
41											
42											
43											
44											
45											
46											

Puncture/sharps	8.2	5.9–11.3	3.0	1.7–5.3	8.2	4.9–13.4	0.0	-	6.7	4.6–9.7
Self-perception of risk										
None/Low	21.6	17.9–25.9	24.9	20.7–29.6	21.9	16.3–28.7	17.2	12.5–23.3	22.0	18.5–26.1
Medium/High	78.4	74.1–82.1	75.1	70.3–79.3	78.1	71.3–83.7	82.8	76.7–87.5	78.0	73.8–81.5
Missing	9		2		6		4		21	

Frequency for each professional category: adjusted for cluster random effect and weighted by network size. Total frequency: adjusted for cluster random effect and weighted by network and population size.

AGPs, aerosol-generating procedures; COVID-19, coronavirus disease 2019; CI, confidence interval; ICU, intensive care unit; PPE, personal protective equipment; WHO, World Health Organization

Table 3. Final multivariate model for factors associated with reported positive PCR COVID-19 results

	Odds Ratio	95% CI	<i>P</i> -value
Occupation			
Nurse	1.0
Physical therapist	1.47	0.80–2.72	0.214
Physician	1.20	0.76–1.90	0.426
Nursing assistant	2.56	1.42–4.61	0.002
Splash on the eyes			
No accident	1.0
Yes	3.37	1.10–10.34	0.034
Any accident	1.59	0.51–4.90	0.421
Used all PPE items while assisting patients with COVID-19			
Yes	1.0
No	2.15	1.02–4.53	0.044

Adjusted for cluster random effect and weighted by network and population size

COVID-19, coronavirus disease 2019; CI, confidence interval; PPE, personal protective equipment

Figure Legends

Figure 1. Respondent-driven sampling recruitment chains.

Figure 2. Frequencies of self-reported SARS-CoV-2 infection by healthcare categories.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. Respondent-driven sampling recruitment chains

338x190mm (170 x 170 DPI)



Occupation

Supplementary Table 1. Characteristics of the study population according to RT-PCR testing

	RT-PCR testing		P-value
	Yes (%)	No (%)	
Occupation category			0.02
	Physician	269 (51.1)	257 (48.9)
	Registered nurse	224(47.6)	247(52.4)
	Nursing assistant	110 (42.0)	152 (58.0)
	Physical therapist	108(41.2)	154(58.8)
Sex			0.43
	Female	530 (46.2)	618 (53.8)
	Male	181 (48.5)	192 (51.5)
Age group, years			0.15
	< 30	523 (45.7)	622 (54.3)
	≥ 30	188 (50.0)	188 (50.0)
Any comorbidity			< 0.001
	Yes	246 (56.8)	187 (43.2)
	No	465 (42.7)	623 (57.3)
Number of workplaces (hospitals/clinics)			< 0.01
	<3	247 (54.0)	210 (46.0)
	≥3	462 (43.5)	599 (56.5)
Work setting			0.39
	Emerg/ICU	565 (47.3)	629 (52.7)
	Output/Inpatients	146 (44.7)	181 (55.3)
Institution provider			< 0.001
	Private	48 (42.1)	66 (57.9)
	Public	393 (43.0)	522 (57.0)
	Both	270 (54.9)	222 (45.1)
Performed aerosol generating procedure			0.36
	Yes	600 (47.3)	669 (52.7)
	No	110 (44.5)	137 (55.5)
	Missing	1 (20.0)	4 (80.0)
Same N95 respirator, use duration, days			0.023
	≤ 7	458 (49.00)	476 (51.0)
	> 7	243 (43.0)	322 (57.0)
Self-perceived risk			0.85
	None/Low	36 (45.1)	43 (54.9)
	Medium/High	665 (46.7)	760 (53.3)
Accident involving biological fluid/respiratory secretion			0.644
	Yes	84 (45.2)	102 (54.8)
	No	627 (47.0)	708 (53.0)
Sick leave due to COVID-19 symptoms			< 0.001
	Yes	576 (79.7)	147 (20.3)
	No	130 (16.5)	659 (83.5)
Had COVID-19-like symptoms/signs			< 0.001
	Yes	601 (68.2)	280 (31.8)
	No	110 (17.0)	530 (82.8)

COVID-19, coronavirus disease 2019; RT-PCR, reverse transcription polymerase chain reaction

Supplementary Table 2. Potential risk factors for reporting a positive PCR COVID-19 result among front line healthcare professionals

	Odds Ratio	95% CI	P-value
Sex			
Female	1.0
Male	1.35	0.78–2.34	0.288
Age, years	1.03	0.65–1.64	0.889
Occupation			
Nurse	1.0
Physical therapist	1.42	0.88–2.27	0.148
Physician	1.32	0.91–1.91	0.142
Nursing Assistant	2.77	1.64–4.67	<0.001
Any comorbidity	1.19	0.75–1.90	0.454
Number of workplaces			
< 3	1.0
≥ 3	0.83	0.53–1.30	0.428
Institution provider			
Private	1.0
Public	0.92	0.42–2.02	0.844
Both	0.93	0.41–2.10	0.863
Work setting			
Outpatient /Inpatient clinics	1.0
ICU/Emergency	1.54	0.92–2.60	0.102
Training on PPE use	1.06	0.62–1.80	0.829
Any accident involving body fluid/respiratory secretion	2.67	1.22–5.82	0.014
Splash in the mouth			
No accident	1.0
Yes	3.84	0.64–22.95	0.140
Other accident	2.30	0.85–6.23	0.102
Splash on the skin			
No accident	1.0
Yes	1.86	0.54–6.44	0.328
Other accident	2.50	0.80–7.85	0.116
Splash in the eyes			
No accident	1.0
Yes	4.07	1.14–14.55	0.031
Other accident	2.07	0.71–6.08	0.184
Puncture/sharp accident			
No accident	1.0
Yes	2.25	0.51–9.89	0.282
Other accident	2.51	1.10–5.72	0.028
Duration N95 respirator use			
< 8 days
≥ 8 days	0.96	0.59–1.55	0.869
Used All PPE items during AGP#			
Did not Always use	1.68	0.97–2.92	0.063

1
2
3 Used all PPE items while assisting
4 COVID-19 patients

5 Yes	1.0
6 No	2.14	1.18–3.88	0.013
7 Time on the front-line, days	0.997	0.994–1.000	0.042

8 Adjusted for cluster random effect and weighted by network and population size.

9
10 AGP, aerosol-generating procedure; COVID-19, coronavirus disease 2019; CI, confidence interval; ICU,
11 intensive care unit; PPE, personal protective equipment
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tabela 1. STROBE-RDS Statement Checklist for the manuscript title “High risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach”

Item	#	STROBE-RDS checklist	Main Document
Title and abstract	1	(a) Indicate “respondent-driven sampling” in the title or abstract	Done, RDS in the Title and abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Pg. 1, lines 5-17. Abstract included methods, results and conclusions.
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction, paragraph 1-3 Done
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction, paragraph 4
Methods			
Study design	4	(a) Present key elements of study design early in the article	Done, Methods, paragraph 1
		(b) State why RDS was chosen as the sampling method	Methods, paragraph 1 “RDS was chosen as a sampling approach for two main reasons: restrictions in conducting face-to-face interviews ..”
Setting	5	(a) Describe the setting, locations, and relevant dates, including periods of recruitment and data collection	Done. Methods, paragraph 3 and 5
		(b) Describe formative research findings used to inform RDS study	Done Methods, paragraph 4
Participants	6	(a) Give the eligibility criteria and the sources and methods of selection of participants. Describe how participants were trained/instructed to recruit others, number of coupons issued per person, any time limits for referral	Done Methods, paragraph 5
		(b) Describe methods of seed selection and state number at start of study and number added later	Methods, paragraph 6 and 7
		(c) State if there was any variation in study procedures during data collection (e.g., changing numbers of coupons per recruiter, interruptions in sampling, or (stopping recruitment chains)	Done
		(d) Report wording of personal network size question(s)	Done. Methods, paragraph 7
		(e) Describe incentives for participation and recruitment	No incentives were offered.

			pg8 line 6. “This study did not offer any incentive.”
Variables	7	(a) If applicable, clearly define all outcomes, correlates, predictors, potential confounders, effect modifiers, and diagnostic criteria	Done. Methods, pg 8; “The variables collected were adapted from the WHO interim guidance”
		(b) State recruitment relationship was tracked	Figure 1 “Respondent-driven sampling recruitment chains”
Data sources/ measurement	8	(a) For each variable of interest, give sources of data and details of methods of measurement. Describe comparability of measurement methods if there is more than one group	Done. Methods, pg 8; the variables of interest were specified.
		(b) Describe methods to assess eligibility and reduce repeat enrollment (e.g., coupon manager software, biometrics)	Methods, pg 9. Data collection. “Data were collected using a web-based software platform by FITec (Recife, Pernambuco, Brazil). The HCWs answered the questionnaire by accessing a link that could be opened on a smartphone or a computer browser.”
Bias	9	Describe any efforts to address potential sources of bias	Not done
Study size	10	Explain how the study size was arrived at	Methods, “We calculated a sample size of 1,100 HCWs, considering a 95% confidence level (CI) to estimate a 40% prevalence of

			infections with a 5% error and a design effect of three.”
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Methods, section “variable” and “Data analysis”,
Statistical methods	12	(a) Describe all statistical methods, including those to account for sampling strategy (e.g., the estimator used) and, if applicable, those used to control for confounding	Methods, section “Data analysis”
		(b) State data analysis software, version number, and specific analysis settings used	Methods, section “Data analysis”
		(c) Describe any methods used to examine subgroups and interactions	Not applicable
		(d) Explain how missing data were addressed	Methods, section “Data analysis”
		(e) Describe any sensitivity analyses	Not done
		(f) Report any criteria used to support statements on whether estimator conditions or assumptions were appropriate	Not done
		(g) Explain how seeds were handled in analysis	Done, pg 9 “Data analysis” The seeds were used to define the cluster of the study.
Results			
Participants	13	(a) Report the numbers of individuals at each stage of the study, for example, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, and analyzed	Done. Results, Text, first paragraph
		(b) Give reasons for nonparticipation at each stage (e.g., not eligible, does not consent, decline to recruit others)	Done
		(c) Consider use of a flow diagram	Not included as Flowchart due to limited number of Figures of the Journal
		(d) Report number of coupons issued and returned	Not applicable
		(e) Report number of recruits by seed and number of RDS recruitment waves for each seed. Consider showing graph of entire recruitment network	Done Figure 1. Presents RDS recruitment chains.
		(f) Report recruitment challenges (e.g., commercial exchange of coupons, imposters, duplicate recruits) and how addressed	Not Done
		(g) Consider reporting estimated design effect for outcomes of interest	Done Figure 2 shows prevalence adjusted “for

			random cluster effects” Pg 11
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and, if applicable, information on correlates and potential confounders. Report unweighted sample size and percentages, estimated population proportions or means with estimated precision (e.g., 95% confidence interval)	Done Table 1 and table 2
		(b) Indicate the number of participants with missing data for each variable of interest	Done. Missing Data presented for each variable (Tables 1 and 2)
Outcome data	15	If applicable, report number of outcome events or summary measures	Done. Presented in Figure 2.
Main results	16	(a) Give unadjusted and study design adjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included	Done. Results section and Tables 3
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If adjustment of primary outcome leads to marked changes, report information on factors influencing the adjustments (e.g., personal network sizes, recruitment patterns by group, key confounders)	The adjustment only modified slightly not affecting the general results
Other analyses	17	Report other analyses done for example, analyses of subgroups and interactions, sensitivity analyses, different RDS estimators and definitions of personal network size	All analyses were reported
Discussion			
Key results	18	Summarize key results with reference to study objectives	Done. Discussion, paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Done. Discussion, paragraph 7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion, paragraph 2-5
Generalizability	21	Discuss the generalizability (external validity) of the study results	Discussion, paragraph 6 and 8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 16, funding section

BMJ Open

Risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058369.R1
Article Type:	Original research
Date Submitted by the Author:	15-Feb-2022
Complete List of Authors:	<p>Albuquerque, Maria de Fátima; Centro de Pesquisas Aggeu Magalhaes Souza, Wayner; Centro de Pesquisas Aggeu Magalhaes Montarroyos, Ulisses; University of Pernambuco Pereira, Cresio ; Ministry of Health of Brazil Braga, Cynthia ; Centro de Pesquisas Aggeu Magalhaes Velho Barreto de Araújo, Thalia ; Universidade Federal de Pernambuco, Departamento de Medicina Social Arraes de Alencar Ximenes, Ricardo; Federal University of Pernambuco, Department of Tropical Medicine Miranda-Filho, Demócrito de Barros; University of Pernambuco Szwarcwald, Célia; Institute of Scientific Communication and Information and Technological (ICIT), FIOCRUZ Souza-Junior , Paulo Roberto ; Institute of Scientific Communication and Information and Technological (ICIT), FIOCRUZ-RJ Xavier, Morgana ; Centro de Pesquisas Aggeu Magalhaes Morais, Clarice ; Centro de Pesquisas Aggeu Magalhaes Albuquerque, Gabriela ; Centro de Pesquisas Aggeu Magalhaes Bresani-Salvi, Cristiane; Centro de Pesquisas Aggeu Magalhaes Araújo Mariz, Carolline ; Centro de Pesquisas Aggeu Magalhaes Teixeira de Siqueira-Filha, Noemia; University of York, Department of Health Sciences Galindo, Jadson ; Centro de Pesquisas Aggeu Magalhaes França-Neto, Cláudio Luiz; University of Pernambuco Barbosa, Jessyka Mary Vasconcelos; Centro de Pesquisas Aggeu Magalhaes Veras, Maria Amelia ; Faculty of Medical Sciences of Santa Casa de São Paulo Lima, Luana ; Universidade do Estado do Para Cruz, Luciane; Institute of Health Technology Assessment (IATS) Kendall, Carl; Universidade Federal do Ceara; Tulane University School of Public Health and Tropical Medicine Kerr, L; Universidade Federal do Ceara Turchi Martelli, Celina Maria; Centro de Pesquisas Aggeu Magalhaes</p>
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, Epidemiology < TROPICAL MEDICINE, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil:**
 2 **a respondent-driven sampling approach**

3
 4 Maria de Fátima Pessoa Militão de Albuquerque¹, PhD, MD, Wayner Vieira de Souza¹, PhD,
 5 Ulisses Ramos Montarroyos², PhD, Cresio Romeu Pereira³, PhD, MD, Cynthia Braga¹, PhD,
 6 MD, Thália Velho Barreto de Araújo⁴, PhD, MD, Ricardo Arraes de Alencar Ximenes^{2,5}, PhD,
 7 MD, Demócrito de Barros Miranda-Filho², PhD, MD, Célia Landmann Szwarcwald⁶, PhD,
 8 Paulo Roberto Borges de Souza Junior⁶, PhD, Morgana do Nascimento Xavier^{1,7}, PhD, Clarice
 9 Neuenschwander Lins de Moraes¹, PhD, Gabriela Diniz Militao de Albuquerque², Spc, Cristiane
 10 C. Bresani Salvi¹, PhD, MD, Carolline de Araújo Mariz^{1,8}, PhD, Noêmia Teixeira de Siqueira
 11 Filha⁹, PhD, Jadson Mendonça Galindo¹, MSc, Cláudio Luiz de França Neto², BSc, Jessyka
 12 Mary Vasconcelos Barbosa¹, PhD, Maria Amelia de Sousa Mascena Veras¹¹, PhD, MD, Luana
 13 Nepomuceno Gondim Costa Lima¹², PhD, Luciane Nascimento Cruz¹⁰, PhD, MD, Carl
 14 Kendall^{13,14}, PhD, Ligia Regina Franco Sansigolo Kerr¹⁴, PhD, MD, Celina Maria Turchi
 15 Martelli^{1*}, PhD, MD

16
 17 ¹Aggeu Magalhaes Institute (IAM), Oswaldo Cruz Foundation (Fiocruz), Recife, Brazil

18 ²University of Pernambuco, Recife, Brazil

19 ³Ministry of Health of Brazil, São Paulo, Brazil

20 ⁴Department of Social Medicine

21 ⁵Department of Tropical Medicine, Federal University of Pernambuco, Recife, Brazil

22 ⁶Institute of Scientific and Technological Communication and Information (ICIT), Oswaldo
 23 Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil

24 ⁷Department of Biology, Federal University of Pernambuco, Vitória de Santo Antão, Brazil

25 ⁸Olinda Medical School, Olinda, Brazil

26 ⁹Department of Health Sciences, University of York, UK

27 ¹⁰Institute for Health Technology Assessment (IATS), Porto Alegre, Brazil and Hospital, Porto
 28 Alegre, Brazil

29 ¹¹Faculty of Medical Sciences of Santa Casa de São Paulo, São Paulo, Brazil

30 ¹²State University of Pará, Belém, Brazil

31 ¹³Department of Social, Behavioral and Population Sciences and Tulane University School of
 32 Public Health and Tropical Medicine, New Orleans, USA

33 ¹⁴Federal University of Ceará, Fortaleza, Brazil

34

1
2
3 1 **Corresponding Author:** Celina Maria Turchi Martelli, PhD
4
5 2 Aggeu Magalhaes Institute (IAM), Oswaldo Cruz Foundation (Fiocruz)
6
7 3 Address: Av. Prof. Moraes Rego, S/N – Cidade Universitária – 50670-420 Recife, Brazil
8
9 4 Telephone: +55 11 98685-5734
10
11 5 E-mail: turchicm@gmail.com
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7 **Keywords:** COVID-19; Health care Workers; Brazil.

9 **Word count:** 4.063

1 Abstract

2 **Objectives:** We assessed the prevalence of severe acute respiratory syndrome coronavirus
3 (SARS-CoV-2) infection, personal protective equipment (PPE) shortages and occurrence of
4 biological accidents among frontline health care workers (HCW).

5 **Design, setting and participants:** Using respondent driven sampling (RDS), the study
6 recruited distinct categories of HCW attending suspected or confirmed COVID-19 patients
7 from May 2020 to February 2021, in the Recife metropolitan area, Northeast Brazil.

8 **Outcome measures:** The criterion to assess SARS-CoV-2 infection among HCW was a
9 positive self-reported PCR test.

10 **Results:** We analyzed 1,525 HCW: 527 physicians, 471 registered nurses, 263 nursing
11 assistants, and 264 physical therapists. Women predominated in all categories (81.1%; 95%
12 CI: 77.8% - 84.1%). Nurses were older with more comorbidities (hypertension and
13 overweight/obesity) than the other staff. The overall prevalence of SARS-CoV-2 infection was
14 61.8% (95% CI: 55.7%-67.5%) after adjustment for the cluster random effect, weighted by
15 network, and the reference population size. Risk factors for a positive RT-PCR test were being
16 a nursing assistant (ORadjusted: 2.56; 95% CI: 1.42 - 4.61), not always using all recommended
17 PPE while assisting patients with COVID-19 (ORadj: 2.15; 95% CI: 1.02 - 4.53) and reporting
18 a splash of biological fluid/respiratory secretion in the eyes (ORadj: 3.37; 95% CI: 1.10 –
19 10.34).

20 **Conclusions:** This study shows the high frequency of SARS-CoV2 infection among HCW
21 presumably due to workplace exposures. In our setting nursing assistant comprised the most
22 vulnerable category. Our findings highlight the need for improving health care facility
23 environments, specific training and supervision to cope with public health emergencies.

Strengths and limitations of this study

- Respondent-driven sampling (RDS) technique applied in this study allowed the enrolment of the healthcare workers (HCW) attending COVID-19 patients. HCW were considered a hard-to-reach population regarding their work conditions during the pandemic.
- The study has a large sample size including the major categories of health care professionals who attended Covid-19 patients in the public, private or newly implemented campaign hospitals.
- Data were collected using a web-based platform, allowing the use of online questionnaire, also facilitating timely data analysis and lesser transcript data errors.
- The Respondent-driven sampling chains could potentially induce the recruitment of participants with similar characteristics, prone to selection bias. However, the study achieved a large and heterogeneous sample.
- The source of SARS-CoV-2 infection among HCW could not be ascertained and this is another limitation of the study.

1 Introduction

2 The unprecedented rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-
3 CoV-2) and its potentially severe outcomes have highly impacted the healthcare system, the
4 global economy, and security.^{1,2} According to the World Health Organization (WHO), the
5 global cumulative number of confirmed coronavirus disease 2019 (COVID-19) cases had
6 reached approximately 364.2 million and 5.6 million deaths by January 28, 2022.³ In Brazil,
7 approximately 24.5 million COVID-19 cases and 624,413 related deaths were reported within
8 the same period. These figures represent almost 7% and 11% of the global COVID-19 cases
9 and registered deaths, respectively, yet the Brazilian population represents approximately 2.5%
10 of the global population. In Brazil Covid-19 epidemiological data showed a high burden on
11 hospital system with 678 235 patients' admission with a positive RT-PCR for SARS-CoV-2
12 between February 2020 and April 2021. Hospital mortality increased from 34.8% in the first
13 wave (February 25, 2020 to November 5, 2020) to 39.3% in the second wave (November 6,
14 2020, to April 30, 2021). The northeast and north states of the country concentrate the worst
15 in-hospital mortality rates, which are the regions with lower Human Development Indexes.⁴
16 Since the beginning of the pandemic, the federal government has opposed the
17 recommendations for social distancing and individual protection measures while endorsing
18 ineffective pharmaceutical interventions, hampering the epidemic control efforts of the public
19 health authorities at the state and municipal levels.⁵
20 Healthcare workers (HCW) are considered a high-risk group due to the nature of their work.
21 An Anglo-American prospective cohort that included approximately 100,000 HCW showed a
22 3.4-fold higher risk of COVID-19 among frontline workers compared with the general
23 community.⁶ A systematic review and meta-analysis, covering the period from the inception
24 of the pandemic to August 2021, showed a significant burden of COVID-19 among HCW in
25 several countries, with a pooled prevalence of 11% (95% CI: 7 to 16%) in studies using PCR
26 test.⁷ Another systematic review and metanalysis suggested that exposure in settings with
27 familiar contact increases SARS-CoV-2 transmission. However, to explore the transmission
28 pattern in health facilities, workplace and social settings is still challenging due to limited data
29 so far.⁸ These previous reviews did not include studies from Brazil.
30 In the Americas, 569,304 COVID-19 cases, including 2,506 deaths, had been reported among
31 HCW by August 2020.⁹ According to public health surveillance, approximately 32% of Mexico
32 City HCW (n=11,226) had been infected with SARS-CoV-2 by July 2020.¹⁰ Additionally,
33 cross-sectional studies conducted in Brazil, Colombia, and Ecuador revealed lack of personal
34 protective equipment (PPE) among 70% of frontline workers in the early pandemic response.¹¹

1 In line with the previous studies a survey among HCW reported PPE shortage in the first
2 COVID-19 wave in Brazil 2020¹², and the inadequate working conditions were also reported
3 by the media¹³. In Brazil, prevalence of SARS-CoV-2 infection using RT-PCR in teaching
4 hospitals varied from 15% to 42.4% among symptomatic HCW in the south region and
5 southeast regions, respectively.^{14,15,16} However, information on the prevalence of SARS-CoV-2
6 infection among frontline HCW and risk factors for most regions of Brazil is limited.

7 This study assessed the prevalence of SARS-CoV-2 infection and evaluated PPE shortages,
8 use of individual protective measures, and biological accidents among HCW in Recife
9 metropolitan area of Northeast Brazil.

11 **Methods**

12 *Study design*

13 This prospective study assessed the frequency of infected HCW and their risk factors, using
14 the respondent-driven sampling (RDS) methodology¹⁷, and collecting data with a smartphone-
15 based application. RDS was chosen as a sampling approach for two main reasons: restrictions
16 in conducting face-to-face interviews due to lockdown and the lack of a frame list of frontline
17 HCW attending emergency rooms, hospitals, and new field hospitals. RDS approach is based
18 upon direct participant involvement.

19 The baseline findings are described following the Strengthening the Reporting of Observational
20 Studies in Epidemiology (STROBE) guidelines for RDS.¹⁸

22 *Setting*

23 The study was conducted in the Recife metropolitan region, Pernambuco State, Northeast
24 Brazil, where the first COVID-19 case was reported on March 12, 2020. The peak of the
25 pandemic was during the 21st epidemiologic week in 2020.^{19,20} This densely populated region
26 comprises 15 municipalities with approximately four million inhabitants, corresponding to
27 42% of the state population.²¹ The Brazilian unified health system (Sistema Unico de Saude—
28 SUS) has provided universal coverage since 1990, with heterogeneity among the regions.²²

30 *Formative research*

31 Formative research (FR) was conducted with the four HCW categories included in the study
32 (physicians, nurses, nurse assistants, and physical therapists). The FR applied in-depth
33 interviews to explore workplace changes, use and access to PPE, routine attendance, and
34 possible acceptability of the study.

1 *Participants and Public Involvement*

2 Participants and/or the public were not involved in the design. However, the formative research
3 was valuable to adequate the research questions considering participants' priorities, experience,
4 and preferences. Also the chosen methodology RDS requires direct involvement of the study
5 participants in the recruitment and in indicating other members of the network. Therefore, the
6 participants had an active role in the enrolment of other participants and in the development of
7 the field work. This project was planned in collaboration with the official health care
8 department and professional associations. The coordinators issued periodic reports with
9 preliminary results to the institutions, local newspapers and social media. The final results will
10 be disseminated by institutional platforms.

11 *Participants*

12 We recruited HCW attending suspected or confirmed COVID-19 patients from May 21, 2020
13 to February 10, 2021. Recruitment started with five "seeds" for each category, non-randomly
14 selected from the target population. We asked each participant to identify five other members
15 of the same professional network category, providing their names and mobile phone numbers
16 to the fieldworkers. The process continued until a suitable sample size was reached. This study
17 did not offer any incentive.

18 We calculated a sample size of 1,100 HCW, considering a 95% confidence level (CI) to
19 estimate a 40% prevalence of infections with a 5% error and a design effect of three.

20 The network size of each HCW was measured by the final answer to the following questions:

21 1) "How many colleagues do you know, who also know you by name, work in the Recife
22 metropolitan region and are assisting COVID-19 patients?"; 2) "How many of those colleagues
23 have been in professional contact with you in the last two weeks?," and 3) "How many of them
24 are close to you and you would invite to participate in this study?."

25 *Variables*

26 We applied the WHO questionnaire developed as an operational tool to determine the risk of
27 COVID-19 virus infection among HCW exposed to a COVID-19 patient in a health care
28 facility. This questionnaire was developed as an interim guidance for risk assessment by the
29 WHO personnel/ experts in response to COVID-19 pandemic in the early months (March
30 2020).²³ The variables were:

- 1 (1) Age, sex, and professional category;
- 2 (2) Self-reported comorbidities (diabetes mellitus, hypertension, overweight or obesity,
3 cardiopathy, nephropathy, and others);
- 4 (3) Healthcare attending—public or private sector, outpatient, emergency rooms and intensive
5 care units (ICU); number of healthcare facilities.
- 6 (4) Adherence to infection prevention and control (IPC). We checked for gloves, medical
7 masks, face shields, goggles or protective glasses, and waterproof aprons. These variables were
8 grouped as: i) always as recommended (more than 95% of the time); ii) most of the time
9 (ranging from 50% to 95%); iii) occasionally (1-49%); iv) never; v) unavailable.
- 10 (5) Adherence to IPC when performing aerosol-generating procedures (AGPs) using the
11 abovementioned grading criteria. In this section, we added the N95 respirator. The variables
12 related to adherence to IPC (items 4 and 5) were grouped as always versus not always.
- 13 (6) Accidents with biological material—I) during the period of healthcare interaction and II) if
14 there was an accident with biological fluid or respiratory secretions, which type it was (splash
15 in the mucous membrane of eyes, mouth, or nose; non-intact skin; and puncture-sharp
16 accident).

17 18 *Outcome measure*

19 The criterion to assess SARS-CoV-2 infection among HCW was a positive self-reported PCR
20 test. Serologic tests were not considered as diagnostic criteria.

21 22 *Data collection*

23 Data were collected using a web-based software platform by FITec (Recife, Pernambuco,
24 Brazil). The HCW answered the questionnaire by accessing a link that could be opened on a
25 smartphone or a computer browser.

26 Providing electronic informed consent was mandatory to participate and access the
27 questionnaire. The project was approved by the National Ethics Committee (CONEP; CAAE:
28 30629220.8.0000.0008).

29 30 *Data analysis*

31 Participants were weighted by the size of each category, provided by each professional board,
32 and by the inverse of the size of their professional network, based on the following question:
33 “How many of these colleagues are close to you and would you invite to participate in this
34 study?” To avoid the influence of extreme network sizes on the weight of each professional,

1 we limited the network size to 3 to 150 for outlier correction.²⁴ For missing data—representing
2 around 8% of the total—we used available information from the other two questions related to
3 network size, and when necessary, we applied the overall mean of the stratum. The seeds
4 (primary) were used to define the cluster of the study.

5 Categorical variables are presented as percentages and 95% CIs by HCW category and overall
6 frequencies adjusted for the design. The chi-squared test was used for comparison between
7 groups. We calculated the means, medians, and 95% CIs for continuous variables. Bivariate
8 analysis was performed to assess the association between potential risk factors and RT-PCR
9 positivity. Variables associated with the outcome at $p < 0.20$ were included in the multivariate
10 model. In the final model, we considered variables at the $p < 0.10$ level statistically significant.
11 All statistical analyses were performed using Stata, version 15.0 (StataCorp LLC, College
12 Station, TX, USA).

14 *Role of the funding source*

15 The funding source had no involvement in any stage of the project.

17 **Results**

18 *Participants*

19 We recruited 2,474 health care workers and 1,525 of them were included in the analysis, in the
20 following categories: 527 physicians, 471 registered nurses, 263 nursing assistants, and 264
21 physical therapists. The exclusions were: 638 HCW who did not sign the informed consent;
22 238 that refused to participate and 28 did not complete the questionnaires. Figure 1 illustrates
23 the recruitment chain for each category.

25 *Descriptive data*

26 Overall, women represented 81.1% (95% CI: 77.8% – 84.1%) of the sample after adjustment
27 to the reference population and for the study design (Table 1). Women also predominated in
28 all professional categories, with the lowest percentage among physicians (63.4%; 95% CI:
29 58.6% – 67.9%) and the highest among nurses (86.7%; 95% CI: 82.7% – 89.9%) and nursing
30 assistants (85.5%; 95% CI: 79.8% – 89.7%). The age distribution was as follows: 32.7% (95%
31 CI: 28.8% – 36.9%) and 35.6% (95% CI: 31.5% – 40.0%) were <30 and 30–39 years old,
32 respectively. Only 0.1% of the participants were aged ≥ 60 years. Physicians and physical
33 therapists were the youngest groups, comprising 56.6% (95% CI: 51.7% – 61.4%) and 45.1%
34 (95% CI: 38.3% – 52.1%), respectively, of those 20–29 years old. Comorbidities affected

1 30.1% (95% IC: 26.1% – 34.3%) of the studied population. Overweight/obesity (12.6%; 95%
2 CI: 9.9% – 15.9%) and hypertension (11.9%; 95% CI: 9.2% – 15.1%) were the most prevalent
3 comorbidities among nursing assistants and nurses than among the other categories. In total,
4 71.4% (95% CI: 67.6% – 74.9%) of HCW attended COVID-19 cases exclusively in the public
5 sector, including hospitals, emergency units, ambulance services, and primary care units. Most
6 HCW (73.5%; 95% CI: 69.2% – 77.3%) worked either in emergency rooms or ICU. Notably,
7 55.8% (95% CI: 51.0% – 60.6%) of the physicians and 37.8% (95% CI: 31.3% – 44.8%) of the
8 physical therapists indicated working in three or more institutions during the pandemic (Table
9 1).

10 Overall, 78.0% (95% CI: 74.2% – 81.3%) of the participants received training on the use of
11 PPE. Physical therapists (87.0%; 95% CI: 81.6% – 91.0%) and nursing assistants (81.1%; 95%
12 CI: 74.8% – 86.1%) received a higher and similar frequency of training compared to the other
13 categories. Almost half of the HCW (47.7%) reported a shortage of PPE items during the
14 COVID-19 pandemic. Regarding wearing PPE in routine activities, the overall frequencies
15 varied widely for each item: 90.1% (95% CI: 87.7% – 92.0%) for single-use gloves to 29.9%
16 (95% CI: 25.9% – 34.2%) for face shields. Most HCW (82.2%; 95% CI: 78.4% – 85.5%)
17 reported performing AGPs on COVID-19 patients. Almost all participants reported having
18 always used single-use gloves (98.4%; 95% CI: 96.4% – 99.3%) and N95 respirators (86.4%;
19 95% CI: 82.5% – 89.5%) during AGPs. The N95/PPF2 respirator was reused for more than
20 seven days by approximately 28.3% (95% CI: 24.7% – 32.1%) of the participants, with highest
21 and lowest frequencies reported by physicians (49.3%; 95% CI: 44.4% – 54.2%) and nursing
22 assistants (20.6%; 95% CI: 15.4% – 27.0%), respectively. Overall, 63.7% (95% CI: 57.8% –
23 69.2%) of the HCW reported always wearing all PPE items as recommended by the WHO. The
24 self-perception of SARS-CoV-2 risk of infection in the previous 15 days varied: 33.4% for
25 “performing a procedure on a patient with COVID-19;” 17.7% for “sharing the break room
26 with their colleagues;” 16% for the “reuse of N95 respirators;” 10.6% for the “use of poor
27 quality PPE;” 10.2% during “doffing;” 9.6% for “working with colleagues with COVID-19
28 symptoms;” 1.9% for “lack of PPE in the service;” and 0.5% for “donning PPE.” HCW reported
29 186 episodes of exposure to biological fluids/respiratory secretions during healthcare
30 interaction with COVID-19 patients. Accidents were more frequent among physicians (13.9%;
31 95% CI: 11.0% – 17.4%) and less frequent among physical therapists (7.6%; 95% CI: 4.9% –
32 11.7%) (Table 2).

33 The frequency of COVID-19 testing varied from 41.2% for physical therapists to 51.1% for
34 physicians. Individuals with any comorbidity were more likely to get tested (56.8%) than those

1 without comorbidities ($p<0.001$). HCW who worked in three or more health services were also
2 more likely to get tested (54.9%) than those who worked in only one health service (42.1%)
3 ($p<0.001$). There was no statistical difference in the likelihood of testing, according to sex, age
4 group (<30 versus ≥ 30 years old), work setting (outpatients, inpatients, and emergency rooms
5 and ICU), self-perception of risk (no risk to high risk of exposure), reported accidents with
6 biological fluid/respiratory secretion, and when performing AGPs (Supplementary Table 1).
7 For the tested HCW, mostly symptomatic, the overall self-reported SARS-CoV-2 infection was
8 61.8% (95% CI: 55.7%-67.5%) compared with 14.9% (CI: 4.9%-37.5%) among asymptomatic,
9 after adjustment for random cluster effects, weighted by network and population size. The
10 highest infection positivity was among nursing assistants (70.0%; 95%CI: 59.0%-79.1%),
11 followed by physicians (55.0%; 95%CI: 47.5%-62.3%), physical therapists (54.7%; 95%CI:
12 43.1%-65.7%), and nurses (48.1%; 95%CI: 40.3%-56.0%), adjusted for random cluster effects
13 (Figure 2). RT-PCR screening was performed mainly among symptomatic cases in all
14 categories, ranging from 81.8% to 91.8% for physicians and nursing assistants, respectively.
15 Almost half of the HCW (47.8%) reported taking sick leave due to COVID-19, with a similar
16 trend among the other categories ($p=0.159$). The median length of health leave was 14 days for
17 all professional categories, reflecting a standard procedure. Of 399 symptomatic SARS-CoV-
18 2 infected HCW, 10% ($n=41$) were hospitalized.
19 In a bivariate analysis, the nursing assistant category was positively associated with infection
20 (odds ratio [OR]=2.77; 95% CI: 1.64–4.67, $p<0.001$) compared to nurses. Reporting any
21 accident involving body fluid/respiratory secretion was associated with infection (OR=2.67;
22 95% CI: 1.22–5.82, $p<0.014$). When considering each accident, splashes in the eyes were a
23 stronger predictor of infection (OR=4.07; 95% CI: 1.14–14.55, $p<0.031$). During routine
24 assistance of COVID-19 patients, not always wearing the complete set of recommended PPE
25 items was associated with infection (OR=2.14; 95% CI: 1.18–3.88, $p=0.013$) when compared
26 to always using PPE. Not always using the complete recommended PPE items during AGPs
27 was also associated with infection (OR=1.68; 95% CI: 0.97–2.92, $p=0.063$) when compared
28 with always using PPE (Supplementary Table 2).
29 In the final multivariate logistic regression model, the following were risk factors for infection:
30 being a nursing assistant (OR adjusted=2.56; 95% CI: 1.42–4.61, $p=0.002$), not always having
31 used PPE during care of patients with COVID-19 (OR adjusted=2.15; 95% CI: 1.02–4.53,
32 $p=0.044$), and having suffered a splash to the eyes (OR adjusted=3.37; 95% CI: 1.10–10.34,
33 $p=0.034$) (Table 3).
34

1 Discussion

2 The current study showed substantial heterogeneity in demographic and self-referred
3 comorbidities between HCW categories during the COVID-19 pandemic. Of note, physicians
4 and physical therapists at the frontline were younger and mainly worked in the Intensive Care
5 Units and emergency rooms when compared with nurses. This reflects the expansion of the
6 healthcare workforce with the inclusion of younger physicians and physical therapists, possibly
7 inexperienced professionals, forcibly driven to work as frontliners in a high-risk environment.
8 Nurses and nursing assistants were older and reported more comorbidities, particularly
9 hypertension and overweight/obesity. According to the accumulated evidence, the public
10 health strategy was to prevent exposure among older age groups and/or individuals with
11 comorbidities, as older age and comorbidities are strong prognostic factors for hospitalization
12 and death.²⁵

13 To our knowledge, our study depicted one of the highest frequencies of SARS-CoV-2
14 infections among HCW, being nursing assistant the most vulnerable category. In consonant
15 with this finding, nursing assistant also had the highest prevalence of infection comparing with
16 the other staff in a university hospital in the southeast of Brazil.¹⁶ One likely explanation is that
17 most of the participants tested were symptomatic, reflecting the policy of making RT-PCR tests
18 for COVID-19 diagnosis available to frontline HCW. Thus far, there has been no mass RT-
19 PCR testing strategy for the Brazilian population despite WHO recommendations.²⁶
20 Worldwide, the prevalence closest to that of our study was 55%, by RT-PCR among 177
21 symptomatic medical residents in New York City at the beginning of the COVID-19
22 pandemic.²⁷ In Southeast Brazil, a high prevalence of SARS-CoV-2 infection (42%) tested by
23 RT-PCR was found among symptomatic HCW at a teaching hospital in Sao Paulo, from March
24 to May 2020.¹⁵ Another study found a prevalence of 14% (701 out of 4,987) using RT-PCR in
25 a group composed of mainly symptomatic HCW, at a hospital in the south of Brazil from April
26 to June 2020.¹⁴ This variation might be attributable to the dynamics of the pandemic in different
27 regions of the country, the availability/quality of PPE, and training in different healthcare
28 settings.

29 Seroprevalence studies cannot be directly compared to our findings, the frequencies of SARS-
30 CoV-2 infection among HCW in São Paulo city ranged from 5.5% (IgG ELISA) in a private
31 hospital to 14% (IgG/IgM antibody, WONDFO™) in a large public hospital in 2020.^{28,29} Both
32 hospital settings stated that they adopted high-quality hospital infection control and provided
33 complete PPE in the early stages of the COVID-19 pandemic. This may reflect especially high-

1
2
3 1 quality healthcare facilities in more developed regions of the country and the rates reported
4 were similar to those reported in another meta-analysis of seroprevalence studies.³⁰
5 2
6 3 In our setting, critical aspects for the high risk of SARS-CoV-2 infection included shortage of
7 PPE items reported by approximately half the HCW. Moreover, 22% of HCW reported not
8 been trained on PPE use. The lack of preparedness of the health workforce to respond to the
9 COVID-19 pandemic was not only encountered by low- and medium-income countries like
10 Brazil but also in high-income countries at the beginning of the pandemic.³¹ At the individual
11 level, one-fourth of the HCW reported that PPE was not always used according to the WHO
12 recommendations.²⁶ When performing AGPs, the nursing staff had the highest frequency (over
13 35%) of not fully adhering to complete PPE.³² However, not always used the recommended
14 PPE during performance of AGPs was not associated with PCR positive report in our analysis.
15 This finding is in line with a recent study questioning the concept of aerosol-generating
16 procedures for risk-stratifying patients since most procedures considered as AGPs do not
17 meaningfully increase respiratory aerosols.³³ In the current study, not using the recommended
18 PPE during routine attendance of COVID-19 cases caused a 2.2-fold increased risk of a SARS-
19 CoV-2 positive RT-PCR test result. Accidents with biological fluids occurred in all categories,
20 however, they were most frequently reported among physicians, the youngest, and perhaps the
21 group with the least experience working in critical conditions. Reporting an accident with
22 biological fluids, such as a splash in the eye, was positively associated with infection in the
23 final multivariable model. Although it is uncertain whether viruses occasionally present in
24 biofluids are infectious, these fluids should be considered potentially infectious.³⁴ Moreover,
25 the eye has been considered a possible route of SARS-CoV-2 entry through drainage via the
26 nasolacrimal duct to the upper respiratory tract.³⁵ These accidents with biological fluids should
27 be further investigated in other studies, as recommended by the WHO guidelines.²³ The
28 prevalence among HCW in the current study was at least 20-fold higher when compared to the
29 3.2% seroprevalence in a population-based survey using SARS-CoV-2 antibody rapid tests
30 conducted during the first wave of the pandemic in the same region.³⁶ Therefore, there is strong
31 evidence that HCW are at a high risk of SARS-CoV-2 infection in low- and medium-income
32 settings, such as Northeast Brazil.
33 To the best of our knowledge, this is the largest South American study of HCW during the
34 COVID-19 pandemic, with the inclusion of the four main healthcare professionals in the public
and private sectors and multiple levels of health services. Previous investigations conducted in
Brazil were mainly restricted to one hospital setting and did not apply the WHO
questionnaire.²³

1 The advantage of using respondent-driven sampling technique was that it allowed the inclusion
2 of HCW from different healthcare settings, including the private and public health services,
3 providing a more comprehensive picture of frontline HCW during the pandemic. Furthermore,
4 as HCW worked in more than one health service and/or in newly implemented “field
5 hospitals/units,” this strategy allowed us to capture the full extent of characteristics of the
6 workforce and the risk factors for infection. Another advantage of applying an online
7 questionnaire was to avoid face-to-face interviews during the lockdown and/or social
8 distancing restrictions, reduce errors in data transcription, and obtain timely results.

9 This study has some limitations. Respondent-driven sampling study are traditionally designed
10 for “hard-to-reach population” in a lack of a sampling frame.¹⁷ In the study setting, the
11 population of health professionals at frontline although not a hard-to-reach population was
12 made more difficult to access due a lack of sampling frame and the enormous time burden on
13 the staff. Therefore, we did not access this population in a probabilistic sampling, but via the
14 chain referral samples (social network), which potentially induce selection bias. Despite of this
15 limitation, inherent of RDS technique, the study had several waves of recruitment chains,
16 achieving a large and heterogeneous sample. In addition, we estimated the weighted prevalence
17 of SARS-CoV-2 infection considering the social network size to minimize the potential
18 selection bias introduced by the study design. Another limitation is that the study was not
19 designed as genomic surveillance or contact tracing to distinguish the setting of the
20 transmission. However, the participants were frontliners attending suspected or confirmed
21 Covid-19 patients. In fact, only 15.2% of them referred to have had contact with COVID-19
22 cases simultaneously in health-care facilities and at the household (data not shown). In our
23 analysis the risk factors associated with infection were higher among nursing assistant; HCW
24 not using all PPE items as recommended to professionals reporting an accident during their
25 activities. It is likely that the high frequency of infection among frontline HCW was
26 presumably healthcare associated infections in line with our findings, with the scenario of
27 shortage of PPE and the high health care pressure during the first pandemic wave. Nevertheless,
28 the source of SARS-CoV-2 infection could not be ascertained in this study.

29 There was an imbalance in recruitment among the HCW categories; physicians and nurses were
30 more rapidly enrolled by RDS than nursing assistants. One possible explanation is that
31 physicians and nurses seem to understand research methodology better and/or to have either
32 better smartphones or data plans required to answer the approximately 15-minute online
33 questionnaire. Physicians and nurses were also a more vocal category early in the pandemic,
34 publicizing the constraints/pressure of the workplace. Conversely, nursing assistants, as routine

1 healthcare assistants, spend more time providing direct patient care and have low wages. They
2 could also be less confident/willing to participate due to work overload or unfavourable socio-
3 economic conditions when compared to the other categories that require university degrees.
4 Additionally, disclosure of the work environment concerning PPE and infection control
5 prevention may be problematic for nursing assistants whose jobs are less stable and more prone
6 to replacement in our setting. Accidents involving biological fluids should be further
7 investigated in other studies to validate this finding.

8 The study shows the high frequency of SARS-CoV2 infection among HCW presumably due
9 to workplace exposures. In our setting nursing assistants comprised the most vulnerable
10 category. Our findings highlight the need for improving health care facility environments,
11 specific training and supervision to cope with public health emergencies.

13 **Data availability statement**

14 Proposals for the dataset (de-identified participant data, data dictionary) should be directed to
15 the corresponding author: turchicm@gmail.com. To gain access, data requestors will need to
16 present their plan of analysis and sign a data access agreement.

18 **Ethics statements**

19 All participants provided electronic informed consent in the web-based platform. HCW could
20 only access the questionnaire after giving the on-line Informed Consent Form (ICF). In our
21 study we applied the ICF in agreement with both: the requirements of the National Ethics
22 Committee (CONEP, 30629220.8.0000.0008); and with the current protocols for electronic
23 survey.

25 **Acknowledgments**

26 We thank HCW for their participation. We acknowledge the Institute of Health Technology
27 Assessment and MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020 for support. The
28 following researchers received scholarship (CNPq-Pq): 308974/2018-2 to CMTM,
29 309722/2017-9 to RAAX, 301905/2017-7 to MFPMA, no. 30735/2018-1 to CB and
30 303661/2017-8 to WVS. CRP received scholarship from CNPq, EV-1 no. 315877/2020-0. We
31 thank all participants for their important contribution in this project.

33 **Author contributions**

1 MFPMA, WVS, CMTM, RAAX, DBMF, TB, CK, and LRFSK contributed to the study
2 concept and design. CB, MNX, CNLM, GDMA, CBS, CAM, NTSF, JMG, CLFN, and JMVB
3 contributed to the acquisition of data. MFPMA, URM, WVS, CLS, PRBSJ, and CRP
4 contributed to the data analysis and creation of tables and figures. MFPMA, WVS, CMTM,
5 RAAX, DMF, TVBA, MASMV, LNGCL, CB, and LNC contributed to data interpretation.
6 MFPMA, WVS, URM have verified the underlying data. CMTM, MFPMA, WVS, and CRP
7 drafted the initial manuscript and all other coauthors contributed scientific inputs equally
8 towards the interpretation of the findings and the final draft of the manuscript. All authors
9 confirm that they had full access to all the data in the study and accept responsibility to submit
10 for publication.

12 Funding

13 This investigation was funded by Health Technology Assessment Institute (IATS) and by
14 MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020. The funding agency had no role in
15 study design; in the collection, analysis, and interpretation of data; in the writing of the
16 report; and in the decision to submit the paper for publication.

18 Declaration of interests

19 We declare no competing interests.

21 References

- 22 1 Fauci AS, Lane HC, Redfield RR. Covid-19—navigating the uncharted. *N Engl J*
23 *Med* 2020; **382**: 1268–9. doi:10.1056/NEJMe2002387.
- 24 2 Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's box—another novel
25 coronavirus. *N Engl J Med* 2020; **382**: 1293–5. doi:10.1056/NEJMp2002106.
- 26 3 World Health Organization. [https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)
27 [coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019) [Accessed January 28 , 2021].
- 28 4 Zeiser FA, Donida B, Costa CA et al. First and second COVID-19 waves in Brazil: A
29 cross-sectional study of patients' characteristics related to hospitalization and in-hospital
30 mortality. *The Lancet Regional Health - Americas* 2022; **6**: 100107. doi:
31 10.1016/j.lana.2021.100107
- 32 5 The Lancet. COVID-19 in Brazil: “So what?”. *Lancet* 2020; **395**: 1461.
33 doi:10.1016/S0140-6736(20)31095-3

- 1
2
3 1 6 Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-
4 care workers and the general community: a prospective cohort study. *Lancet Public*
5 *Health* 2020; **5**: 475–83. doi:10.1101/2020.04.29.20084111.
6
7 3
8 4 7 Dzinamarira T, Murewanhema G, Mhango M et al. COVID-19 Prevalence among
9 Healthcare Workers. A Systematic Review and Meta-Analysis. *Int. J. Environ. Res.*
10 *Public Health* 2022; **19**: 146. doi: 10.3390/ijerph19010146.
11
12 6
13 7 8 Thompson HA Mousa A, Digheet A al, Severe Acute Respiratory Coronavirus 2
14 (SARS-CoV-2) Setting Specific Transmission rates : A systematic Review and Meta-
15 Analysis. *Clin Infect Dis* 2021; **743**: e754-64. doi: 10.1093/cid/ciab100.
16
17 9
18 10 9 Pan American Health Organization/World Health Organization. Epidemiological alert:
19 COVID-19 among health workers. August 31, 2020
20
21
22 12 [https://www.paho.org/en/documents/epidemiological-alert-covid-19-among-health-](https://www.paho.org/en/documents/epidemiological-alert-covid-19-among-health-workers-31-august-2020)
23 [workers-31-august-2020](https://www.paho.org/en/documents/epidemiological-alert-covid-19-among-health-workers-31-august-2020) [Accessed May 8, 2021].
24
25 13
26 14 10 Antonio-Villa NE, Bello-Chavolla OY, Vargas-Vázquez A, et al. Assessing the burden
27 of coronavirus disease 2019 (COVID-19) among healthcare workers in Mexico City: a
28 data-driven call to action. *Clin Infect Dis* 2021; **73**: e191–8. doi:10.1093/cid/ciaa1487.
29
30 16
31 17 11 Martin-Delgado J, Viteri E, Mula A, et al. Availability of personal protective
32 equipment and diagnostic and treatment facilities for healthcare workers involved in
33 COVID-19 care: a cross-sectional study in Brazil, Colombia, and Ecuador. *PLoS*
34 *One* 2020; **15**: e0242185. doi:10.1371/journal.pone.0242185.
35
36 20
37 21 12 Cotrin P, Moura W, Gambardela-Tkacz CM, et al. Healthcare Workers in Brazil during
38 the COVID-19 Pandemic: A Cross Sectional online survey. *Inquiry* 2020; **57**:
39
40 22
41 23 46958020963711. doi: 10.1177/0046958020963711
42
43 24 13 Vedovato TG, Andrade CB, Santos DL, et al Health workers and COVID-19: flailing
44 working conditions? *Revista Brasileira de Saúde Ocupacional* 2021, **46**: e1. doi:
45
46 25 10.1590/2317-6369000028520.
47
48 27 14 Schmidt Fernandes F, de Castro Cardoso Toniasso S, Castelo Branco Leitune J, et al.
49 COVID-19 among healthcare workers in a Southern Brazilian hospital and evaluation
50 of a diagnostic strategy based on the RT-PCR test and retest for Sars-CoV-2. *Eur Rev*
51 *Med Pharmacol Sci* 2021; **25**: 3365–74. doi:10.26355/eurrev_202104_25748.
52
53 30
54 31 15 Buonafine CP, Paiatto BNM, Leal FB, et al. High prevalence of SARS-CoV-2
55 infection among symptomatic healthcare workers in a large university tertiary hospital
56 in São Paulo, Brazil. *BMC Infect Dis* 2020; **20**: 917. doi:10.1186/s12879-020-05662-8.
57
58 33
59
60

- 1
2
3 1 16 Faíco-Filho KS, Carvalho JMA, Conte DD et al. COVID-19 in health care workers in a
4 university hospital during the quarantine in São Paulo city. *The Brazilian Journal of*
5 *Infectious Diseases* 2020; **24**: 462-465. doi:10.1016/j.bjid.2020.08.003
6
7 3
8 4 17 Heckathorn DD. Respondent-Driven Sampling: A New Approach to the Study of
9 Hidden Populations. *Social Problems* 1997; **44**: 174–199. doi: 10.2307/3096941
10
11 5
12 6 18 White RG, Hakim AJ, Salganik MJ, et al. Strengthening the reporting of observational
13 studies in epidemiology for respondent-driven sampling studies: "STROBE-RDS"
14 statement. *J Clin Epidemiol* 2015; **68**: 1463–71. doi:10.1016/j.jclinepi.2015.04.002.
15
16 8
17 9 19 Souza WV, Martelli CMT, Silva APSC, et al. The first hundred days of COVID-19 in
18 Pernambuco State, Brazil: epidemiology in historical context. *Cad Saude Publica* 2020;
19 36: e00228220. doi:10.1590/0102-311X00228220.
20
21 11
22 12 20 Ximenes RAA, Albuquerque MFPM, Martelli CMT, et al. Covid-19 in the Northeast of
23 Brazil: from lockdown to the relaxation of social distancing measures. *Cien Saude*
24 *Colet* 2021; **26**: 1441–56. doi:10.1590/1413-81232021264.39422020.
25
26 14
27 15 21 IBGE. Instituto Brasileiro de Geografia e Estatística. Censo demográfico Brasileiro.
28 2010. <https://www.ibge.gov.br/cidades-e-estados/pe/recife.html> [Accessed July 10,
29 2021].
30
31 17
32 18 22 Castro MC, Massuda A, Almeida G, et al. Brazil's unified health system: the first 30
33 years and prospects for the future. *Lancet* 2019; **394**: 345–56. doi:10.1016/S0140-
34 6736(19)31243-7.
35
36 20
37 21 23 World Health Organization. Health workers exposure risk assessment and management
38 in the context of COVID-19 virus: interim guidance. March 4, 2020.
39 <https://apps.who.int/iris/handle/10665/331340> [accessed April 15, 2020].
40
41 23
42 24 24 Gonçalves B, Perra N, Vespignani A. Modeling users' activity on twitter networks:
43 validation of Dunbar's number. *PLoS One* 2011; **6**: e22656.
44
45 25
46 26
47 26
48 27 25 Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with
49 covid-19 using the ISARIC WHO clinical characterisation protocol: development and
50 validation of the 4C mortality score. *BMJ* 2020; **370**: m3339. doi:10.1136/bmj.m3339.
51
52 29
53 30 26 World Health Organization. Responding to community spread of COVID-19: Interim
54 guidance 7 March 2020. [https://www.who.int/publications/i/item/responding-to-](https://www.who.int/publications/i/item/responding-to-community-spread-of-covid-19)
55 [community-spread-of-covid-19](https://www.who.int/publications/i/item/responding-to-community-spread-of-covid-19) [accessed February 7, 2022].
56
57 32
58
59
60

- 1
2
3 1 27 Breazzano MP, Shen J, Abdelhakim AH, et al. New York City COVID-19 resident
4 physician exposure during exponential phase of pandemic. *J Clin Invest* 2020; **130**:
5 2 4726–33. doi:10.1172/JCI139587.
6 3
7 4 28 Costa SF, Giavina-Bianchi P, Buss L, et al. SARS-CoV-2 seroprevalence and risk
8 5 factors among oligo/asymptomatic healthcare workers (HCW): estimating the impact of
9 6 community transmission. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa1845.
10 7 29 Oliveira MS, Lobo RD, Detta FP, et al. SARS-Cov-2 seroprevalence and risk factors
11 8 among health care workers: Estimating the risk of COVID-19 dedicated units. *Am J*
12 9 *Infect Control* 2021; **49**: 1197–9. doi:10.1016/j.ajic.2021.03.010.
13 10 30 Hossain A, Nasrullah SM, Tasnim Z, Hasan MK, Hasan MM. Seroprevalence of
14 11 SARS-CoV-2 IgG antibodies among health care workers prior to vaccine
15 12 administration in Europe, the USA and East Asia: a systematic review and meta-
16 13 analysis. *E Clinical Medicine* 2021; **33**: 100770. doi:10.1016/j.eclinm.2021.100770.
17 14 31 Paffenholz P, Peine A, Hellmich M, et al. Perception of the 2020 SARS-CoV-2
18 15 pandemic among medical professionals in Germany: results from a nationwide online
19 16 survey. *Emerg Microbes Infect* 2020; **9**: 1590–9. doi:10.1080/22221751.2020.1785951.
20 17 32 Anvisa Nota Técnica Gvims/Ggtes/Anvisa N° 04/2020. Orientações para Serviços de
21 18 Saúde: Medidas de prevenção e controle que devem ser adotadas durante a assistência
22 19 aos casos suspeitos ou confirmados de infecção pelo novo Coronavírus (SARS-CoV-2)
23 20 (updated 08/05/2020).
24 21 33 Klompas M, Milton DK, Rhee C, et al. Current Insights Into Respiratory Virus
25 22 Transmission and Potential Implications for Infection Control Programs. *Annals of*
26 23 *Internal Medicine* 2021; **174**: 1710-1718. doi:10.7326/M21-2780.
27 24 34 Schindler SE, Jicha GA, Nelson PT, et al. Maximizing safety in the conduct of
28 25 Alzheimer’s Disease fluid biomarker research in the era of COVID-19. *J Alzheimer’s*
29 26 *Dis* 2020; **76**: 27–31. doi:10.3233/JAD-20068.
30 27 35 Abobaker A, Alzwi A. The eye: a possible new route of infection in COVID-
31 28 19. *Disaster Med Public Health Prep* 2020; **14**: e25–6. doi:10.1017/dmp.2020.270.
32 29 36 Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil:
33 30 results from two successive nationwide serological household surveys. *Lancet Glob*
34 31 *Health* 2020; **8**: e1390–8. doi:10.1016/S2214-109X(20)30387-9.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic, clinical, and working baseline characteristics of health care workers in the metropolitan region of Recife, Northeast Brazil, 2020 to 2021

	Physicians (n = 527)		Nurses (n = 471)		Nursing assistants (n = 263)		Physical therapists (n = 264)		Total	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Sex										
Female	63.4	58.6–67.9	86.7	82.7–89.9	85.5	79.8–89.7	70.3	63.6–76.3	81.1	77.8–84.1
Male	36.6	32.1–41.4	13.2	10.1–17.3	14.5	10.2–20.2	29.7	23.7–36.4	18.9	15.9–22.2
Age, years										
< 30	56.6	51.7–61.4	25.8	21.6–30.6	26.9	20.8–33.9	45.1	38.3–52.1	32.7	28.8–36.9
30– 39	34.1	29.6–38.9	37.3	32.5–42.4	34.5	28.0–41.6	45.3	38.5–52.4	35.6	31.5–40.0
≥ 40	9.3	6.8–12.6	36.9	32.1–41.9	38.6	32.0–45.7	9.6	6.2–14.4	31.7	27.6–36.0
Any comorbidity										
Any	23.3	19.5–27.6	33.9	29.2–38.8	32.0	25.8–38.9	19.0	14.1–25.1	30.1	26.1–34.3
None	76.7	72.4–80.5	66.1	61.2–70.8	68.0	61–74.2	81.0	74.9–85.9	69.9	65.7–73.8
Diabetes	1.0	0.4–2.6	2.1	1.1–4.1	2.0	0.8–5.1	0.4	0.1–3.1	1.8	0.9–3.4
Hypertension	4.0	2.5–6.4	13.2	10.0–17.1	14.4	10.1–19.9	4.8	2.5–8.9	11.9	9.2–15.1
Overweight/Obesity	7.3	5.3–10.0	11.1	8.2–14.6	14.9	10.6–20.4	8.9	5.6–13.7	12.6	9.9–15.9
Heart disease	0.4	0.1–1.3	1.2	0.5–3.0	0.9	0.2–3.5	0.0	..	0.1	0.3–2.1
Kidney disease	0.0	..	0.2	0.03–1.5	0.1	0.02–1.1	0.8	0.2–3.1	0.2	0.1–0.6
Others comorbidities	13.1	10.1–16.7	14.8	11.6–18.8	9.4	5.9–14.7	6.9	4.2–11.4	10.8	8.4–13.8
Number of workplaces										
< 3	44.2	39.4–49.0	91.8	88.4–94.2	95.2	92.0–97.2	62.2	55.2–68.7	84.2	82.1–86.1
≥ 3	55.8	51.0–60.6	8.2	5.8–11.6	4.8	2.8–8.0	37.8	31.3–44.8	15.8	13.9–17.9
Missing	2		0		1		0		3	
Institution provider										
Private	5.2	3.5–7.8	7.2	4.8–10.5	7.0	4.1–11.5	14.8	10.4–20.5	7.2	5.3–9.8
Public	44.5	39.7–49.3	81.2	76.8–85.0	79.8	73.5–85.0	35.2	28.9–42.2	71.4	67.6–74.9
Both	50.3	45.5–55.2	11.6	8.7–15.4	13.2	9.1–18.9	50.0	43–56.9	21.4	18.4–24.7
Work setting										
Outpatient/Inpatient clinics	12.0	9.1–15.6	41.6	36.6–46.8	27.7	21.6–34.7	11.5	7.6–17.0	26.5	22.7–30.8
ICU/Emergency	88.0	84.4–90.9	58.4	53.2–63.4	72.3	65.3–78.4	88.5	83.0–92.4	73.5	69.2–77.3

Frequency for each professional category: adjusted for cluster random effect and weighted by network size. Total frequency: adjusted for cluster random effect and weighted by network and population size. CI, confidence interval; ICU, intensive care unit

Table 2. Adherence to infection prevention and control during healthcare interactions with COVID-19 patients and accidents with biological materials

	Physicians (n = 527)		Nurses (n = 471)		Nursing assistants (n = 263)		Physical therapists (n = 264)		Total	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Training on PPE use										
Yes	68.9	64.2–73.2	72.3	67.4–76.7	81.1	74.8–86.1	87.0	81.6–91.0	78.0	74.2–81.3
No	31.1	26.8–35.8	27.7	23.3–32.6	18.9	13.9–25.2	13.0	9.0–18.4	22.0	18.7–25.8
Missing	3		0		0		0		3	
While providing routine assistance to patients with COVID-19, have you used these PPE:										
Single Gloves										
Always	74.1	69.6–78.1	84.4	80.3–87.8	95.4	90.9–97.7	96.1	92.1–98.1	90.1	87.7–92.0
Not always	25.9	21.9–30.4	15.6	12.2–19.7	4.6	2.3–9.1	3.9	1.9–7.9	9.9	8.0–12.3
Missing	2		2		0		1		5	
Surgical mask										
Always	45.3	40.6–50.2	58.6	53.5–63.6	51.0	43.8–58.1	36.9	30.3–44.0	50.5	46.0–54.9
Not always	54.7	49.8–59.4	41.4	36.4–46.5	49.0	41.9–56.1	63.1	56.0–69.6	49.5	45.1–53.9
Missing	2		2		0		1		5	
N95 respirator										
Always	64.4	59.6–68.9	57.4	52.3–62.4	66.3	59.1–72.9	87.3	81.6–91.4	65.9	61.4–70.0
Not always	35.6	31.1–40.3	42.6	37.6–47.7	33.7	27.1–40.9	12.7	8.6–18.4	34.1	30.0–38.6
Missing	2		2		0		1		5	
Face shield										
Always	19.6	16.0–23.9	28.8	24.4–33.7	31.6	25.3–38.6	42.4	35.7–49.3	29.9	25.9–34.2
Not always	80.4	76.1–84.0	71.2	66.3–75.6	68.4	61.4–74.7	57.6	50.7–64.3	70.1	65.8–74.1
Missing	2		2		0		1		5	
Goggles/protective glasses										
Always	18.7	15.3–22.7	24.6	20.4–29.3	38.3	31.6–45.4	45.6	38.7 - 52.6	33.2	29.1–37.6
Not always	81.3	77.2–84.7	75.4	70.7–79.5	61.7	54.6–68.4	54.4	47.4–61.3	66.8	62.3–70.9
Missing	2		2		0		1		5	
Disposable gown										

1											
2											
3	Always	48.0	43.3–52.9	50.8	45.6–55.9	63.8	56.6–70.4	67.2	60.3–73.3	59.2	54.8–63.5
4	Not always	52.0	47.1–56.7	49.2	44.1–54.4	36.2	29.5–43.4	32.8	26.7–39.7	40.8	36.5–45.2
5	Missing	2		2		0		1		5	
6	Waterproof apron										
7	Always	30.5	26.2–35.2	38.6	33.7–43.7	48.9	41.6–56.3	62.6	55.3–69.4	44.9	40.5–49.5
8	Not always	69.5	64.8–73.8	61.4	56.3–66.3	51.1	43.7–58.4	37.4	30.6–44.7	55.1	50.5–59.5
9	Missing	14		11		11		18		54	
10											
11	During provision of routine										
12	assistance to COVID-19										
13	patients, did you wear all PPE										
14	items as recommended by the										
15	WHO?										
16	Always	89.6	86.2–92.3	79.2	74.7–83.1	70.0	63.1–76.1	69.0	62.2–75.1	74.7	70.5–78.5
17	Not always	10.4	7.7–13.8	20.8	16.9–25.3	30.0	23.9–36.9	31.0	24.9–37.8	25.3	21.5–29.5
18	Missing	2		2		0		1		5	
19	Participated in AGP*										
20	Yes	79.6	75.3–83.2	75.6	70.8–79.8	83.4	77–88.3	95.8	91.7–97.8	82.2	78.4–85.5
21	No	20.4	16.8–24.7	24.4	20.2–29.2	16.6	11.7 - 23	4.2	2.1–8.3	17.8	14.5–21.6
22	Missing	1		1		1		2		5	
23											
24	While participating in AGPs,										
25	have you used:										
26	Single Gloves										
27	Always	97.8	95.5–98.9	97.7	95.1–99	98.5	94.2–99.6	99.7	98.1–99.9	98.4	96.4–99.3
28	Not always	2.2	1.1–4.5	2.3	1–4.9	1.5	0.4–5.8	0.3	0.04–1.9	1.6	0.7–3.6
29	Missing	0		0		0		1		1	
30	Surgical mask										
31	Always	61.5	56.2–66.6	49.9	44.1–55.7	46.5	38.9–54.3	60.2	52.9–67.1	50.5	45.6–55.3
32	Not always	38.5	33.4–43.8	50.1	44.3–55.9	53.5	45.7–61.1	39.8	32.9–47.1	49.5	44.7–54.4
33	Missing	0		0		0		1		1	
34	N95 respirator										
35	Always	92.4	89–94.9	85.0	80.3–88.8	84.2	77.8–89.1	93.3	88.2–96.3	86.4	82.5–89.5
36	Not always	7.6	3.1–11	15.0	11.2–19.7	15.7	10.9–22.2	6.7	3.7–11.8	13.6	10.5–17.5
37	Missing	0		0		0		1		1	
38	Face shield										
39											
40											
41											
42											
43											
44											
45											
46											

1											
2											
3	Always	51.6	46.2–56.9	48.3	42.6–54.1	48.0	40.3–55.7	41.4	34.5–48.6	48.1	43.2–53.0
4	Not always	48.4	43.1–53.8	51.7	45.8–57.4	52.0	44.2–59.7	58.6	51.4–65.5	51.9	47.0–56.8
5	Missing	0		0		0		1		1	
6											
7	Goggles/Protective glasses										
8	Always	62.5	57.1–67.6	59.3	53.5–64.9	51.4	43.6–59.1	47.1	40–54.3	54.0	49.1–58.9
9	Not always	37.5	32.4–42.8	40.7	35.1–46.5	48.6	40.9–56.4	52.9	45.7 - 60	46.0	41.1–50.9
10	Missing	0		0		0		1		1	
11	Disposable gown										
12	Always	60.3	55.0–65.4	60.1	54.3 - 65.7	64.0	60.3–74.9	68.3	61.3–74.4	65.6	60.8–70.1
13	Not always	39.7	34.6–45.0	39.9	34.3–45.7	32.0	25.1–39.7	31.7	25.6–38.7	34.4	29.9–39.2
14	Missing	0		0		0		1		1	
15	Waterproof apron										
16	Always	55.2	49.7–60.6	60.7	54.8–66.3	62.5	54.4–69.9	74.6	67.4–80.7	61.9	57.0–66.7
17	Not always	44.8	39.4–50.3	39.3	33.7–45.2	37.5	30.1–45.6	25.4	19.3–32.6	38.1	33.3–43.0
18	Missing	9		7		9		17		42	
19											
20	When performing an AGP in										
21	COVID-19 patients, did you										
22	wear all recommended PPE										
23	items as in WHO guidance?										
24	Always	66.0	60.0–71.4	58.0	51.4–64.3	63.8	54.1–72.6	74.7	64.2–82.8	63.7	57.8–69.2
25	Not always	34.0	28.6–40.0	42.0	35.7–48.6	36.2	27.4–45.9	25.3	17.2–35.8	36.3	30.8–42.2
26	Missing	0		0		0		1		1	
27											
28	Duration of N95 respirator use										
29	< 8 days	50.7	45.8–55.6	71.4	66.6–75.8	79.4	73.0–84.6	54.6	47.6–61.5	71.7	67.9–75.3
30	≥ 8 days	49.3	44.4–54.2	28.6	24.2–33.4	20.6	15.4–27.0	45.4	38.5–52.4	28.3	24.7–32.1
31	Missing	9		5		8		4		26	
32	Any accident involving body										
33	fluid/respiratory secretion										
34	Yes	13.9	11–17.4	10.8	7.9–14.5	11.7	7.9–17.1	7.6	4.9–11.7	11.6	9.1–14.8
35	No	86.1	82.6–89	89.2	85.5–92.1	88.3	82.9–92.1	92.4	88.3–95.1	88.4	85.2–90.9
36	Organ involved										
37	Splash in the Mouth	1.9	1.02–3.8	1.9	0.85–4.3	0.2	0.04–1.5	0.7	0.2–3.1	0.8	0.5–1.4
38	Splash on the Skin	2.4	1.4–3.9	3.4	1.9–6.0	1.3	0.5–3.2	3.9	1.9–7.7	2.0	1.3–3.0
39	Splash on the Eyes	2.3	1.4–3.9	3.5	1.9–6.1	2.1	0.8–5.8	2.5	1.2–5.0	2.4	1.4–4.2
40											
41											
42											
43											
44											
45											
46											

Puncture/sharps	8.2	5.9–11.3	3.0	1.7–5.3	8.2	4.9–13.4	0.0	-	6.7	4.6–9.7
Self-perception of risk										
None/Low	21.6	17.9–25.9	24.9	20.7–29.6	21.9	16.3–28.7	17.2	12.5–23.3	22.0	18.5–26.1
Medium/High	78.4	74.1–82.1	75.1	70.3–79.3	78.1	71.3–83.7	82.8	76.7–87.5	78.0	73.8–81.5
Missing	9		2		6		4		21	

Frequency for each professional category: adjusted for cluster random effect and weighted by network size. Total frequency: adjusted for cluster random effect and weighted by network and population size.

AGPs, aerosol-generating procedures; COVID-19, coronavirus disease 2019; CI, confidence interval; ICU, intensive care unit; PPE, personal protective equipment; WHO, World Health Organization

Table 3. Final multivariate model for factors associated with reported positive PCR COVID-19 results

	Odds Ratio	95% CI	<i>P</i> -value
Occupation			
Nurse	1.0
Physical therapist	1.47	0.80–2.72	0.214
Physician	1.20	0.76–1.90	0.426
Nursing assistant	2.56	1.42–4.61	0.002
Splash on the eyes			
No accident	1.0
Yes	3.37	1.10–10.34	0.034
Any accident	1.59	0.51–4.90	0.421
Used all PPE items while assisting patients with COVID-19			
Yes	1.0
No	2.15	1.02–4.53	0.044

Adjusted for cluster random effect and weighted by network and population size

COVID-19, coronavirus disease 2019; CI, confidence interval; PPE, personal protective equipment

1
2
3 **Figure Legends**
4

5 Figure 1. Respondent-driven sampling recruitment chains.
6

7 Figure 2. Frequencies of self-reported SARS-CoV-2 infection by healthcare categories.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. Respondent-driven sampling recruitment chains

338x190mm (170 x 170 DPI)



Supplementary Table 1. Characteristics of the study population according to RT-PCR testing

	RT-PCR testing		P-value
	Yes (%)	No (%)	
Occupation category			0.02
	Physician	269 (51.1)	257 (48.9)
	Registered nurse	224(47.6)	247(52.4)
	Nursing assistant	110 (42.0)	152 (58.0)
	Physical therapist	108(41.2)	154(58.8)
Sex			0.43
	Female	530 (46.2)	618 (53.8)
	Male	181 (48.5)	192 (51.5)
Age group, years			0.15
	< 30	523 (45.7)	622 (54.3)
	≥ 30	188 (50.0)	188 (50.0)
Any comorbidity			< 0.001
	Yes	246 (56.8)	187 (43.2)
	No	465 (42.7)	623 (57.3)
Number of workplaces (hospitals/clinics)			< 0.01
	<3	247 (54.0)	210 (46.0)
	≥3	462 (43.5)	599 (56.5)
Work setting			0.39
	Emerg/ICU	565 (47.3)	629 (52.7)
	Output/Inpatients	146 (44.7)	181 (55.3)
Institution provider			< 0.001
	Private	48 (42.1)	66 (57.9)
	Public	393 (43.0)	522 (57.0)
	Both	270 (54.9)	222 (45.1)
Performed aerosol generating procedure			0.36
	Yes	600 (47.3)	669 (52.7)
	No	110 (44.5)	137 (55.5)
	Missing	1 (20.0)	4 (80.0)
Same N95 respirator, use duration, days			0.023
	≤ 7	458 (49.00)	476 (51.0)
	> 7	243 (43.0)	322 (57.0)
Self-perceived risk			0.85
	None/Low	36 (45.1)	43 (54.9)
	Medium/High	665 (46.7)	760 (53.3)
Accident involving biological fluid/respiratory secretion			0.644
	Yes	84 (45.2)	102 (54.8)
	No	627 (47.0)	708 (53.0)
Sick leave due to COVID-19 symptoms			< 0.001
	Yes	576 (79.7)	147 (20.3)
	No	130 (16.5)	659 (83.5)
Had COVID-19-like symptoms/signs			< 0.001
	Yes	601 (68.2)	280 (31.8)
	No	110 (17.0)	530 (82.8)

COVID-19, coronavirus disease 2019; RT-PCR, reverse transcription polymerase chain reaction

Supplementary Table 2. Potential risk factors for reporting a positive PCR COVID-19 result among front line healthcare professionals

	Odds Ratio	95% CI	P-value
Sex			
Female	1.0
Male	1.35	0.78–2.34	0.288
Age, years	1.03	0.65–1.64	0.889
Occupation			
Nurse	1.0
Physical therapist	1.42	0.88–2.27	0.148
Physician	1.32	0.91–1.91	0.142
Nursing Assistant	2.77	1.64–4.67	<0.001
Any comorbidity	1.19	0.75–1.90	0.454
Number of workplaces			
< 3	1.0
≥ 3	0.83	0.53–1.30	0.428
Institution provider			
Private	1.0
Public	0.92	0.42–2.02	0.844
Both	0.93	0.41–2.10	0.863
Work setting			
Outpatient /Inpatient clinics	1.0
ICU/Emergency	1.54	0.92–2.60	0.102
Training on PPE use	1.06	0.62–1.80	0.829
Any accident involving body fluid/respiratory secretion	2.67	1.22–5.82	0.014
Splash in the mouth			
No accident	1.0
Yes	3.84	0.64–22.95	0.140
Other accident	2.30	0.85–6.23	0.102
Splash on the skin			
No accident	1.0
Yes	1.86	0.54–6.44	0.328
Other accident	2.50	0.80–7.85	0.116
Splash in the eyes			
No accident	1.0
Yes	4.07	1.14–14.55	0.031
Other accident	2.07	0.71–6.08	0.184
Puncture/sharp accident			
No accident	1.0
Yes	2.25	0.51–9.89	0.282
Other accident	2.51	1.10–5.72	0.028
Duration N95 respirator use			
< 8 days
≥ 8 days	0.96	0.59–1.55	0.869
Used All PPE items during AGP#			
Did not Always use	1.68	0.97–2.92	0.063

1
2
3 Used all PPE items while assisting
4 COVID-19 patients

5 Yes	1.0
6 No	2.14	1.18–3.88	0.013
7 Time on the front-line, days	0.997	0.994–1.000	0.042

8 Adjusted for cluster random effect and weighted by network and population size.

9
10 AGP, aerosol-generating procedure; COVID-19, coronavirus disease 2019; CI, confidence interval; ICU,
11 intensive care unit; PPE, personal protective equipment
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Tabela 1. STROBE-RDS Statement Checklist for the manuscript title “High risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach”

Item	#	STROBE-RDS checklist	Main Document
Title and abstract	1	(a) Indicate “respondent-driven sampling” in the title or abstract	Page:1/ Line: 1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page:3/ Line:2-23
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page:5/ Line: 2-34; Page:6/ Line: 1-6
Objectives	3	State specific objectives, including any prespecified hypotheses	Page:6/ Line: 7-9
Methods			
Study design	4	(a) Present key elements of study design early in the article	Page:6/ Line: 13-18
		(b) State why RDS was chosen as the sampling method	Page:6/ Line: 15-17
Setting	5	(a) Describe the setting, locations, and relevant dates, including periods of recruitment and data collection	Page:6/ Line: 23-28 Page:7/ Line: 13-14
		(b) Describe formative research findings used to inform RDS study	Page:6/ Line: 31-34
Participants	6	(a) Give the eligibility criteria and the sources and methods of selection of participants. Describe how participants were trained/instructed to recruit others, number of coupons issued per person, any time limits for referral	Page:7/ Line: 13-18
		(b) Describe methods of seed selection and state number at start of study and number added later	Page:7/ Line: 19-25
		(c) State if there was any variation in study procedures during data collection (e.g., changing numbers of coupons per recruiter, interruptions in sampling, or (stopping recruitment chains)	Page:7/ Line: 17
		(d) Report wording of personal network size question(s)	Page:7/ Line: 21-25
Variables	7	(e) Describe incentives for participation and recruitment	Page:7/ Line: 17-18
		(a) If applicable, clearly define all outcomes, correlates, predictors, potential confounders, effect modifiers, and diagnostic criteria	Page:7/ Line: 28-32 Page:8/ Line: 1-20
		(b) State recruitment relationship was tracked	Page:9/ Line: 22-23
Data sources/ measurement	8	(a) For each variable of interest, give sources of data and details of methods of measurement. Describe comparability of measurement methods if there is more than one group	Page:8/ Line: 31-34 Page:9/ Line: 1-10
		(b) Describe methods to assess eligibility and reduce repeat enrollment (e.g., coupon manager software, biometrics)	Page:8/ Line: 23-25
Bias	9	Describe any efforts to address potential sources of bias	Not done
Study size	10	Explain how the study size was arrived at	Page:7/ Line: 19-20
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page:7/ Line: 28-32 Page:8/ Line: 1-16 Page:8/ Line: 31-34 Page:9/ Line: 1-10
		(a) Describe all statistical methods, including those to account for sampling strategy (e.g., the estimator used) and, if applicable, those used to control for confounding	Page:8/ Line: 31-34 Page:9/ Line: 1-10
Statistical methods	12	(b) State data analysis software, version number, and specific analysis settings used	Page:9/ Line: 11-12
		(c) Describe any methods used to examine subgroups and interactions	Not applicable
		(d) Explain how missing data were addressed	Page: 9/ Line: 1-3
		(e) Describe any sensitivity analyses	Not done
		(f) Report any criteria used to support statements on whether estimator conditions or assumptions were appropriate	Not done
		(g) Explain how seeds were handled in analysis	Page:9/ Line: 3-4
		(g) Explain how seeds were handled in analysis	Page:9/ Line: 3-4
Results			
Participants	13	(a) Report the numbers of individuals at each stage of the study, for example, numbers potentially eligible,	Page:9/ Line: 19-23

		examined for eligibility, confirmed eligible, included in the study, and analyzed	
		(b) Give reasons for nonparticipation at each stage (e.g., not eligible, does not consent, decline to recruit others)	Page:9/ Line: 21-22
		(c) Consider use of a flow diagram	Not included as Flowchart due to limited number of Figures of the Journal
		(d) Report number of coupons issued and returned	Not applicable
		(e) Report number of recruits by seed and number of RDS recruitment waves for each seed. Consider showing graph of entire recruitment network	Page:9/ Line: 22-23 Figure 1
		(f) Report recruitment challenges (e.g., commercial exchange of coupons, imposters, duplicate recruits) and how addressed	Not Done
		(g) Consider reporting estimated design effect for outcomes of interest	Page:11/ Line:7-13
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and, if applicable, information on correlates and potential confounders. Report unweighted sample size and percentages, estimated population proportions or means with estimated precision (e.g., 95% confidence interval)	Page:9/ Line: 26-34 Page:10/ Line: 1-32
		(b) Indicate the number of participants with missing data for each variable of interest	Page: 20-24
Outcome data	15	If applicable, report number of outcome events or summary measures	Page:11/ Line: 7-13
Main results	16	(a) Give unadjusted and study design adjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included	Page:11/ Line: 19-33
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If adjustment of primary outcome leads to marked changes, report information on factors influencing the adjustments (e.g., personal network sizes, recruitment patterns by group, key confounders)	The adjustment only modified slightly not affecting the general results
Other analyses	17	Report other analyses done for example, analyses of subgroups and interactions, sensitivity analyses, different RDS estimators and definitions of personal network size	All analyses were reported
Discussion			
Key results	18	Summarize key results with reference to study objectives	Page:12/ Line: 2-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page:14/ Line: 9-34 Page:15/ Line: 1-7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page:12/ Line: 14-33 Page:13/ Line: 1-34
Generalizability	21	Discuss the generalizability (external validity) of the study results	Page:13/ Line:30-34 Page:14/ Line: 1-8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page:16/ Line: 13-16

BMJ Open

Risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-058369.R2
Article Type:	Original research
Date Submitted by the Author:	16-Mar-2022
Complete List of Authors:	<p>Albuquerque, Maria de Fátima; Centro de Pesquisas Aggeu Magalhaes Souza, Wayner; Centro de Pesquisas Aggeu Magalhaes Montarroyos, Ulisses; University of Pernambuco Pereira, Cresio ; Ministry of Health of Brazil Braga, Cynthia ; Centro de Pesquisas Aggeu Magalhaes Velho Barreto de Araújo, Thalia ; Universidade Federal de Pernambuco, Departamento de Medicina Social Arraes de Alencar Ximenes, Ricardo; Federal University of Pernambuco, Department of Tropical Medicine Miranda-Filho, Demócrito de Barros; University of Pernambuco Szwarcwald, Célia; Institute of Scientific Communication and Information and Technological (ICIT), FIOCRUZ Souza-Junior , Paulo Roberto ; Institute of Scientific Communication and Information and Technological (ICIT), FIOCRUZ-RJ Xavier, Morgana ; Centro de Pesquisas Aggeu Magalhaes Morais, Clarice ; Centro de Pesquisas Aggeu Magalhaes Albuquerque, Gabriela ; Centro de Pesquisas Aggeu Magalhaes Bresani-Salvi, Cristiane; Centro de Pesquisas Aggeu Magalhaes Araújo Mariz, Carolline ; Centro de Pesquisas Aggeu Magalhaes Teixeira de Siqueira-Filha, Noemia; University of York, Department of Health Sciences Galindo, Jadson ; Centro de Pesquisas Aggeu Magalhaes França-Neto, Cláudio Luiz; University of Pernambuco Barbosa, Jessyka Mary Vasconcelos; Centro de Pesquisas Aggeu Magalhaes Veras, Maria Amelia ; Faculty of Medical Sciences of Santa Casa de São Paulo Lima, Luana ; Universidade do Estado do Para Cruz, Luciane; Institute of Health Technology Assessment (IATS) Kendall, Carl; Universidade Federal do Ceara; Tulane University School of Public Health and Tropical Medicine Kerr, L; Universidade Federal do Ceara Turchi Martelli, Celina Maria; Centro de Pesquisas Aggeu Magalhaes</p>
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Infectious diseases
Keywords:	COVID-19, Epidemiology < TROPICAL MEDICINE, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **Risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil:**
 2 **a respondent-driven sampling approach**

3
 4 Maria de Fátima Pessoa Militão de Albuquerque¹, PhD, MD, Wayner Vieira de Souza¹, PhD,
 5 Ulisses Ramos Montarroyos², PhD, Cresio Romeu Pereira³, PhD, MD, Cynthia Braga¹, PhD,
 6 MD, Thália Velho Barreto de Araújo⁴, PhD, MD, Ricardo Arraes de Alencar Ximenes^{2,5}, PhD,
 7 MD, Demócrito de Barros Miranda-Filho³, PhD, MD, Célia Landmann Szwarcwald⁶, PhD,
 8 Paulo Roberto Borges de Souza Junior⁶, PhD, Morgana do Nascimento Xavier^{1,7}, PhD, Clarice
 9 Neuenschwander Lins de Moraes¹, PhD, Gabriela Diniz Militao de Albuquerque², Spc, Cristiane
 10 C. Bresani Salvi¹, PhD, MD, Carolline de Araújo Mariz^{1,8}, PhD, Noêmia Teixeira de Siqueira
 11 Filha⁹, PhD, Jadson Mendonça Galindo¹, MSc, Cláudio Luiz de França Neto², BSc, Jessyka
 12 Mary Vasconcelos Barbosa¹, PhD, Maria Amelia de Sousa Mascena Veras¹¹, PhD, MD, Luana
 13 Nepomuceno Gondim Costa Lima¹², PhD, Luciane Nascimento Cruz¹⁰, PhD, MD, Carl
 14 Kendall^{13,14}, PhD, Ligia Regina Franco Sansigolo Kerr¹⁴, PhD, MD, Celina Maria Turchi
 15 Martelli^{1*}, PhD, MD

16
 17 ¹Aggeu Magalhaes Institute (IAM), Oswaldo Cruz Foundation (Fiocruz), Recife, Brazil

18 ²University of Pernambuco, Recife, Brazil

19 ³Ministry of Health of Brazil, São Paulo, Brazil

20 ⁴Department of Social Medicine

21 ⁵Department of Tropical Medicine, Federal University of Pernambuco, Recife, Brazil

22 ⁶Institute of Scientific and Technological Communication and Information (ICIT), Oswaldo
 23 Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil

24 ⁷Department of Biology, Federal University of Pernambuco, Vitória de Santo Antão, Brazil

25 ⁸Olinda Medical School, Olinda, Brazil

26 ⁹Department of Health Sciences, University of York, UK

27 ¹⁰Institute for Health Technology Assessment (IATS), Porto Alegre, Brazil and Hospital, Porto
 28 Alegre, Brazil

29 ¹¹Faculty of Medical Sciences of Santa Casa de São Paulo, São Paulo, Brazil

30 ¹²State University of Pará, Belém, Brazil

31 ¹³Department of Social, Behavioral and Population Sciences and Tulane University School of
 32 Public Health and Tropical Medicine, New Orleans, USA

33 ¹⁴Federal University of Ceará, Fortaleza, Brazil

34

1
2
3 1 **Corresponding Author:** Celina Maria Turchi Martelli, PhD
4
5 2 Aggeu Magalhaes Institute (IAM), Oswaldo Cruz Foundation (Fiocruz)
6
7 3 Address: Av. Prof. Moraes Rego, S/N – Cidade Universitária – 50670-420 Recife, Brazil
8
9 4 Telephone: +55 11 98685-5734
10
11 5 E-mail: turchicm@gmail.com
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7 **Keywords:** COVID-19; Health care Workers; Brazil.

9 **Word count:** 4.226

1 **Abstract**

2 **Objectives:** We assessed the prevalence of severe acute respiratory syndrome coronavirus
3 (SARS-CoV-2) infection, personal protective equipment (PPE) shortages and occurrence of
4 biological accidents among frontline health care workers (HCW).

5 **Design, setting and participants:** Using respondent driven sampling (RDS), the study
6 recruited distinct categories of HCW attending suspected or confirmed COVID-19 patients
7 from May 2020 to February 2021, in the Recife metropolitan area, Northeast Brazil.

8 **Outcome measures:** The criterion to assess SARS-CoV-2 infection among HCW was a
9 positive self-reported PCR test.

10 **Results:** We analyzed 1,525 HCW: 527 physicians, 471 registered nurses, 263 nursing
11 assistants, and 264 physical therapists. Women predominated in all categories (81.1%; 95%
12 CI: 77.8% - 84.1%). Nurses were older with more comorbidities (hypertension and
13 overweight/obesity) than the other staff. The overall prevalence of SARS-CoV-2 infection was
14 61.8% (95% CI: 55.7%-67.5%) after adjustment for the cluster random effect, weighted by
15 network, and the reference population size. Risk factors for a positive RT-PCR test were being
16 a nursing assistant (ORadjusted: 2.56; 95% CI: 1.42 - 4.61), not always using all recommended
17 PPE while assisting patients with COVID-19 (ORadj: 2.15; 95% CI: 1.02 - 4.53) and reporting
18 a splash of biological fluid/respiratory secretion in the eyes (ORadj: 3.37; 95% CI: 1.10 –
19 10.34).

20 **Conclusions:** This study shows the high frequency of SARS-CoV2 infection among HCW
21 presumably due to workplace exposures. In our setting nursing assistant comprised the most
22 vulnerable category. Our findings highlight the need for improving health care facility
23 environments, specific training and supervision to cope with public health emergencies.

Strengths and limitations of this study

- Respondent-driven sampling (RDS) technique applied in this study allowed the enrolment of the healthcare workers (HCW), a hard-to-reach population regarding their work conditions, during the pandemic.
- The study has a large sample size including the major categories of health care professionals who attended Covid-19 patients in the public, private or newly implemented campaign hospitals.
- Data were collected using a web-based platform, allowing the use of an online questionnaire, also facilitating timely data analysis and less transcript data errors.
- The respondent-driven sampling chains could potentially induce the recruitment of participants with similar characteristics, which was prone to selection bias.
- The source of SARS-CoV-2 infection among HCW could not be ascertained and this is another limitation of the study.

1 Introduction

2 The unprecedented rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-
3 CoV-2) and its potentially severe outcomes have greatly impacted the healthcare system, the
4 global economy, and security.^{1,2} According to the World Health Organization (WHO), the
5 global cumulative number of confirmed coronavirus disease 2019 (COVID-19) cases had
6 reached approximately 364.2 million infections and 5.6 million deaths by January 28, 2022.³
7 In Brazil, approximately 24.5 million COVID-19 cases and 624,413 related deaths were
8 reported within the same period. These figures represent almost 7% and 11% of the global
9 COVID-19 cases and registered deaths, respectively, yet the Brazilian population represents
10 approximately 2.5% of the global population. In Brazil Covid-19 epidemiological data showed
11 a high burden on the hospital system with 678,235 patients admitted with a positive RT-PCR
12 for SARS-CoV-2 between February 2020 and April 2021. Hospital mortality increased from
13 34.8% in the first wave (February 25, 2020 to November 5, 2020) to 39.3% in the second wave
14 (November 6, 2020, to April 30, 2021). The highest in-hospital mortality rates are concentrated
15 in the northeast and north states of the country, which are also the regions with lower Human
16 Development Indexes.⁴ Since the beginning of the pandemic, the federal government has
17 opposed the recommendations for social distancing and individual protection measures while
18 endorsing ineffective pharmaceutical interventions, hampering the epidemic control efforts of
19 the public health authorities at the state and municipal levels.⁵

20 Healthcare workers (HCW) are considered a high-risk group due to the nature of their work.
21 An Anglo-American prospective cohort that included approximately 100,000 HCW showed a
22 3.4-fold higher risk of self-reporting a positive test for COVID-19 among frontline workers
23 compared with the general community using a smartphone application.⁶ A systematic review
24 and meta-analysis covering the period from the inception of the pandemic to August 2021,
25 showed a significant burden of COVID-19 among HCW in several countries, with a pooled
26 prevalence of 11% (95% CI: 7 to 16%) in studies using PCR testing.⁷ Another systematic
27 review and metanalysis suggested that exposure in settings with familiar contact increases
28 SARS-CoV-2 transmission. However, exploring the transmission pattern in health facilities,
29 workplace and social settings has been challenging due to limited data thus far.⁸ These previous
30 reviews did not include studies from Brazil.

31 In the Americas, 569,304 COVID-19 cases, including 2,506 deaths, had been reported among
32 HCW by August 2020.⁹ According to public health surveillance, approximately 32% of Mexico
33 City HCW (n=11,226) had been infected with SARS-CoV-2 by July 2020.¹⁰ Additionally,
34 cross-sectional studies conducted in Brazil, Colombia, and Ecuador revealed lack of personal

1 protective equipment (PPE) among 70% of frontline workers in the early pandemic response.¹¹
2 In line with the previous studies a survey among HCW reported PPE shortages during the first
3 COVID-19 wave in Brazil 2020¹², and the inadequate working conditions were also reported
4 by the media¹³. In Brazil, the prevalence of SARS-CoV-2 infection using RT-PCR in teaching
5 hospitals varied from 15% to 42.4% among symptomatic HCW in the south region and
6 southeast regions, respectively.^{14,15,16} However, information on the prevalence of SARS-CoV-2
7 infection among frontline HCW and risk factors for most regions of Brazil is limited.
8 This study assessed the prevalence of SARS-CoV-2 infection and evaluated PPE shortages, the
9 use of individual protective measures, and biological accidents among HCW in Recife
10 metropolitan area of Northeast Brazil.

11 12 **Methods**

13 *Study design*

14 This prospective study assessed the frequency of infected HCW and their risk factors, using
15 the respondent-driven sampling (RDS) methodology¹⁷, and collecting data with a smartphone-
16 based application. RDS was chosen as a sampling approach for two main reasons: restrictions
17 in conducting face-to-face interviews due to lockdown and the lack of a frame list of frontline
18 HCW attending emergency rooms, hospitals, and new field hospitals. RDS approach is based
19 upon direct participant involvement.

20 The baseline findings are described following the Strengthening the Reporting of Observational
21 Studies in Epidemiology (STROBE) guidelines for RDS.¹⁸

22 23 *Setting*

24 The study was conducted in the Recife metropolitan region, Pernambuco State, Northeast
25 Brazil, where the first COVID-19 case was reported on March 12, 2020. The peak of the first
26 pandemic wave was during the 21st epidemiologic week in 2020.^{19,20} This densely populated
27 region comprises 15 municipalities with approximately four million inhabitants, corresponding
28 to 42% of the state population.²¹ The Brazilian unified health system (Sistema Unico de
29 Saude—SUS) has provided universal coverage since 1990, with heterogeneity among the
30 regions.²²

31 32 *Formative research*

33 Formative research (FR) was conducted with the four HCW categories included in the study
34 (physicians, nurses, nurse assistants, and physical therapists). The FR applied in-depth

1
2
3 1 interviews to explore workplace changes, use and access to PPE, routine attendance, and
4 possible acceptability of the study.
5 2

6 7 3 *Participants and Public Involvement*

8
9
10 4 Participants and/or the public were not involved in the design. However, the formative research
11 was valuable to adequate the research questions considering participants' priorities, experience,
12 and preferences. Also the chosen methodology RDS requires direct involvement of the study
13 participants in the recruitment and in indicating other members of the network. Therefore, the
14 participants had an active role in the enrolment of other participants and in the development of
15 the field work. This project was planned in collaboration with the official health care
16 department and professional associations. The coordinators issued periodic reports with
17 preliminary results to the institutions, local newspapers and social media. The final results will
18 be disseminated by institutional platforms.
19 9
20 10
21 11
22 12
23 13
24 14
25 15
26 16
27 17
28 18
29 19
30 20
31 21
32 22
33 23
34 24
35 25
36 26
37 27
38 28
39 29
40 30
41 31
42 32
43 33
44 34
45 35
46 36
47 37
48 38
49 39
50 40
51 41
52 42
53 43
54 44
55 45
56 46
57 47
58 48
59 49
60 50

14 *Participants*

15 We recruited HCW attending suspected or confirmed COVID-19 patients from May 21, 2020
16 to February 10, 2021. Recruitment started with five “seeds” for each category, non-randomly
17 selected from the target population. We asked each participant to identify five other members
18 of the same professional network category, providing their names and mobile phone numbers
19 to the fieldworkers. The process continued until a suitable sample size was reached. This study
20 did not offer any incentive.

21 We calculated a sample size of 1,100 HCW, considering a 95% confidence level (CI) to
22 estimate a 40% prevalence of infections with a 5% error and a design effect of three.

23 The network size of each HCW was measured by the final answer to the following questions:

24 1) “How many colleagues do you know, who also know you by name, work in the Recife
25 metropolitan region and are assisting COVID-19 patients?”, 2) “How many of those colleagues
26 have been in professional contact with you in the last two weeks?,” and 3) “How many of them
27 are close to you and you would invite to participate in this study?.”

29 *Variables*

30 We applied the WHO questionnaire developed as an operational tool to determine the risk of
31 COVID-19 virus infection among HCW exposed to a COVID-19 patient in a health care
32 facility. This questionnaire was developed as an interim guidance for risk assessment by the

1 WHO personnel/ experts in response to COVID-19 pandemic in the early months (March
2 2020).²³ The variables were:

3 (1) Age, sex, and professional category;

4 (2) Self-reported comorbidities (diabetes mellitus, hypertension, overweight or obesity,
5 cardiopathy, nephropathy, and others);

6 (3) Healthcare attending—public or private sector, outpatient, emergency rooms and intensive
7 care units (ICU); number of healthcare facilities.

8 (4) Adherence to infection prevention and control (IPC). We checked for gloves, medical
9 masks, face shields, goggles or protective glasses, and waterproof aprons. These variables were
10 grouped as: i) always as recommended (more than 95% of the time); ii) most of the time
11 (ranging from 50% to 95%); iii) occasionally (1-49%); iv) never; v) unavailable.

12 (5) Adherence to IPC when performing aerosol-generating procedures (AGPs) using the
13 abovementioned grading criteria. In this section, we added the N95 respirator. The variables
14 related to adherence to IPC (items 4 and 5) were grouped as always versus not always.

15 (6) Accidents with biological material—I) during the period of healthcare interaction and II) if
16 there was an accident with biological fluid or respiratory secretions, which type it was (splash
17 in the mucous membrane of eyes, mouth, or nose; non-intact skin; and puncture-sharp
18 accident).

19 *Outcome measure*

20 The primary outcome was the frequency of positive self-reported PCR tests. In the study, HCW
21 were considered as a priority population for COVID-19 tests as part of the COVID-19 public
22 health response at state level. Laboratory confirmation was performed at the Pernambuco
23 LACEN, which is the public health reference laboratory for the diagnosis of SARS-CoV-2
24 regionally. Also, PCR-based swab was the most available test for HCW, and the technique
25 used has been previously published.²⁴

26 *Data collection*

27 Data were collected using a web-based software platform by FITec (Recife, Pernambuco,
28 Brazil). The HCW answered the questionnaire by accessing a link that could be opened on a
29 smartphone or a computer browser.

30 Providing electronic informed consent was mandatory to participate and access the
31 questionnaire. The project was approved by the National Ethics Committee (CONEP; CAAE:
32 30629220.8.0000.0008).

1 *Data analysis*

2 Participants were weighted by the size of each category, provided by each professional board,
3 and by the inverse of the size of their professional network, based on the following question:
4 “How many of these colleagues are close to you and would you invite to participate in this
5 study?” To avoid the influence of extreme network sizes on the weight of each professional,
6 we limited the network size to 3 to 150 for outlier correction.²⁵ For missing data—representing
7 around 8% of the total—we used available information from the other two questions related to
8 network size, and when necessary, we applied the overall mean of the stratum. The seeds
9 (primary) were used to define the cluster of the study.

10 Categorical variables are presented as percentages and 95% CIs by HCW category and overall
11 frequencies adjusted for the design. The chi-squared test was used for comparison between
12 groups. We calculated the means, medians, and 95% CIs for continuous variables. Bivariate
13 analysis was performed to assess the association between potential risk factors and RT-PCR
14 positivity. Variables associated with the outcome at $p < 0.20$ were included in the multivariate
15 model. In the final model, we considered variables at the $p < 0.10$ level statistically significant.
16 All statistical analyses were performed using Stata, version 15.0 (StataCorp LLC, College
17 Station, TX, USA).

19 *Role of the funding source*

20 The funding source had no involvement in any stage of the project.

22 **Results**

23 *Participants*

24 We recruited 2,474 health care workers and 1,525 of them were included in the analysis, in the
25 following categories: 527 physicians, 471 registered nurses, 263 nursing assistants, and 264
26 physical therapists. The exclusions were: 638 HCW who did not sign the informed consent;
27 238 that refused to participate and 28 did not complete the questionnaires. Figure 1 illustrates
28 the recruitment chain for each category.

30 *Descriptive data*

31 Overall, women represented 81.1% (95% CI: 77.8% – 84.1%) of the sample after adjustment
32 to the reference population and for the study design (Table 1). Women also predominated in
33 all professional categories, with the lowest percentage among physicians (63.4%; 95% CI:
34 58.6% – 67.9%) and the highest among nurses (86.7%; 95% CI: 82.7% – 89.9%) and nursing

1 assistants (85.5%; 95% CI: 79.8% – 89.7%). The age distribution was as follows: 32.7% (95%
2 CI: 28.8% – 36.9%) and 35.6% (95% CI: 31.5% – 40.0%) were <30 and 30–39 years old,
3 respectively. Only 0.1% of the participants were aged ≥ 60 years. Physicians and physical
4 therapists were the youngest groups, comprising 56.6% (95% CI: 51.7% – 61.4%) and 45.1%
5 (95% CI: 38.3% – 52.1%), respectively, of those 20–29 years old. Comorbidities affected
6 30.1% (95% IC: 26.1% – 34.3%) of the studied population. Overweight/obesity (12.6%; 95%
7 CI: 9.9% – 15.9%) and hypertension (11.9%; 95% CI: 9.2% – 15.1%) were the most prevalent
8 comorbidities among nursing assistants and nurses than among the other categories. In total,
9 71.4% (95% CI: 67.6% – 74.9%) of HCW attended COVID-19 cases exclusively in the public
10 sector, including hospitals, emergency units, ambulance services, and primary care units. Most
11 HCW (73.5%; 95% CI: 69.2% – 77.3%) worked either in emergency rooms or ICU. Notably,
12 55.8% (95% CI: 51.0% – 60.6%) of the physicians and 37.8% (95% CI: 31.3% – 44.8%) of the
13 physical therapists indicated working in three or more institutions during the pandemic (Table
14 1).

15 Overall, 78.0% (95% CI: 74.2% – 81.3%) of the participants received training on the use of
16 PPE. Physical therapists (87.0%; 95% CI: 81.6% – 91.0%) and nursing assistants (81.1%; 95%
17 CI: 74.8% – 86.1%) received a higher and similar frequency of training compared to the other
18 categories. Almost half of the HCW (47.7%) reported a shortage of PPE items during the
19 COVID-19 pandemic. Regarding wearing PPE in routine activities, the overall frequencies
20 varied widely for each item: 90.1% (95% CI: 87.7% – 92.0%) for single-use gloves to 29.9%
21 (95% CI: 25.9% – 34.2%) for face shields. Most HCW (82.2%; 95% CI: 78.4% – 85.5%)
22 reported performing AGPs on COVID-19 patients. Almost all participants reported having
23 always used single-use gloves (98.4%; 95% CI: 96.4% – 99.3%) and N95 respirators (86.4%;
24 95% CI: 82.5% – 89.5%) during AGPs. The N95/PPF2 respirator was reused for more than
25 seven days by approximately 28.3% (95% CI: 24.7% – 32.1%) of the participants, with highest
26 and lowest frequencies reported by physicians (49.3%; 95% CI: 44.4% – 54.2%) and nursing
27 assistants (20.6%; 95% CI: 15.4% – 27.0%), respectively. Overall, 63.7% (95% CI: 57.8% –
28 69.2%) of the HCW reported always wearing all PPE items as recommended by the WHO. The
29 self-perception of SARS-CoV-2 risk of infection in the previous 15 days varied: 33.4% for
30 “performing a procedure on a patient with COVID-19;” 17.7% for “sharing the break room
31 with their colleagues;” 16% for the “reuse of N95 respirators;” 10.6% for the “use of poor
32 quality PPE;” 10.2% during “doffing;” 9.6% for “working with colleagues with COVID-19
33 symptoms;” 1.9% for “lack of PPE in the service;” and 0.5% for “donning PPE.” HCW reported
34 186 episodes of exposure to biological fluids/respiratory secretions during healthcare

1 interaction with COVID-19 patients. Accidents were more frequent among physicians (13.9%;
2 95% CI: 11.0% – 17.4%) and less frequent among physical therapists (7.6%; 95% CI: 4.9% –
3 11.7%) (Table 2).

4 The frequency of COVID-19 testing varied from 41.2% for physical therapists to 51.1% for
5 physicians. Individuals with any comorbidity were more likely to get tested (56.8%) than those
6 without comorbidities ($p<0.001$). HCW who worked in three or more health services were also
7 more likely to get tested (54.9%) than those who worked in only one health service (42.1%)
8 ($p<0.001$). There was no statistical difference in the likelihood of testing, according to sex, age
9 group (<30 versus ≥ 30 years old), work setting (outpatients, inpatients, and emergency rooms
10 and ICU), self-perception of risk (no risk to high risk of exposure), reported accidents with
11 biological fluid/respiratory secretion, and when performing AGPs (Supplementary Table 1).

12 For the tested HCW, mostly symptomatic, the overall self-reported SARS-CoV-2 infection was
13 61.8% (95% CI: 55.7%-67.5%) compared with 14.9% (CI: 4.9%-37.5%) among asymptomatic,
14 after adjustment for random cluster effects, weighted by network and population size. The
15 highest infection positivity was among nursing assistants (70.0%; 95%CI: 59.0%-79.1%),
16 followed by physicians (55.0%; 95%CI: 47.5%-62.3%), physical therapists (54.7%; 95%CI:
17 43.1%-65.7%), and nurses (48.1%; 95%CI: 40.3%-56.0%), adjusted for random cluster effects
18 (Figure 2). RT-PCR screening was performed mainly among symptomatic cases in all
19 categories, ranging from 81.8% to 91.8% for physicians and nursing assistants, respectively.

20 Almost half of the HCW (47.8%) reported taking sick leave due to COVID-19, with a similar
21 trend among the other categories ($p=0.159$). The median length of health leave was 14 days for
22 all professional categories, reflecting a standard procedure. Of 399 symptomatic SARS-CoV-
23 2 infected HCW, 10% ($n=41$) were hospitalized.

24 In a bivariate analysis, the nursing assistant category was positively associated with infection
25 (odds ratio [OR]=2.77; 95% CI: 1.64–4.67, $p<0.001$) compared to nurses. Reporting any
26 accident involving body fluid/respiratory secretion was associated with infection (OR=2.67;
27 95% CI: 1.22–5.82, $p<0.014$). When considering each accident, splashes in the eyes were a
28 stronger predictor of infection (OR=4.07; 95% CI: 1.14–14.55, $p<0.031$). During routine
29 assistance of COVID-19 patients, not always wearing the complete set of recommended PPE
30 items was associated with infection (OR=2.14; 95% CI: 1.18–3.88, $p=0.013$) when compared
31 to always using PPE. Not always using the complete recommended PPE items during AGPs
32 was also associated with infection (OR=1.68; 95% CI: 0.97–2.92, $p=0.063$) when compared
33 with always using PPE (Supplementary Table 2).

1
2
3 1 In the final multivariate logistic regression model, the following were risk factors for infection:
4
5 2 being a nursing assistant (OR adjusted=2.56; 95% CI: 1.42–4.61, $p=0.002$), not always having
6
7 3 used PPE during care of patients with COVID-19 (OR adjusted=2.15; 95% CI: 1.02–4.53,
8
9 4 $p=0.044$), and having suffered a splash to the eyes (OR adjusted=3.37; 95% CI: 1.10–10.34,
10
11 5 $p=0.034$) (Table 3).
12
13 6

14 7 **Discussion**

15 8 The current study showed substantial heterogeneity in demographic and self-referred
16
17 9 comorbidities between HCW categories during the COVID-19 pandemic. Of note, physicians
18
19 10 and physical therapists at the frontline were younger and mainly worked in the Intensive Care
20
21 11 Units and emergency rooms when compared with nurses. This reflects the expansion of the
22
23 12 healthcare workforce with the inclusion of younger physicians and physical therapists, possibly
24
25 13 inexperienced professionals, forcibly driven to work as frontliners in a high-risk environment.
26
27 14 Nurses and nursing assistants were older and reported more comorbidities, particularly
28
29 15 hypertension and overweight/obesity. According to the accumulated evidence, the public
30
31 16 health strategy was to prevent exposure among older age groups and/or individuals with
32
33 17 comorbidities, as older age and comorbidities are strong prognostic factors for hospitalization
34
35 18 and death.²⁶

36 19 To the best of our knowledge, our study depicted one of the highest frequencies of SARS-CoV-
37
38 20 2 infections among HCW, with nursing assistants being the most vulnerable category. In
39
40 21 consonance with this finding, nursing assistants also had the highest prevalence of infection
41
42 22 comparing with the other staff in a university hospital in the southeast of Brazil.¹⁶ One likely
43
44 23 explanation is that most of the participants tested were symptomatic, reflecting the policy of
45
46 24 making RT-PCR tests for COVID-19 diagnosis available to frontline HCW. Thus far, there has
47
48 25 been no mass RT-PCR testing strategy for the Brazilian population despite WHO
49
50 26 recommendations.²⁷ Worldwide, the prevalence closest to that of our study was 55%, by RT-
51
52 27 PCR among 177 symptomatic medical residents in New York City at the beginning of the
53
54 28 COVID-19 pandemic.²⁸ In Southeast Brazil, a high prevalence of SARS-CoV-2 infection
55
56 29 (42%) tested by RT-PCR was found among symptomatic HCW at a teaching hospital in Sao
57
58 30 Paulo, from March to May 2020.¹⁵ Another study found a prevalence of 14% (701 out of 4,987)
59
60 31 using RT-PCR in a group composed of mainly symptomatic HCW, at a hospital in the south of
32
33 32 Brazil from April to June 2020.¹⁴ This variation might be attributable to the dynamics of the
34
35 33 pandemic in different regions of the country, the availability/quality of PPE, and training in
36
37 34 different healthcare settings.

1 Finding of seroprevalence studies cannot be directly compared to our results. The frequencies
2 of SARS-CoV-2 infection among HCW in São Paulo city ranged from 5.5% (IgG ELISA) in a
3 private hospital to 14% (IgG/IgM antibody, WONDFO™) in a large public hospital in
4 2020.^{29,30} Both hospital settings stated that they adopted high-quality hospital infection control
5 and provided complete PPE in the early stages of the COVID-19 pandemic. This may reflect
6 especially high-quality healthcare facilities in more developed regions of the country and the
7 rates reported were similar to those reported in another meta-analysis of seroprevalence
8 studies.³¹

9 In our setting, critical aspects for the high risk of SARS-CoV-2 infection included a shortage
10 of PPE items reported by approximately half the HCW. Moreover, 22% of HCW reported not
11 been trained on PPE use. The lack of preparedness of the health workforce to respond to the
12 COVID-19 pandemic was not only encountered by low- and medium-income countries like
13 Brazil but also in high-income countries at the beginning of the pandemic.³² At the individual
14 level, one-fourth of the HCW reported that PPE was not always used according to the WHO
15 recommendations.²⁷ When performing aerosol-generating procedures (AGPs), the nursing staff
16 had the highest frequency (over 35%) of not fully adhering to complete PPE.³³ However, not
17 always using the recommended PPE during performance of AGPs was not associated with PCR
18 positive reports in our analysis. This finding is in line with a recent study questioning the
19 concept of AGPs for risk-stratifying patients since most procedures considered as AGPs do not
20 meaningfully increase respiratory aerosols.³⁴ In the current study, not using the recommended
21 PPE during routine attendance of COVID-19 cases caused a 2.2-fold increased risk of a SARS-
22 CoV-2 positive RT-PCR test result. Accidents with biological fluids occurred in all categories,
23 however, they were most frequently reported among physicians, the youngest, and perhaps the
24 group with the least experience working in critical conditions. Reporting an accident with
25 biological fluids, such as a splash in the eye, was positively associated with infection in the
26 final multivariable model. Although it is uncertain whether viruses occasionally present in
27 biofluids are infectious, these fluids should be considered potentially infectious.³⁵ Moreover,
28 the eye has been considered a possible route of SARS-CoV-2 entry through drainage via the
29 nasolacrimal duct to the upper respiratory tract.³⁶ These accidents with biological fluids should
30 be further investigated in other studies, as recommended by the WHO guidelines.²³ The
31 prevalence among HCW in the current study was at least 20-fold higher when compared to the
32 3.2% seroprevalence in a population-based survey using SARS-CoV-2 antibody rapid tests
33 conducted during the first wave of the pandemic in the same region.³⁷ Therefore, there is strong

1 evidence that HCW are at a high risk of SARS-CoV-2 infection in low- and medium-income
2 settings, such as Northeast Brazil.

3 To the best of our knowledge, this is the largest South American study of HCW during the
4 COVID-19 pandemic, with the inclusion of the four main healthcare professionals in the public
5 and private sectors and multiple levels of health services. Previous investigations conducted in
6 Brazil were mainly restricted to one hospital setting and did not apply the WHO
7 questionnaire.²³

8 The advantage of using the respondent-driven sampling technique was that it allowed the
9 inclusion of HCW from different healthcare settings, including the private and public health
10 services, providing a more comprehensive picture of frontline HCW during the pandemic.
11 Furthermore, as HCW worked in more than one health service and/or in newly implemented
12 “field hospitals/units,” this strategy allowed us to capture the full extent of characteristics of
13 the workforce and the risk factors for infection. Another advantage of applying an online
14 questionnaire was to avoid face-to-face interviews during the lockdown and/or social
15 distancing restrictions, reduce errors in data transcription, and obtain timely results.

16 We acknowledge as a potential limitation that our result was based on self-report COVID-19
17 results. In fact, this outcome is in consonance with previously large-scale online surveys
18 published during COVID-19 pandemic.^{6,38,39} HCW have the ability by their professional
19 training for reporting a positive PCR test for COVID-19. It is important to mention that during
20 this study period, the most available test was the PCR-based nasal swab, mainly performed by
21 the reference laboratory in charge of the COVID-19 public health response regionally.
22 Nevertheless, some misclassification of the outcome cannot be excluded.

23 Respondent-driven sampling study are traditionally designed for “hard-to-reach population” in
24 a lack of a sampling frame.¹⁷ In the study setting, the population of health professionals at
25 frontline although not a hard-to-reach population was made more difficult to access due a lack
26 of sampling frame and the enormous time burden on the staff. Therefore, we did not access this
27 population in a probabilistic sampling, but via the chain referral samples (social network),
28 which potentially induce selection bias. Despite of this limitation, inherent of RDS technique,
29 the study had several waves of recruitment chains, achieving a large and heterogeneous sample.
30 In addition, we estimated the weighted prevalence of SARS-CoV-2 infection considering the
31 social network size to minimize the potential selection bias introduced by the study design.
32 Another limitation is that the study was not designed as genomic surveillance or contact tracing
33 to distinguish the setting of the transmission. However, the participants were frontliners
34 attending suspected or confirmed Covid-19 patients. In fact, only 15.2% of them referred to

1 have had contact with COVID-19 cases simultaneously in health-care facilities and at the
2 household (data not shown). In our analysis the risk factors associated with infection were
3 higher among nursing assistants; HCW not using all PPE items as recommended, and to
4 professionals reporting an accident during their activities. It is likely that the high frequency of
5 infections among frontline HCW was presumably healthcare associated infections in line with
6 our findings, with the scenario of shortage of PPE and the high health care pressure during the
7 first pandemic wave. Nevertheless, the source of SARS-CoV-2 infection could not be
8 ascertained in this study.

9 There was an imbalance in recruitment among the HCW categories; physicians and nurses were
10 more rapidly enrolled by RDS than nursing assistants. One possible explanation is that
11 physicians and nurses seem to understand research methodology better and/or to have either
12 better smartphones or data plans required to answer the approximately 15-minute online
13 questionnaire. Physicians and nurses were also a more vocal category early in the pandemic,
14 publicizing the constraints/pressure of the workplace. Conversely, nursing assistants, as routine
15 healthcare assistants, spend more time providing direct patient care and have low wages. They
16 could also be less confident/willing to participate due to work overload or unfavourable socio-
17 economic conditions when compared to the other categories that require university degrees.
18 Additionally, disclosure of the work environment concerning PPE and infection control
19 prevention may be problematic for nursing assistants whose jobs are less stable and more prone
20 to replacement in our setting. Accidents involving biological fluids should be further
21 investigated in other studies to validate this finding.

22 The study shows the high frequency of SARS-CoV2 infection among HCW presumably due
23 to workplace exposures. In our setting nursing assistants comprised the most vulnerable
24 category. Our findings highlight the need for improving health care facility environments,
25 specific training and supervision to cope with public health emergencies.

27 **Data availability statement**

28 Proposals for the dataset (de-identified participant data, data dictionary) should be directed to
29 the corresponding author: turchicm@gmail.com. To gain access, data requestors will need to
30 present their plan of analysis and sign a data access agreement.

32 **Ethics statements**

33 All participants provided electronic informed consent in the web-based platform. HCW could
34 only access the questionnaire after giving the on-line Informed Consent Form (ICF). In our

1 study we applied the ICF in agreement with both: the requirements of the National Ethics
2 Committee (CONEP, 30629220.8.0000.0008); and with the current protocols for electronic
3 survey.
4

5 **Acknowledgments**

6 We thank HCW for their participation. We acknowledge the Institute of Health Technology
7 Assessment and MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020 for support. The
8 following researchers received scholarship (CNPq-Pq): 308974/2018-2 to CMTM,
9 309722/2017-9 to RAAX, 301905/2017-7 to MFPMA, no. 30735/2018-1 to CB and
10 303661/2017-8 to WVS. CRP received scholarship from CNPq, EV-1 no. 315877/2020-0. We
11 thank all participants for their important contribution in this project. We would like to thank
12 Editage (www.editage.com) for English language editing.
13

14 **Author contributions**

15 MFPMA, WVS, CMTM, RAAX, DBMF, TB, CK, and LRFSK contributed to the study
16 concept and design. CB, MNX, CNLM, GDMA, CBS, CAM, NTSF, JMG, CLFN, and JMVB
17 contributed to the acquisition of data. MFPMA, URM, WVS, CLS, PRBSJ, and CRP
18 contributed to the data analysis and creation of tables and figures. MFPMA, WVS, CMTM,
19 RAAX, DMF, TVBA, MASMV, LNGCL, CB, and LNC contributed to data interpretation.
20 MFPMA, WVS, URM have verified the underlying data. CMTM, MFPMA, WVS, and CRP
21 drafted the initial manuscript and all other coauthors contributed scientific inputs equally
22 towards the interpretation of the findings and the final draft of the manuscript. All authors
23 confirm that they had full access to all the data in the study and accept responsibility to submit
24 for publication.
25

26 **Funding**

27 This investigation was funded by Health Technology Assessment Institute (IATS) and by
28 MCTIC/CNPq/FNDCT/MS/SCTIE/Decit N° 07/2020. The funding agency had no role in
29 study design; in the collection, analysis, and interpretation of data; in the writing of the
30 report; and in the decision to submit the paper for publication.
31

32 **Declaration of interests**

33 We declare no competing interests.
34

References

- 1 Fauci AS, Lane HC, Redfield RR. Covid-19—navigating the uncharted. *N Engl J Med* 2020; **382**: 1268–9. doi:10.1056/NEJMe2002387.
- 2 Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's box—another novel coronavirus. *N Engl J Med* 2020; **382**: 1293–5. doi:10.1056/NEJMp2002106.
- 3 World Health Organization. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> [Accessed January 28 , 2021].
- 4 Zeiser FA, Donida B, Costa CA et al. First and second COVID-19 waves in Brazil: A cross-sectional study of patients' characteristics related to hospitalization and in-hospital mortality. *The Lancet Regional Health - Americas* 2022; **6**: 100107. doi: 10.1016/j.lana.2021.100107
- 5 The Lancet. COVID-19 in Brazil: “So what?”. *Lancet* 2020; **395**: 1461. doi:10.1016/S0140-6736(20)31095-3
- 6 Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. *Lancet Public Health* 2020; **5**: 475–83. doi:10.1101/2020.04.29.20084111.
- 7 Dzinamarira T, Murewanhema G, Mhango M et al. COVID-19 Prevalence among Healthcare Workers. A Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* 2022; **19**: 146. doi: 10.3390/ijerph19010146.
- 8 Thompson HA Mousa A, Digheet A al, Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) Setting Specific Transmission rates : A systematic Review and Meta-Analysis. *Clin Infect Dis* 2021; **743**: e754-64. doi: 10.1093/cid/ciab100.
- 9 Pan American Health Organization/World Health Organization. Epidemiological alert: COVID-19 among health workers. August 31, 2020 <https://www.paho.org/en/documents/epidemiological-alert-covid-19-among-health-workers-31-august-2020> [Accessed May 8, 2021].
- 10 Antonio-Villa NE, Bello-Chavolla OY, Vargas-Vázquez A, et al. Assessing the burden of coronavirus disease 2019 (COVID-19) among healthcare workers in Mexico City: a data-driven call to action. *Clin Infect Dis* 2021; **73**: e191–8. doi:10.1093/cid/ciaa1487.
- 11 Martin-Delgado J, Viteri E, Mula A, et al. Availability of personal protective equipment and diagnostic and treatment facilities for healthcare workers involved in COVID-19 care: a cross-sectional study in Brazil, Colombia, and Ecuador. *PLoS One* 2020; **15**: e0242185. doi:10.1371/journal.pone.0242185.

- 1
2
3 1 12 Cotrin P, Moura W, Gambardela-Tkacz CM, et al. Healthcare Workers in Brazil during
4 the COVID-19 Pandemic: A Cross Sectional online survey. *Inquiry* 2020; **57**:
5 2 46958020963711. doi: 10.1177/0046958020963711
6 3
7 8
8 4 13 Vedovato TG, Andrade CB, Santos DL, et al Health workers and COVID-19: flailing
9 working conditions? *Revista Brasileira de Saúde Ocupacional* 2021, **46**: e1. doi:
10 5 10.1590/2317-6369000028520.
11 6
12 7 14 Schmidt Fernandes F, de Castro Cardoso Toniasso S, Castelo Branco Leitune J, et al.
13 COVID-19 among healthcare workers in a Southern Brazilian hospital and evaluation
14 of a diagnostic strategy based on the RT-PCR test and retest for Sars-CoV-2. *Eur Rev*
15 8 *Med Pharmacol Sci* 2021; **25**: 3365–74. doi:10.26355/eurrev_202104_25748.
16 9
17 10 15 Buonafine CP, Paiatto BNM, Leal FB, et al. High prevalence of SARS-CoV-2
18 infection among symptomatic healthcare workers in a large university tertiary hospital
19 in São Paulo, Brazil. *BMC Infect Dis* 2020; **20**: 917. doi:10.1186/s12879-020-05662-8.
20 11
21 12 16 Faico-Filho KS, Carvalho JMA, Conte DD et al. COVID-19 in health care workers in a
22 university hospital during the quarantine in São Paulo city. *The Brazilian Journal of*
23 *Infectious Diseases* 2020; **24**: 462-465. doi:10.1016/j.bjid.2020.08.003
24 14
25 15 17 Heckathorn DD. Respondent-Driven Sampling: A New Approach to the Study of
26 Hidden Populations. *Social Problems* 1997; **44**: 174–199. doi: 10.2307/3096941
27 18
28 19 18 White RG, Hakim AJ, Salganik MJ, et al. Strengthening the reporting of observational
29 studies in epidemiology for respondent-driven sampling studies: "STROBE-RDS"
30 statement. *J Clin Epidemiol* 2015; **68**: 1463–71. doi:10.1016/j.jclinepi.2015.04.002.
31 21
32 22 19 Souza WV, Martelli CMT, Silva APSC, et al. The first hundred days of COVID-19 in
33 Pernambuco State, Brazil: epidemiology in historical context. *Cad Saude Publica* 2020;
34 23 36: e00228220. doi:10.1590/0102-311X00228220.
35 24
36 25 20 Ximenes RAA, Albuquerque MFPM, Martelli CMT, et al. Covid-19 in the Northeast of
37 Brazil: from lockdown to the relaxation of social distancing measures. *Cien Saude*
38 *Colet* 2021; **26**: 1441–56. doi:10.1590/1413-81232021264.39422020.
39 27
40 28 21 IBGE. Instituto Brasileiro de Geografia e Estatística. Censo demográfico Brasileiro.
41 2010. <https://www.ibge.gov.br/cidades-e-estados/pe/recife.html> [Accessed July 10,
42 2021].
43 30
44 31 22 Castro MC, Massuda A, Almeida G, et al. Brazil's unified health system: the first 30
45 years and prospects for the future. *Lancet* 2019; **394**: 345–56. doi:10.1016/S0140-
46 6736(19)31243-7.
47 32
48 33
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 23 World Health Organization. Health workers exposure risk assessment and management
4 in the context of COVID-19 virus: interim guidance. March 4, 2020.
5
6
7 3 <https://apps.who.int/iris/handle/10665/331340> [accessed April 15, 2020].
8
9 4 24 Magalhães JJF, Mendes RPG, Silva CTA et al. Epidemiological and clinical
10 characteristics of the first 557 successive patients with COVID-19 in Pernambuco state,
11 Northeast Brazil. *Travel Medicine and Infectious Disease* 2020; 38:101884. doi:
12 6 10.1016/j.tmaid.2020.101884.
13
14 7
15 8 25 Gonçalves B, Perra N, Vespignani A. Modeling users' activity on twitter networks:
16 validation of Dunbar's number. *PLoS One* 2011; 6: e22656.
17 9 doi:10.1371/journal.pone.0022656.
18
19 10
20 11 26 Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with
21 covid-19 using the ISARIC WHO clinical characterisation protocol: development and
22 12 validation of the 4C mortality score. *BMJ* 2020; 370: m3339. doi:10.1136/bmj.m3339.
23 13
24 14 27 World Health Organization. Responding to community spread of COVID-19: Interim
25 guidance 7 March 2020. [https://www.who.int/publications/i/item/responding-to-](https://www.who.int/publications/i/item/responding-to-community-spread-of-covid-19)
26 15 [community-spread-of-covid-19](https://www.who.int/publications/i/item/responding-to-community-spread-of-covid-19) [accessed February 7, 2022].
27 16
28
29 17 28 Breazzano MP, Shen J, Abdelhakim AH, et al. New York City COVID-19 resident
30 physician exposure during exponential phase of pandemic. *J Clin Invest* 2020; 130:
31 18 4726–33. doi:10.1172/JCI139587.
32 19
33 20 29 Costa SF, Giavina-Bianchi P, Buss L, et al. SARS-CoV-2 seroprevalence and risk
34 factors among oligo/asymptomatic healthcare workers (HCW): estimating the impact of
35 community transmission. *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa1845.
36 21
37 22 30 Oliveira MS, Lobo RD, Detta FP, et al. SARS-Cov-2 seroprevalence and risk factors
38 among health care workers: Estimating the risk of COVID-19 dedicated units. *Am J*
39 *Infect Control* 2021; 49: 1197–9. doi:10.1016/j.ajic.2021.03.010.
40 23
41 24 31 Hossain A, Nasrullah SM, Tasnim Z, Hasan MK, Hasan MM. Seroprevalence of
42 SARS-CoV-2 IgG antibodies among health care workers prior to vaccine
43 administration in Europe, the USA and East Asia: a systematic review and meta-
44 analysis. *E Clinical Medicine* 2021; 33: 100770. doi:10.1016/j.eclinm.2021.100770.
45 25
46 26 32 Paffenholz P, Peine A, Hellmich M, et al. Perception of the 2020 SARS-CoV-2
47 pandemic among medical professionals in Germany: results from a nationwide online
48 survey. *Emerg Microbes Infect* 2020; 9: 1590–9. doi:10.1080/22221751.2020.1785951.
49 27
50 28
51 29 33 Anvisa Nota Técnica Gvims/Ggtes/Anvisa N° 04/2020. Orientações para Serviços de
52 Saúde: Medidas de prevenção e controle que devem ser adotadas durante a assistência
53 30
54 31
55 32
56 33
57 34
58
59
60

- 1
2
3 1 aos casos suspeitos ou confirmados de infecção pelo novo Coronavírus (SARS-CoV-2)
4 (updated 08/05/2020).
5 2
6 3 34 Klompas M, Milton DK, Rhee C, et al. Current Insights Into Respiratory Virus
7 Transmission and Potential Implications for Infection Control Programs. *Annals of*
8 *Internal Medicine* 2021; **174**: 1710-1718. doi:10.7326/M21-2780.
9 4
10 5
11 6 35 Schindler SE, Jicha GA, Nelson PT, et al. Maximizing safety in the conduct of
12 Alzheimer's Disease fluid biomarker research in the era of COVID-19. *J Alzheimer's*
13 *Dis* 2020; **76**: 27–31. doi:10.3233/JAD-20068.
14 7
15 8
16 9 36 Abobaker A, Alzwi A. The eye: a possible new route of infection in COVID-
17 19. *Disaster Med Public Health Prep* 2020; **14**: e25–6. doi:10.1017/dmp.2020.270.
18 10
19 11 37 Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in Brazil:
20 results from two successive nationwide serological household surveys. *Lancet Glob*
21 *Health* 2020; **8**: e1390–8. doi:10.1016/S2214-109X(20)30387-9.
22 12
23 13
24 14 38 Firew T, Sano ED, Lee JW et al. Protecting the front line: a cross-sectional survey
25 analysis of the occupational factors contributing to healthcare workers' infection and
26 psychological distress during the COVID-19 pandemic in the USA. *BMJ Open* 2020
27 Oct 21; **10**: e042752. doi: 10.1136/bmjopen-2020-042752.
28 15
29 16
30 17
31 18 39 Varsavsky T, Graham MS, Canas LS et al. Detecting COVID-19 infection hotspots in
32 England using large-scale self-reported data from a mobile application: a prospective,
33 observational study. *Lancet Public Health* 2021; **6**: e21-e29. doi: 10.1016/S2468-
34 2667(20)30269-3.
35 19
36 20
37 21
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographic, clinical, and working baseline characteristics of health care workers in the metropolitan region of Recife, Northeast Brazil, 2020 to 2021

	Physicians (n = 527)		Nurses (n = 471)		Nursing assistants (n = 263)		Physical therapists (n = 264)		Total	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Sex										
Female	63.4	58.6–67.9	86.7	82.7–89.9	85.5	79.8–89.7	70.3	63.6–76.3	81.1	77.8–84.1
Male	36.6	32.1–41.4	13.2	10.1–17.3	14.5	10.2–20.2	29.7	23.7–36.4	18.9	15.9–22.2
Age, years										
< 30	56.6	51.7–61.4	25.8	21.6–30.6	26.9	20.8–33.9	45.1	38.3–52.1	32.7	28.8–36.9
30– 39	34.1	29.6–38.9	37.3	32.5–42.4	34.5	28.0–41.6	45.3	38.5–52.4	35.6	31.5–40.0
≥ 40	9.3	6.8–12.6	36.9	32.1–41.9	38.6	32.0–45.7	9.6	6.2–14.4	31.7	27.6–36.0
Any comorbidity										
Any	23.3	19.5–27.6	33.9	29.2–38.8	32.0	25.8–38.9	19.0	14.1–25.1	30.1	26.1–34.3
None	76.7	72.4–80.5	66.1	61.2–70.8	68.0	61–74.2	81.0	74.9–85.9	69.9	65.7–73.8
Diabetes	1.0	0.4–2.6	2.1	1.1–4.1	2.0	0.8–5.1	0.4	0.1–3.1	1.8	0.9–3.4
Hypertension	4.0	2.5–6.4	13.2	10.0–17.1	14.4	10.1–19.9	4.8	2.5–8.9	11.9	9.2–15.1
Overweight/Obesity	7.3	5.3–10.0	11.1	8.2–14.6	14.9	10.6–20.4	8.9	5.6–13.7	12.6	9.9–15.9
Heart disease	0.4	0.1–1.3	1.2	0.5–3.0	0.9	0.2–3.5	0.0	..	0.1	0.3–2.1
Kidney disease	0.0	..	0.2	0.03–1.5	0.1	0.02–1.1	0.8	0.2–3.1	0.2	0.1–0.6
Others comorbidities	13.1	10.1–16.7	14.8	11.6–18.8	9.4	5.9–14.7	6.9	4.2–11.4	10.8	8.4–13.8
Number of workplaces										
< 3	44.2	39.4–49.0	91.8	88.4–94.2	95.2	92.0–97.2	62.2	55.2–68.7	84.2	82.1–86.1
≥ 3	55.8	51.0–60.6	8.2	5.8–11.6	4.8	2.8–8.0	37.8	31.3–44.8	15.8	13.9–17.9
Missing	2		0		1		0		3	
Institution provider										
Private	5.2	3.5–7.8	7.2	4.8–10.5	7.0	4.1–11.5	14.8	10.4–20.5	7.2	5.3–9.8
Public	44.5	39.7–49.3	81.2	76.8–85.0	79.8	73.5–85.0	35.2	28.9–42.2	71.4	67.6–74.9
Both	50.3	45.5–55.2	11.6	8.7–15.4	13.2	9.1–18.9	50.0	43–56.9	21.4	18.4–24.7
Work setting										
Outpatient/Inpatient clinics	12.0	9.1–15.6	41.6	36.6–46.8	27.7	21.6–34.7	11.5	7.6–17.0	26.5	22.7–30.8
ICU/Emergency	88.0	84.4–90.9	58.4	53.2–63.4	72.3	65.3–78.4	88.5	83.0–92.4	73.5	69.2–77.3

Frequency for each professional category: adjusted for cluster random effect and weighted by network size. Total frequency: adjusted for cluster random effect and weighted by network and population size. CI, confidence interval; ICU, intensive care unit

Table 2. Adherence to infection prevention and control during healthcare interactions with COVID-19 patients and accidents with biological materials

	Physicians (n = 527)		Nurses (n = 471)		Nursing assistants (n = 263)		Physical therapists (n = 264)		Total	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Training on PPE use										
Yes	68.9	64.2–73.2	72.3	67.4–76.7	81.1	74.8–86.1	87.0	81.6–91.0	78.0	74.2–81.3
No	31.1	26.8–35.8	27.7	23.3–32.6	18.9	13.9–25.2	13.0	9.0–18.4	22.0	18.7–25.8
Missing	3		0		0		0		3	
While providing routine assistance to patients with COVID-19, have you used these PPE:										
Single Gloves										
Always	74.1	69.6–78.1	84.4	80.3–87.8	95.4	90.9–97.7	96.1	92.1–98.1	90.1	87.7–92.0
Not always	25.9	21.9–30.4	15.6	12.2–19.7	4.6	2.3–9.1	3.9	1.9–7.9	9.9	8.0–12.3
Missing	2		2		0		1		5	
Surgical mask										
Always	45.3	40.6–50.2	58.6	53.5–63.6	51.0	43.8–58.1	36.9	30.3–44.0	50.5	46.0–54.9
Not always	54.7	49.8–59.4	41.4	36.4–46.5	49.0	41.9–56.1	63.1	56.0–69.6	49.5	45.1–53.9
Missing	2		2		0		1		5	
N95 respirator										
Always	64.4	59.6–68.9	57.4	52.3–62.4	66.3	59.1–72.9	87.3	81.6–91.4	65.9	61.4–70.0
Not always	35.6	31.1–40.3	42.6	37.6–47.7	33.7	27.1–40.9	12.7	8.6–18.4	34.1	30.0–38.6
Missing	2		2		0		1		5	
Face shield										
Always	19.6	16.0–23.9	28.8	24.4–33.7	31.6	25.3–38.6	42.4	35.7–49.3	29.9	25.9–34.2
Not always	80.4	76.1–84.0	71.2	66.3–75.6	68.4	61.4–74.7	57.6	50.7–64.3	70.1	65.8–74.1
Missing	2		2		0		1		5	
Goggles/protective glasses										
Always	18.7	15.3–22.7	24.6	20.4–29.3	38.3	31.6–45.4	45.6	38.7 - 52.6	33.2	29.1–37.6
Not always	81.3	77.2–84.7	75.4	70.7–79.5	61.7	54.6–68.4	54.4	47.4–61.3	66.8	62.3–70.9
Missing	2		2		0		1		5	
Disposable gown										

1											
2											
3	Always	48.0	43.3–52.9	50.8	45.6–55.9	63.8	56.6–70.4	67.2	60.3–73.3	59.2	54.8–63.5
4	Not always	52.0	47.1–56.7	49.2	44.1–54.4	36.2	29.5–43.4	32.8	26.7–39.7	40.8	36.5–45.2
5	Missing	2		2		0		1		5	
6	Waterproof apron										
7	Always	30.5	26.2–35.2	38.6	33.7–43.7	48.9	41.6–56.3	62.6	55.3–69.4	44.9	40.5–49.5
8	Not always	69.5	64.8–73.8	61.4	56.3–66.3	51.1	43.7–58.4	37.4	30.6–44.7	55.1	50.5–59.5
9	Missing	14		11		11		18		54	
10											
11	During provision of routine										
12	assistance to COVID-19										
13	patients, did you wear all PPE										
14	items as recommended by the										
15	WHO?										
16	Always	89.6	86.2–92.3	79.2	74.7–83.1	70.0	63.1–76.1	69.0	62.2–75.1	74.7	70.5–78.5
17	Not always	10.4	7.7–13.8	20.8	16.9–25.3	30.0	23.9–36.9	31.0	24.9–37.8	25.3	21.5–29.5
18	Missing	2		2		0		1		5	
19	Participated in AGP*										
20	Yes	79.6	75.3–83.2	75.6	70.8–79.8	83.4	77–88.3	95.8	91.7–97.8	82.2	78.4–85.5
21	No	20.4	16.8–24.7	24.4	20.2–29.2	16.6	11.7 - 23	4.2	2.1–8.3	17.8	14.5–21.6
22	Missing	1		1		1		2		5	
23											
24	While participating in AGPs,										
25	have you used:										
26	Single Gloves										
27	Always	97.8	95.5–98.9	97.7	95.1–99	98.5	94.2–99.6	99.7	98.1–99.9	98.4	96.4–99.3
28	Not always	2.2	1.1–4.5	2.3	1–4.9	1.5	0.4–5.8	0.3	0.04–1.9	1.6	0.7–3.6
29	Missing	0		0		0		1		1	
30	Surgical mask										
31	Always	61.5	56.2–66.6	49.9	44.1–55.7	46.5	38.9–54.3	60.2	52.9–67.1	50.5	45.6–55.3
32	Not always	38.5	33.4–43.8	50.1	44.3–55.9	53.5	45.7–61.1	39.8	32.9–47.1	49.5	44.7–54.4
33	Missing	0		0		0		1		1	
34	N95 respirator										
35	Always	92.4	89–94.9	85.0	80.3–88.8	84.2	77.8–89.1	93.3	88.2–96.3	86.4	82.5–89.5
36	Not always	7.6	3.1–11	15.0	11.2–19.7	15.7	10.9–22.2	6.7	3.7–11.8	13.6	10.5–17.5
37	Missing	0		0		0		1		1	
38	Face shield										
39											
40											
41											
42											
43											
44											
45											
46											

1											
2											
3	Always	51.6	46.2–56.9	48.3	42.6–54.1	48.0	40.3–55.7	41.4	34.5–48.6	48.1	43.2–53.0
4	Not always	48.4	43.1–53.8	51.7	45.8–57.4	52.0	44.2–59.7	58.6	51.4–65.5	51.9	47.0–56.8
5	Missing	0		0		0		1		1	
6	Goggles/Protective glasses										
7	Always	62.5	57.1–67.6	59.3	53.5–64.9	51.4	43.6–59.1	47.1	40–54.3	54.0	49.1–58.9
8	Not always	37.5	32.4–42.8	40.7	35.1–46.5	48.6	40.9–56.4	52.9	45.7 - 60	46.0	41.1–50.9
9	Missing	0		0		0		1		1	
10	Disposable gown										
11	Always	60.3	55.0–65.4	60.1	54.3 - 65.7	64.0	60.3–74.9	68.3	61.3–74.4	65.6	60.8–70.1
12	Not always	39.7	34.6–45.0	39.9	34.3–45.7	32.0	25.1–39.7	31.7	25.6–38.7	34.4	29.9–39.2
13	Missing	0		0		0		1		1	
14	Waterproof apron										
15	Always	55.2	49.7–60.6	60.7	54.8–66.3	62.5	54.4–69.9	74.6	67.4–80.7	61.9	57.0–66.7
16	Not always	44.8	39.4–50.3	39.3	33.7–45.2	37.5	30.1–45.6	25.4	19.3–32.6	38.1	33.3–43.0
17	Missing	9		7		9		17		42	
18	When performing an AGP in COVID-19 patients, did you wear all recommended PPE items as in WHO guidance?										
19	Always	66.0	60.0–71.4	58.0	51.4–64.3	63.8	54.1–72.6	74.7	64.2–82.8	63.7	57.8–69.2
20	Not always	34.0	28.6–40.0	42.0	35.7–48.6	36.2	27.4–45.9	25.3	17.2–35.8	36.3	30.8–42.2
21	Missing	0		0		0		1		1	
22	Duration of N95 respirator use										
23	< 8 days	50.7	45.8–55.6	71.4	66.6–75.8	79.4	73.0–84.6	54.6	47.6–61.5	71.7	67.9–75.3
24	≥ 8 days	49.3	44.4–54.2	28.6	24.2–33.4	20.6	15.4–27.0	45.4	38.5–52.4	28.3	24.7–32.1
25	Missing	9		5		8		4		26	
26	Any accident involving body fluid/respiratory secretion										
27	Yes	13.9	11–17.4	10.8	7.9–14.5	11.7	7.9–17.1	7.6	4.9–11.7	11.6	9.1–14.8
28	No	86.1	82.6–89	89.2	85.5–92.1	88.3	82.9–92.1	92.4	88.3–95.1	88.4	85.2–90.9
29	Organ involved										
30	Splash in the Mouth	1.9	1.02–3.8	1.9	0.85–4.3	0.2	0.04–1.5	0.7	0.2–3.1	0.8	0.5–1.4
31	Splash on the Skin	2.4	1.4–3.9	3.4	1.9–6.0	1.3	0.5–3.2	3.9	1.9–7.7	2.0	1.3–3.0
32	Splash on the Eyes	2.3	1.4–3.9	3.5	1.9–6.1	2.1	0.8–5.8	2.5	1.2–5.0	2.4	1.4–4.2
33											
34											
35											
36											
37											
38											
39											
40											
41											
42											
43											
44											
45											
46											

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Puncture/sharps	8.2	5.9–11.3	3.0	1.7–5.3	8.2	4.9–13.4	0.0	-	6.7	4.6–9.7
Self-perception of risk										
None/Low	21.6	17.9–25.9	24.9	20.7–29.6	21.9	16.3–28.7	17.2	12.5–23.3	22.0	18.5–26.1
Medium/High	78.4	74.1–82.1	75.1	70.3–79.3	78.1	71.3–83.7	82.8	76.7–87.5	78.0	73.8–81.5
Missing	9		2		6		4		21	

Frequency for each professional category: adjusted for cluster random effect and weighted by network size. Total frequency: adjusted for cluster random effect and weighted by network and population size.

AGPs, aerosol-generating procedures; COVID-19, coronavirus disease 2019; CI, confidence interval; ICU, intensive care unit; PPE, personal protective equipment; WHO, World Health Organization

For peer review only

Table 3. Final multivariate model for factors associated with reported positive PCR COVID-19 results

	Odds Ratio	95% CI	<i>P</i> -value
Occupation			
Nurse	1.0
Physical therapist	1.47	0.80–2.72	0.214
Physician	1.20	0.76–1.90	0.426
Nursing assistant	2.56	1.42–4.61	0.002
Splash on the eyes			
No accident	1.0
Yes	3.37	1.10–10.34	0.034
Any accident	1.59	0.51–4.90	0.421
Used all PPE items while assisting patients with COVID-19			
Yes	1.0
No	2.15	1.02–4.53	0.044

Adjusted for cluster random effect and weighted by network and population size

COVID-19, coronavirus disease 2019; CI, confidence interval; PPE, personal protective equipment

1
2
3 **Figure Legends**
4

5 Figure 1. Respondent-driven sampling recruitment chains.
6

7 Figure 2. Frequencies of self-reported SARS-CoV-2 infection by healthcare categories.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only





Figure 1. Respondent-driven sampling recruitment chains

338x190mm (170 x 170 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Occupation

Supplementary Table 1. Characteristics of the study population according to RT-PCR testing

	RT-PCR testing		P-value
	Yes (%)	No (%)	
Occupation category			0.02
	Physician	269 (51.1)	257 (48.9)
	Registered nurse	224(47.6)	247(52.4)
	Nursing assistant	110 (42.0)	152 (58.0)
	Physical therapist	108(41.2)	154(58.8)
Sex			0.43
	Female	530 (46.2)	618 (53.8)
	Male	181 (48.5)	192 (51.5)
Age group, years			0.15
	< 30	523 (45.7)	622 (54.3)
	≥ 30	188 (50.0)	188 (50.0)
Any comorbidity			< 0.001
	Yes	246 (56.8)	187 (43.2)
	No	465 (42.7)	623 (57.3)
Number of workplaces (hospitals/clinics)			< 0.01
	<3	247 (54.0)	210 (46.0)
	≥3	462 (43.5)	599 (56.5)
Work setting			0.39
	Emerg/ICU	565 (47.3)	629 (52.7)
	Outpat/Inpatients	146 (44.7)	181 (55.3)
Institution provider			< 0.001
	Private	48 (42.1)	66 (57.9)
	Public	393 (43.0)	522 (57.0)
	Both	270 (54.9)	222 (45.1)
Performed aerosol generating procedure			0.36
	Yes	600 (47.3)	669 (52.7)
	No	110 (44.5)	137 (55.5)
	Missing	1 (20.0)	4 (80.0)
Same N95 respirator, use duration, days			0.023
	≤ 7	458 (49.00)	476 (51.0)
	> 7	243 (43.0)	322 (57.0)
Self-perceived risk			0.85
	None/Low	36 (45.1)	43 (54.9)
	Medium/High	665 (46.7)	760 (53.3)
Accident involving biological fluid/respiratory secretion			0.644
	Yes	84 (45.2)	102 (54.8)
	No	627 (47.0)	708 (53.0)
Sick leave due to COVID-19 symptoms			< 0.001
	Yes	576 (79.7)	147 (20.3)
	No	130 (16.5)	659 (83.5)
Had COVID-19-like symptoms/signs			< 0.001
	Yes	601 (68.2)	280 (31.8)
	No	110 (17.0)	530 (82.8)

COVID-19, coronavirus disease 2019; RT-PCR, reverse transcription polymerase chain reaction

Supplementary Table 2. Potential risk factors for reporting a positive PCR COVID-19 result among front line healthcare professionals

	Odds Ratio	95% CI	P-value
Sex			
Female	1.0
Male	1.35	0.78–2.34	0.288
Age, years	1.03	0.65–1.64	0.889
Occupation			
Nurse	1.0
Physical therapist	1.42	0.88–2.27	0.148
Physician	1.32	0.91–1.91	0.142
Nursing Assistant	2.77	1.64–4.67	<0.001
Any comorbidity	1.19	0.75–1.90	0.454
Number of workplaces			
< 3	1.0
≥ 3	0.83	0.53–1.30	0.428
Institution provider			
Private	1.0
Public	0.92	0.42–2.02	0.844
Both	0.93	0.41–2.10	0.863
Work setting			
Outpatient /Inpatient clinics	1.0
ICU/Emergency	1.54	0.92–2.60	0.102
Training on PPE use	1.06	0.62–1.80	0.829
Any accident involving body fluid/respiratory secretion	2.67	1.22–5.82	0.014
Splash in the mouth			
No accident	1.0
Yes	3.84	0.64–22.95	0.140
Other accident	2.30	0.85–6.23	0.102
Splash on the skin			
No accident	1.0
Yes	1.86	0.54–6.44	0.328
Other accident	2.50	0.80–7.85	0.116
Splash in the eyes			
No accident	1.0
Yes	4.07	1.14–14.55	0.031
Other accident	2.07	0.71–6.08	0.184
Puncture/sharp accident			
No accident	1.0
Yes	2.25	0.51–9.89	0.282
Other accident	2.51	1.10–5.72	0.028
Duration N95 respirator use			
< 8 days
≥ 8 days	0.96	0.59–1.55	0.869
Used All PPE items during AGP#			
Did not Always use	1.68	0.97–2.92	0.063

1
2
3 Used all PPE items while assisting
4 COVID-19 patients

5 Yes	1.0
6 No	2.14	1.18–3.88	0.013
7 Time on the front-line, days	0.997	0.994–1.000	0.042

8 Adjusted for cluster random effect and weighted by network and population size.

9
10 AGP, aerosol-generating procedure; COVID-19, coronavirus disease 2019; CI, confidence interval; ICU,
11 intensive care unit; PPE, personal protective equipment
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tabela 1. STROBE-RDS Statement Checklist for the manuscript title “High risk of SARS-CoV-2 infection among frontline healthcare workers in Northeast Brazil: a respondent-driven sampling approach”

Item	#	STROBE-RDS checklist	Main Document
Title and abstract	1	(a) Indicate “respondent-driven sampling” in the title or abstract	Page:1/ Line: 1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page:3/ Line:2-23
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page:5/ Line: 2-34; Page:6/ Line: 1-6
Objectives	3	State specific objectives, including any prespecified hypotheses	Page:6/ Line: 7-9
Methods			
Study design	4	(a) Present key elements of study design early in the article	Page:6/ Line: 13-18
		(b) State why RDS was chosen as the sampling method	Page:6/ Line: 15-17
Setting	5	(a) Describe the setting, locations, and relevant dates, including periods of recruitment and data collection	Page:6/ Line: 23-28 Page:7/ Line: 13-14
		(b) Describe formative research findings used to inform RDS study	Page:6/ Line: 31-34
Participants	6	(a) Give the eligibility criteria and the sources and methods of selection of participants. Describe how participants were trained/instructed to recruit others, number of coupons issued per person, any time limits for referral	Page:7/ Line: 13-18
		(b) Describe methods of seed selection and state number at start of study and number added later	Page:7/ Line: 19-25
		(c) State if there was any variation in study procedures during data collection (e.g., changing numbers of coupons per recruiter, interruptions in sampling, or (stopping recruitment chains)	Page:7/ Line: 17
		(d) Report wording of personal network size question(s)	Page:7/ Line: 21-25
Variables	7	(e) Describe incentives for participation and recruitment	Page:7/ Line: 17-18
		(a) If applicable, clearly define all outcomes, correlates, predictors, potential confounders, effect modifiers, and diagnostic criteria	Page:7/ Line: 28-32 Page:8/ Line: 1-20
		(b) State recruitment relationship was tracked	Page:9/ Line: 22-23
Data sources/ measurement	8	(a) For each variable of interest, give sources of data and details of methods of measurement. Describe comparability of measurement methods if there is more than one group	Page:8/ Line: 31-34 Page:9/ Line: 1-10
		(b) Describe methods to assess eligibility and reduce repeat enrollment (e.g., coupon manager software, biometrics)	Page:8/ Line: 23-25
Bias	9	Describe any efforts to address potential sources of bias	Not done
Study size	10	Explain how the study size was arrived at	Page:7/ Line: 19-20
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page:7/ Line: 28-32 Page:8/ Line: 1-16 Page:8/ Line: 31-34 Page:9/ Line: 1-10
Statistical methods	12	(a) Describe all statistical methods, including those to account for sampling strategy (e.g., the estimator used) and, if applicable, those used to control for confounding	Page:8/ Line: 31-34 Page:9/ Line: 1-10
		(b) State data analysis software, version number, and specific analysis settings used	Page:9/ Line: 11-12
		(c) Describe any methods used to examine subgroups and interactions	Not applicable
		(d) Explain how missing data were addressed	Page: 9/ Line: 1-3
		(e) Describe any sensitivity analyses	Not done
		(f) Report any criteria used to support statements on whether estimator conditions or assumptions were appropriate	Not done
		(g) Explain how seeds were handled in analysis	Page:9/ Line: 3-4
Results			
Participants	13	(a) Report the numbers of individuals at each stage of the study, for example, numbers potentially eligible,	Page:9/ Line: 19-23

		examined for eligibility, confirmed eligible, included in the study, and analyzed	
		(b) Give reasons for nonparticipation at each stage (e.g., not eligible, does not consent, decline to recruit others)	Page:9/ Line: 21-22
		(c) Consider use of a flow diagram	Not included as Flowchart due to limited number of Figures of the Journal
		(d) Report number of coupons issued and returned	Not applicable
		(e) Report number of recruits by seed and number of RDS recruitment waves for each seed. Consider showing graph of entire recruitment network	Page:9/ Line: 22-23 Figure 1
		(f) Report recruitment challenges (e.g., commercial exchange of coupons, imposters, duplicate recruits) and how addressed	Not Done
		(g) Consider reporting estimated design effect for outcomes of interest	Page:11/ Line:7-13
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and, if applicable, information on correlates and potential confounders. Report unweighted sample size and percentages, estimated population proportions or means with estimated precision (e.g., 95% confidence interval)	Page:9/ Line: 26-34 Page:10/ Line: 1-32
		(b) Indicate the number of participants with missing data for each variable of interest	Page: 20-24
Outcome data	15	If applicable, report number of outcome events or summary measures	Page:11/ Line: 7-13
Main results	16	(a) Give unadjusted and study design adjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included	Page:11/ Line: 19-33
		(b) Report category boundaries when continuous variables were categorized	Not applicable
		(c) If adjustment of primary outcome leads to marked changes, report information on factors influencing the adjustments (e.g., personal network sizes, recruitment patterns by group, key confounders)	The adjustment only modified slightly not affecting the general results
Other analyses	17	Report other analyses done for example, analyses of subgroups and interactions, sensitivity analyses, different RDS estimators and definitions of personal network size	All analyses were reported
Discussion			
Key results	18	Summarize key results with reference to study objectives	Page:12/ Line: 2-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page:14/ Line: 9-34 Page:15/ Line: 1-7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page:12/ Line: 14-33 Page:13/ Line: 1-34
Generalizability	21	Discuss the generalizability (external validity) of the study results	Page:13/ Line:30-34 Page:14/ Line: 1-8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page:16/ Line: 13-16